Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists

Abstract

The use of a compound of formula (1): wherein R1 is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4CONR5R6, NR4CONR5R6NR4CO2R7 and NR4SO2R7; R2 is selected from aryl attached via an unsaturated carbon; R3 is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6 and SO2R7; R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an NR5R6 group, R5 and R6 may be linked to form a heterocyclic group, or where R4,R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic group; and R7 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 1

Description

[0001] The present invention relates to triazolo[4,5-d]pyrimidine derivatives and their use in therapy. In particular, the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to the blockade of adenosine receptors and particularly adenosine A2A receptors, and to the treatment of movement disorders such as Parkinson's disease.

[0002] Movement disorders constitute a serious health problem, especially amongst the elderly sector of the population. These movement disorders are often the result of brain lesions. Disorders involving the basal ganglia which result in movement disorders include Parkinson's disease, Huntington's chorea and Wilson's disease. Furthermore, dyskinesias often arise as sequelae of cerebral ischaemia and other neurological disorders.

[0003] There are four classic symptoms of Parkinson's disease: tremor, rigidity, akinesia and postural changes. The disease is also commonly associated with depression, dementia and overall cognitive decline. Parkinson's disease has a prevalence of 1 per 1,000 of the total population. The incidence increases to 1 per 100 for those aged over 60 years. Degeneration of dopaminergic neurones in the substantia nigra and the subsequent reductions in interstitial concentrations of dopamine in the striatum are critical to the development of Parkinson's disease. Some 80% of cells from the substantia nigra need to be destroyed before the clinical symptoms of Parkinson's disease are manifested.

[0004] Current strategies for the treatment of Parkinson's disease are based on transmitter replacement therapy (Ldihydroxyphenylacetic acid (LDOPA)), inhibition of monoamine oxidase (e.g. Deprenyl®), dopamine receptor agonists (e.g. bromocriptine and apomorphine) and anticholinergics (e.g. benztrophine, orphenadrine). Transmitter replacement therapy in particular does not provide consistent clinical benefit, especially after prolonged treatment when “on-off” symptoms develop, and this treatment has also been associated with involuntary movements of athetosis and chorea, nausea and vomiting. Additionally current therapies do not treat the underlying neurodegenerative disorder resulting in a continuing cognitive decline in patients. Despite new drug approvals, there is still a medical need in terms of improved therapies for movement disorders, especially Parkinson's disease. In particular, effective treatments requiring less frequent dosing, effective treatments which are associated with less severe side-effects, and effective treatments which control or reverse the underlying neurodegenerative disorder, are required.

[0005] Blockade of A2 adenosine receptors has recently been implicated in the treatment of movement disorders such as Parkinson's disease (Richardson, P. J. et al., Trends Pharmacol. Sci. 1997, 18, 338-344) and in the treatment of cerebral ischaemia (Gao, Y. and Phillis, J. W., Life Sci. 1994, 55, 61-65). The potential utility of adenosine A2A receptor antagonists in the treatment of movement disorders such as Parkinson's Disease has recently been reviewed (Mally, J. and Stone, T. W., CNS Drugs, 1998, 10, 311-320).

[0006] Adenosine is a naturally occurring purine nucleoside which has a wide variety of well-documented regulatory functions and physiological effects. The central nervous system (CNS) effects of this endogenous nucleoside have attracted particular attention in drug discovery, owing to the therapeutic potential of purinergic agents in CNS disorders (Jacobson, K. A. et al., J. Med. Chems 1992, 35, 407-422). This therapeutic potential has resulted in considerable recent research endeavour within the field of adenosine receptor agonists and antagonists (Bhagwhat, S. S.; Williams, M. E. Opin. Ther. Patents 1995, 5,547-558).

[0007] Adenosine receptors represent a subclass (P1) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. The main pharmacologically distinct adenosine receptor subtypes are known as A1, A2A, A2B (of high and low affinity) and A3 (Fredholm, B. B., et al., Pharmacol. Rev. 1994, 46, 143-156). The adenosine receptors are present in the CNS (Fredholm, B. B., News Physiol. Sci., 1995, 10, 122-128).

[0008] The design of P1 receptor-mediated agents has been reviewed (Jacobson, K. A., Suzuki, F., Drug Dev. Res., 1997, 39, 289-300; Baraldi, P. G. et al., Curr. Med. Chem. 1995, 2, 707-722), and such compounds are claimed to be useful in the treatment of cerebral ischemia or neurodegenerative disorders, such as Parkinson's disease (Williams, M. and Bumnstock, G. Purinergic Approaches Exp. Ther. (1997), 3-26. Editor. Jacobson, Kenneth A.; Jarvis, Michael F. Publisher: Wiley-liss, New York, N.Y.)

[0009] It has been speculated that xanthine derivatives such as caffeine may offer a form of treatment for attention-deficit hyperactivity disorder (ADHD). A number of studies have demonstrated a beneficial effect of caffeine on controlling the symptoms of ADHD (Garfinkel, B. D. et al., Psychiatry, 1981, 26, 395-401). Antagonism of adenosine receptors is thought to account for the majority of the behavioural effects of caffeine in humans and thus blockade of adenosine A2A receptors may account for the observed effects of caffeine in ADSD patients. Therefore a selective A2A receptor antagonist may provide an effective treatment for ADHD but without the unwanted side-effects associated with current therapy.

[0010] Adenosine receptors have been recognised to play an important role in regulation of sleep patterns, and indeed adenosine antagonists such as caffeine exert potent stimulant effects and can be used to prolong wakefulness Porkka-Heiskanen, T. et al., Science, 1997, 276, 1265-1268). Recent evidence suggests that a substantial part of the actions of adenosine in regulating sleep is mediated through the adenosine A2A receptor (Satoh, S., et al., Proc. Natl. Acad. Sci., USA, 1996). Thus, a selective A2A receptor antagonist may be of benefit in counteracting excessive sleepiness in sleep disorders such as hypersomnia or narcolepsy.

[0011] It has recently been observed that patients with major depression demonstrate a blunted response to adenosine agonist-induced stimulation in platelets, suggesting that a dysregulation of A2A receptor function may occur during depression (Berk, M. et al, 2001, Eur. Neuropsycdopharnacol. 11, 183-186). Experimental evidence in animal models has shown that blockade of A2A receptor function confers antidepressant activity (El Yacoubi, M et al. Br. J. Phannacol. 2001, 134, 68-77). Thus, A2A receptor antagonists may offer a novel therapy for the treatment of major depression and other affective disorders in patients.

[0012] The pharmacology of adenosine A2A receptors has been reviewed (Ongini, E.; Fredholm, B. B. Trends PharmacoL Sci. 1996, 17(10), 364-372). One potential underlying mechanism in the aforementioned treatment of movement disorders by the blockade of A2 adenosine receptors is the evidence of a functional link between adenosine A2A receptors to dopamine D2 receptors in the CNS. Some of the early studies (e.g. Ferre, S. et al., Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 723841) have been summarised in two more recent articles (Puxe, K. et al., Adenosine Adenine Nucleotides Mol. Biol. Integr. Physiol., [Proc. Int. Symp.], 5th (1995), 499-507. Editors: Belardinelr, Luiz; Pelleg, Amir. Publisher: KIuwer, Boston, Mass.; Ferre, S. et al., Trends Neurosci. 1997, 20, 482-487).

[0013] As a result of these investigations into the functional role of adenosine A2A receptors in the CNS, especially in vivo studies linking A2 receptors with catalepsy (Ferre et al., Neurosci. Leuf. 1991, 130, 1624; Mandhane, S. N. et al., Eur. J. Pharmacol. 1997, 328, 135-141) investigations have been made into agents which selectively bind to adenosine A2A receptors as potentially effective treatments for Parkinson's disease.

[0014] While many of the potential drugs for treatment of Parkinson's disease have shown benefit in the treatment of movement disorders, an advantage of adenosine A2A antagonist therapy is that the underlying neurodegenerative disorder may also be treated. The neuroprotective effect of adenosine A2A antagonists has been reviewed (Ongini, E.; Adami, M.; Ferri, C.; Bertorelli, R., Ann. N.Y. Acad. Sci. 1997, 825(Neuroprotective Agents), 3048). In particular, compelling recent evidence suggests that blockade of A2A receptor function confers neuroprotection against MP,IPinduced neurotoxicity in mice (Chen, J- F., J. Neurosci. 2001, 21, RC143). In addition, several recent studies have shown that consumption of dietary caffeine, a known adenosine A2A receptor antagonist, is associated with a reduced risk of Parkinson's disease in man (Ascherio, A. et al, Ann Neurol., 2001, 50, 56-63; Ross G W, et al., JAMA, 2000, 283, 2674-9). Thus, A2A receptor antagonists may offer a novel treatment for conferring neuroprotection in neurodegenerative diseases such as Parkinson's disease.

[0015] Xanthine derivatives have been disclosed as adenosine A2 receptor antagonists as useful for treating various diseases caused by hyperfunctioning of adenosine A2 receptors, such as Parkinson's disease (see, for example, EP-A-565377).

[0016] One prominent xanthine-derived adenosine A2A selective antagonist is CSC [8-(3-chlorostyryl)caffeine] (Jacobson et al., FEBS Lett., 1993, 323, 141-144).

[0017] Theophylline (1,3-dimethylxanthine), a bronchodilator drug which is a mixed antagonist at adenosine A1 and A2A receptors, has been studied clinically. To determine whether a formulation of this adenosine receptor antagonist would be of value in Parkinson's disease an open trial was conducted on 15 Parkinsonian patients, treated for up to 12 weeks with a slow release oral theophylline preparation (150 mg/day), yielding serum theophylline levels of 4.44 mg/L after one week. The patients exhibited significant improvements in mean objective disability scores and 11 reported moderate or marked subjective improvement (Mally, J., Stone, T. W. J. Pharin. Pharmacol. 1994, 46, 515-517).

[0018] KF 17837 [E)-8-(3,4dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] is a selective adenosine A2A receptor antagonist which on oral administration significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680. KF 17837 also reduced the catalepsy induced by haloperidol and reserpine. Moreover, KF 17837 potentiated the anticataleptic effects of a subthreshold dose of L-DOPA plus benserazide, suggesting that KF 17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists (Kanda, T. et al., Eur. J. Pharmacol. 1994, 256, 263-268). The structure activity relationship (SAR) of KF 17837 has been published (Shimada, J. et al., Bioorg. Med. Chem. Lea. 1997, 7, 2349-2352). Recent data has also been provided on the A2A receptor antagonist KW-6002 (Kuwana, Y et al., Soc. Neurosci. Abstr. 1997,23, 119.14; and Kanda, T. et al., Ann. Neurol. 1998,43(4), 507-513).

[0019] New non-xanthine structures sharing these pharmacological properties include SCH 58261 and its derivatives (B3araldi, P. G. et al., Pyrazolo[4,3-e]-1,2,4-triazolo[1,5c]-pyrimidine Derivatives: Potent and Selective A2A Adenosine Antagonists. J. Med Chem. 1996, 39, 1164-71). SCH 58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4triazolo[1,5-c] pyrimidine) is reported as effective in the treatment of movement disorders (Ongini, E. Drug Dev. Res. 1997, 42(2), 63-70) and has been followed up by a later series of compounds (Baraldi, P. G. et al., J. Med. Chem. 1998,41(12), 2126-2133).

[0020] The foregoing discussion indicates that a potentially effective treatment for movement disorders in humans would comprise agents which act as antagonists at adenosine A2A receptors.

[0021] It has now been found that triazolo[4,5-d]pyrimidine derivatives, which are structurally unrelated to known adenosine receptor antagonists, exhibit unexpected antagonist binding affinity at adenosine (P1) receptors, and in particular at the adenosine A2A receptor. Such compounds may therefore be useful for the treatment of disorders in which the blocldng of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial. In particular such compounds may be suitable for the treatment of movement disorders, such as disorders of the basal ganglia which result in dyskinesias. Disorders of of particular interest include Parkinson's disease, Alzheimer's disease, spasticity, Huntington's chorea and Wilson's disease.

[0022] Such compounds may also be particularly suitable for the treatment of depression, cognitive or memory impairment including Alzheimer's disease, acute or chronic pain, ADSD and narcolepsy, or for neuroprotection.

[0023] According to the present invention there is provided the use of a compound of formula (I): 2

[0024] wherein

[0025] R1 is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R, and NR4SO2R7;

[0026] R2 is selected from aryl attached via an unsaturated carbon;

[0027] R3 is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6 and SO2R7;

[0028] R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an NR5R6 group, R5 and R6 may be linked to form a heterocyclic group, or where R4, R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic group; and

[0029] R7 is selected from alkyl and aryl,

[0030] or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blQcking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial.

[0031] As used herein, the term “alkyl” means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical which may be substituted or unsubstituted. Where cyclic, the alkyl group is preferably C3 to C12, more preferably C5 to C10, more preferably C5, C6 or C7. Where acyclic, the alkyl group is preferably C1 to C10, more preferably C1 to C6, more preferably methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, isobutyl or terdary-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl. It will be appreciated therefore that the term “alkyl” as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl.

[0032] As used herein, the term “lower alkyl” means methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).

[0033] As used herein, the term “aryl” means an aromatic group, such as phenyl or naphthyl, or a heteroaromatic group containing one or more heteroatom(s), such as pyridyl, pyrrolyl, quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl and indazolyl.

[0034] As used herein, the term “heteroaryl” means an aromatic group containing one or more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quinolinyl, fuiranyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl and indazolyl.

[0035] As used herein, the term “non-aromatic heterocyclyl” means a non-aromatic cyclic group containing one or more heteroatom(s) preferably selected from N, O and S, such as a cyclic amino group (including aziridinyl, azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl) or a cyclic ether (including tetrahydrofuranyl).

[0036] As used herein, the term “alkoxy” means alkyl-O-. As used herein, the term “aryloxy” means aryl-O-.

[0037] As used herein, the term “halogen” means a fluorine, chlorine, bromine or iodine radical.

[0038] As used herein, the term “prodrug” means any pharmaceutically acceptable prodrug of a compound of the present invention.

[0039] Where any of R1 to R14 is selected from alkyl, alkoxy and alkylthio, particularly from alkyl and alkoxy, in accordance with formula (I) as defined above, then that alkyl group, or the alkyl group of the alkoxy or alkylthio group, may be substituted or unsubstituted. Where any of R1 to R14is selected from aryl, aryloxy and arylthio, particularly from aryl and aryloxy, in accordance with formula (I) as defined above, then said aryl group, or the aryl group of the aryloxy group, may be substituted or unsubstituted. Where R5 and R6, or R4 and R5, are linked to form a heterocyclic group, the heterocyclic group may be substituted or unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 substituent. Substituents may include:

[0040] carbon-containing groups such as

[0041] alkyl,

[0042] aryl, (e.g. substituted and unsubstituted phenyl (including alkylphenyl, alkoxyphenyl and halophenyl),

[0043] arylalkyl; (e.g. substituted and unsubstituted benzyl);

[0044] halogen atoms and halogen containing groups such as

[0045] haloalkyl (e.g. trifluoromethyl),

[0046] haloaryl (e.g. chlorophenyl);

[0047] oxygen containing groups such as

[0048] alcohols (e.g. hydroxy, hydroxyalkyl, hydroxyaryl, (aryl)(hydroxy)alkyl),

[0049] ethers (e.g. alkoxy, aryloxy, alkoxyalkyl, aryloxyalkyl, alkoxyaryl, aryloxyaryl),

[0050] aldehydes (e.g. carboxaldehyde),

[0051] ketones (e.g. alkylcarbonyl, arylcarbonyl, alkylcarbonylalkyl, alkylcarbonylaryl, arylcarbonylalkyl, arylcarbonylaryl, arylalkylcarbonyl, arylalkylcarbonylalkyl, arylalkylcarbonylaryl)

[0052] acids (e.g. carboxy, carboxyalkyl, carboxyaryl),

[0053] acid derivatives such as esters (e.g. alkoxycarbonyl, aryloxycarbonyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, alkoxycarbonylaryl, aryloxycarbonylaryl, alkylcarbonyloxy, alkylcarbonyloxyalkyl), amides

[0054] (e.g. aminocarbonyl, mono- or di-alkylaminocarbonyl, cyclicaminocarbonyl, aminocarbonylalkyl, mono- or di-alkylaminocarbonylakyl, arylaminocarbonyl or arylalkylaninocarbonyl, alkylcarbonylamino, arylcarbonylamino or arylalkylcarbonylamino), carbamates

[0055] (eg. alkoxycarbonylamnino, aryloxycarbonylamino,

[0056] arylaikyloxycarbonylamino, aminocarbonyloxy, mono- or di-alkylaminocarbonyloxy, arylaminocarbonyloxy or

[0057] arylalkylaminocarbonyloxy) and ureas

[0058] (eg. mono- or di-alkylaminocarbonylamino, arylaminocarbonylamino or

[0059] arylalkylaminocarbonylarnino);

[0060] nitrogen containing groups such as

[0061] amines (e.g. amilno, mono- or diallylamino, cyclicamino, arylamino, aminoalkyl, mono- or dialkylaminoalkyl),

[0062] azides,

[0063] nitriles (e.g. cyano, cyanoalkyl),

[0064] nitro,

[0065] sulfonamides (e.g. aminosulfonyl, mono- or di-alkylamino sulfonyl, mono- or di-arylaminosulfonyl, alkyl- or aryl-sulfonyl amino, alkyl- or aryl-sulfonyl(alkyl)amino, alkyl- or aryl-sulfonyl(aryl)amino);

[0066] sulfur containing groups such as

[0067] thiols, thioethers, sulfoxides, and sulfones

[0068] (e.g. alkylthio, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsumfinylalkyl, alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl)

[0069] and heterocyclic groups containing one or more, preferably one, heteroatom,

[0070] (e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, . pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, hexahydroazepinyl, piperazinyl, morpholinyl, thianaphthyl, benzofuranyl, isobenzofuranyl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolinyl, isoquinolinyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxalinyl, chromenyl, chrornanyl, isochromanyl, phthalazinyl and carbolinyl).

[0071] Where any of R1 to R14 is selected from aryl or from an aryl-containing group such as aryloxy or arylthio, preferred substituent group(s) are selected from halogen, alkyl (substituted or unsubstituted; and where substituted particularly from alkoxyalkyl, hydroxyallyl, aminoalkyl and haloalkyl), hydroxy, alkoxy, CN, NO2, amines (including amino, mono- and di-alkylamino), alkoxycarbonyl, aminocarbonyl, carboxaamido, sulfonamido, alkoxycarbonylamino and aryl, and particularly from unsubstituted alkyl, substituted alkyl (including alkoxyalkyl and aminoalkyl), halogen and amines.

[0072] In one embodiment, where any of R1 to R14 is directly substituted by an alkyl substituent group, or by an alkyl-containing substituent group (such as alkoxy or alkylcarbonylamino for example), then the alkyl moiety of the substituent group directly attached to any of R1 to R14 may be further substituted by the substituent groups hereinbefore described and particularly by halogen, hydroxy, alkoxy, CN, amines (including amino, mono- and di-alkyl amino) and aryl.

[0073] In a furter embodiment, where any of R1 to R14 is directly substituted by an aryl substitutent group, or by an aryl-containing substituent group (such as aryloxy or aylaminocarbonylamino for example), then the aryl moiety of the substituent group directly attached to any of R1 to R14 may be further substituted by the substituent groups hereinbefore described and particularly by halogen, alkyl (substituted or unsubstituted; and where substituted particularly from alkoxyalkyl, hydroxyalkyl, aminoalkyl and haloalkyl), hydroxy, alkoxy, CN, NO2, amines (including amino, mono- and dialkylamino), alkoxycarbonyl, aminocarbonyl, carboxamido, sulfonamido, alkoxycarbonylamino and aryl. In a further embodiment, said aryl moiety is substituted by halogen, alkyl (including CF3), hydroxy, alkoxy, CN, amines (including amino, mono- and di-alkyl amino) and NO2. In a further embodiment, said aryl moiety is substituted by unsubstituted alkyl, substituted alkyl (particularly alkoxyalkyl and aminoalkyl), halogen and amines.

[0074] The terms “directly substituted” and “directly attached”, as used herein, mean that the substituent group is bound directly to any of R1 to R14 without any intervening divalent atoms or groups.

[0075] In the compounds of formula (I), R1 is selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), aryl (including heteroaryl), alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6 (including NH2), NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7.

[0076] In one embodiment, the compounds of formula (I) are those wherein R1 is selected from alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), aryl (including heteroaryl), alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6 (including NH2), NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7.

[0077] Preferably, R1 is selected from alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), alkoxy, alkylthio, NRsR (including NH2), NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7preferably from NR5R6 (including NH2), NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7, more preferably from NR5R6 (including NH2) and NR4COR5, more preferably from NR5R6 (including NH2) and most preferably from NH2.

[0078] Where R1 is selected from NR5R6, in one embodiment R5 and R6 are independently selected from hydrogen, alkyl and aryl, preferably from hydrogen.

[0079] Where R1 is selected from NR4COR5, in one embodiment R4 is hydrogen.

[0080] Where R1 is selected from alkyl, R1 is preferably C1-6 alkyl, more preferably C1-6 saturated alkyl, and more preferably lower alkyl. In one embodiment, R1 is selected from substituted alkyl, particularly haloalkyl (including CF3) and arylalkyl (including heteroarylalkyl), and particularly haloalkyl (including CF3).

[0081] Preferably, R2 is a heteroaryl group, and preferably a heteroaryl group which is attached to the pyrimidine ring of formula (I) such that at least one heteroatom is adjacent to the unsaturated carbon atom attached to said pytimidine ring. Preferably, R2 is an N, O or S-containing heteroaryl group. R2 may contain one or more heteroatom(s) selected from N, O and S.

[0082] In one embodiment, the aryl group of R2 (including wherein R2 is a heteroaryl group) is not ortho,ortho-disubstituted. Preferably, the aryl group of R2 (including wherein R2 is a heteroaryl group) is not substituted at either ortho position. As used herein, reference to ortho-substitution of the R2 group means the ortho positions of the R2 group relative to the point of attachment of R2 to the pytimidine moiety of formula (D.

[0083] In a preferred embodiment, R2 is selected from furyl (including 2-furyl), thienyl (including 2-thienyl), pyridyl (including 2-pyridyl), thiazolyl (including 2- and 5-thiazolyl), pyrazolyl (including 3-pyrazolyl), triazolyl (including 4-triazolyl), pyrrolyl (including 2-pyrrolyl) and oxazolyl (including 5-oxazolyl). In a flrher embodiment, R2 is selected from 2-flryl, 2-thienyl, 2-thiazolyl, 2-pyridyl, 3-pyrazolyl, 2-pyrrolyl, 4-triazolyl and 5-oxazolyl. In a futter preferred embodiment, R2 is selected from furyl, thienyl, pyridyl, thiazolyl and pyrazolyl, and particularly from 2-furyl, 2-thienyl, 2-thiazolyl, 2-pyridyl and 3-pyrazolyl. In a further embodiment, R2 is selected from furyl, thienyl and pyridyl, preferably 2-frryl, 2-thienyl and 2-pyridyl. In a particularly preferred embodiment, R2 is selected from furyl, and preferably from 2-furyl, substituted or unsubstituted.

[0084] Where R2 is other than a heteroaryl group, R2 is preferably phenyl.

[0085] In the compounds of formula (I), R3 is selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl), COR5, CO2R7, CONR5R6, CONR4NR5R6 and SO2R7.

[0086] Where R3 is selected from alkyl, R3 is preferably acyclic alkyl, preferably acyclic C1-6 alkyl (including alkenyl and alkynyl), preferably acyclic C1-6 saturated alkyl, preferably lower alkyl. In one embodiment, R3 is selected from substituted or unsubstituted methyl, ethyl and propyl (n-propyl or isopropyl) groups.

[0087] Where R3 is selected from alkyl, particularly from saturated acyclic C1-6 alkyl, particularly from lower alkyl and particularly from methyl, ethyl and propyl, it is preferred that R3 is substituted alkyl. Preferred substituents are aryl (including heteroaryl), cycloalkyl, non-aromatic heterocyclyl, CN, COR5, C2R5, CONR5R6, CONR4NR5R6 and C(═NR4)NR5R6, preferably aryl (including heteroaryl), CONR5R6, CO2R5 and COR5 (preferably wherein R5 is aryl), more preferably aryl (including heteroaryl), CONR5R6 and COR5, more preferably aryl (including heteroaryl) and CONR5R6, and most preferably aryl (including heteroaryl).

[0088] Where R3 is selected from arylalkyl (including heteroarylalkyl), the aryl (including heteroaryl) group may be unsubstituted, or substituted as defined in detail below in respect of the group referred to as RI1. Preferably, the arylalkyl (including heteroarylalkyl group) is an arylmethyl (including heteroarylmethyl) group. The preferred aryl groups are set out below in detail in respect of the group referred to as Ar.

[0089] Where R3 is selected from CONR5R6, R5 and R6 are selected from H, alkyl (including substituted alkyl such as arylalkyl (including heteroarylalkyl)) and aryl (including heteroaryl) or R5 and R6 may be linked to form a heterocyclic ring. In one embodiment, R5 and R6 are selected from unsubstituted alkyl and arylalkyl (including heteroarylalkyl). Said aryl groups may be substituted or unsubstituted. In a preferred embodiment one of R5 and R6 is hydrogen. In a fiuther preferred embodiment, R5 is H and R6 is selected from arylalkyl (including heteroarylalkyl), preferably arylmethyl (including heteroarylmethyl).

[0090] In a preferred embodiment, R3 is selected from H and substituted alkyl, preferably wherein said alkyl is substituted by aryl (including heteroaryl) or CONR5R6,and preferably by aryl (including heteroaryl), and more preferably by substituted Myl (including heteroaryl).In one embodiment, R3 is selected from (CR9R10)nR8 wherein n is 1 to 6 (preferably n is 1, 2 or 3, and preferably n is 1), R9 and R10 are independently selected from H, alkyl and aryl, and Rs is selected from aryl (including heteroaryl), cycloalkyl, non-aromatic heterocyclic, CN, COR5, CO2R5, CONR5R6,CONR4NR5R6 and C(═NR4)NR5R6,preferably aryl (including heteroaryl), CONR5R6,CO2R5 and COR5 (preferably wherein R5 is aryl), more preferably aryl (including heteroaryl), CONR5R6 and CO2R5, more preferably aryl (including heteroaryl) and CONR5R6, and most preferably aryl (including heteroaryl). Preferably, R9 and R10 are independently selected from H and alkyl (preferably acyclic saturated C1-6 alkyl, preferably lower alkyl, preferably methyl, ethyl or propyl), more preferably H. Preferably, at least one of R9 and R10 is hydrogen, and preferably both R9 and R10 are hydrogen.

[0091] Where R9 is aryl (including heteroaryl), the aryl (including heteroaryl) group may be unsubstituted, or may be substituted as defined in detail below for R11. The preferred aryl groups are set out below in detail in respect of the group referred to as Ar.

[0092] Where R8 is selected from CONR5R6, R5 and R6 are selected from H, alkyl (including substituted alkyl such as arylalkyl (including heteroarylalkyl)) and aryl (including heteroaryl) or R5 and R6 may be linked to form a heterocyclic ring. Ih one embodiment, one or both of R5 and R6 are selected from unsubstituted alkyl and arylalkyl (including heteroarylalkyl). In a fiwder embodiment, at least one of R5 and R6 is selected from aryl (including heteroaryl). Said aryl group may be substituted or unsubstituted. In a preferred embodiment, one of R5 and R6 is hydrogen.

[0093] Where R8 is selected from COR5, R5 is preferably aryl (including heteroaryl).

[0094] Where R8 is selected from CO2R5, R5 is preferably alkyl or aryl.

[0095] In a further preferred embodiment, R3 is selected from H and (CR9R10)nR8, more preferably from (CH2)R8, preferably wherein R8 is selected from aryl (including heteroaryl) and CONR5R6, more preferably wherein R8 is selected from aryl (including heteroaryl), and more preferably wherein R8 is selected from substituted aryl (including heteroaryl).

[0096] In a further embodiment, R3 is selected from (CR9R10)nR11 wherein R9, R10 and n are as defined above and R11 is selected from the group consisting of substituted aryl (including heteroaryl) groups, preferably mono-, di- or tri-substituted aryl (including heteroaryl) groups represented by the formula Ar(R12)a(R13)b(R14)c wherein Ar is an aryl (including heteroaryl) group; wherein R12, R13 and R14 are substituent group(s), the same or different; and wherein a, b and c are 0 or 1 such that a+b+c≧1.

[0097] In one embodiment, the group Ar is selected from phenyl. In an alternative embodiment, the group Ar is selected from heteroaryl groups such as those described hereinabove, preferably from mono or bicyclic heteroaryl groups, more preferably from pyridyl (including 2-pyridyl, 3-pyridyl and 4pyridyl, preferably 2-pyridyl), indolyl (including 2-indolyl, 3-indolyl, 4indolyl, 5-indolyl, 6-indolyl and 7-indolyl), furyl (including 2-furyl and 3-furyl, preferably 2-furyl), thienyl (including 2-thienyl and 3-thienyl, preferably 2-thienyl), isoindolyl, indolinyl, isoxazolyl, oxazolyl, thiazolyl, pyrazinyl, pyrimidinyl, quinolinyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, indazolyl, benzodioxolyl and dihydrobenzofuranyl, more preferably from pyridyl (preferably 2-pyridyl), indolyl, furyl (preferably 2-furyl) and thienyl (preferably 2-thienyl), and most preferably from pyridyl (preferably 2-pyridyl), furyl (preferably 2-furyl) and thienyl (preferably 2-thienyl).

[0098] In one embodiment, the group Ar is selected from phenyl, pyridyl (preferably 2-pyridyl), furyl (preferably 2-filryl), thienyl (preferably 2-thienyl) and indolyl, and particularly from phenyl, pyridyl (preferably 2-pyridyl), furyl (preferably 2-frryl) and thienyl (preferably 2-thienyl).

[0099] The substituent groups R12, R13 and R14 may be selected from any of the substituent groups described herein above.

[0100] In a preferred embodiment, R12, R13 and R14 are selected from NR5R6 (including NH2, and NHR5) alkyl (substituted or unsubstituted; preferably C1-6 acyclic alkyl), alkoxy (including fluoroalkoxy), halogen (including F, Cl, Br and I), NO2, CN, hydroxy, NHOH, CHO, CONR5R6,CO2R5, NR4COR5 preferably NHCOR5), NR4CO2R7 (preferably NHCO2R7), NR4SO2R7 (preferably NHSO027), OCO2R7 and aryl (including heteroaryl).

[0101] In a more preferred embodiment, R12, R13 and R14 are selected from NR5R6 (including NH2 and NHR5), alkyl (substituted or unsubstituted; and preferably C1-6 acyclic saturated alkyl) and halogen (preferably P or Cl, particularly P).

[0102] In a particularly preferred embodiment, R12, R13 and R14 are selected from NR5R6 (including NH2 and NHR5, preferably NH2) and alkyl (substituted or unsubstituted; preferably C1-6 acyclic saturated alkyl);

[0103] Where R12, R13 and R14 are selected from substituted alkyl, said alkyl is preferably selected from alkoxyalkyl, hydroxyalkyl, aminoalkyl (including NH2-alkyl, mono-alkylaminoalkyl and di-alkylaminoalkyl), haloalkyl (particularly fluoroalkyl (including CF3)), cyanoalkyl, alkylthioalkyl, alkylcarboxyaminoalkyl, alkoxycarbonylaminoalkyl and alkylsulfonylamino, more preferably from alkoxyalkyl, hydroxyalkyl, aminoalkyl and haloalkyl (particularly fluoroalkyl (including CF3)) and most preferably from alkoxyalkyl and aminoalkyl.

[0104] In one embodiment, the substituent groups R12, R13 and R14 are selected from halogen, al.lyl (including CF3), hydroxy, alkoxy, alkylthio, CN, amines (including amino, monoand di-alkyl amino) and NO2.

[0105] Where the Ar group is phenyl, the phenyl ring may be mono-, di- or tri-substituted, preferably wherein the substituent group is selected from NR5R6,alkyl, alkoxy, halogen, NO2, CN, hydroxy, CONR5R6,CO2R5, NR4COR5, NR4CO2R7, NR4SO2R7 and OCO2R7, as described above, and more preferably from NR5R6 (including NH2 and NHR5, and preferably NH2), alkyl (substituted or unsubstituted; preferably C1-6 acyclic saturated alkyl; and, where substituted, preferably from alkoxyalkyl, hydroxyalkyl, aminoalkyl and haloalkyl (particularly fluoroalkyl (including CF3)), and more preferably from alkoxyalkyl and aminoalkyl) and halogen (preferably P or Cl, particularly F). Where (a+b+c) is 2 or 3, it is preferred that at least one of the substituent groups is NR5R6, particularly NH2.

[0106] Where the Ar group is pyridyl, the pyridyl group (which is preferably a 2-pyridyl group) is preferably mono-substituted, preferably 6-substituted. The preferred substituent group(s) are selected from alkyl (including substituted and unsubstituted, saturated and unsaturated (such as alkenyl, including vinyl); and preferably C1-6 acyclic alkyl), alkoxy, halogen, aryl, NO2, NHOH and CHO, as described above, and more preferably from alkyl (substituted or unsubstituted; preferably C1-6 acyclic saturated alkyl; and, where substituted, preferably from alkoxyalkyl, hydroxyalkyl, aminoallyl and haloalkyl (particularly fluoroalkyl (including CF3)), and more preferably from alkoxyalkyl and aminoalkyl).

[0107] In a preferred embodiment R3 is selected from CHR9R11 wherein R9 and R11 are as defined above, and preferably wherein Ar is substituted pyridyl or substituted phenyl. Where Ar is substituted phenyl, preferably at least one of R12 and R13, or at least one of R12, R13 and R14, is NR5R6,preferably NH2.

[0108] In the compounds of formula (I), R4, R5 and R6 are independently selected from H, alkyl (including branched and unbranched allyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl) or where R5 and R6 are in any NR5R6 group, R5 and R6 may be linked to form a heterocyclic ring, or where R4, R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic ring.

[0109] In the compounds of formula (I), R7 is selected from alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl).

[0110] Where R4 to R7 are independently selected from alkyl, preferably R4 to R7 are selected from C1-6 alkyl, preferably C1-6 saturated alkyl and more preferably from lower alkyl.

[0111] Where R5 and R6, or R4 and R5, are linked to form a heterocyclic ring said heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated.

[0112] Said heterocyclic ring is preferably a 5, 6 or 7-membered ring, preferably a 5 or 6-membered ring, and may contain one or more flirther heteroatom(s) preferably selected from N, O and S.

[0113] In a preferred embodiment, R1 is NH2, R2 is 2-furyl and R3 is arylmethyl (including heteroarylmethyl).

[0114] In one embodiment of the invention, the compounds of formula (I) are selected from those set out in claim 41.

[0115] In a further embodiment of the invention, the compounds of formula (I) are selected from those set out in claim 42.

[0116] Where chiral the compounds of formula (I) may be in the form of a racemic mixture of pairs of enantiomers or in enantiomerically pure form.

[0117] According to a further aspect of the present invention there is provided a method of treating or preventing a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.

[0118] The disorder may be caused by the hyperfunctioning of the pufine receptors.

[0119] The disorders of particular interest are those in which the blocking of purine receptors, partiucularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial. These may include movement disorders such as Parkinson's disease, drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MIP, manganese, carbon monoxide) and post-traumatic Parkinson's disease (punch-drunk syndrome).

[0120] Other movement disorders in which the blocking of purine receptors, may be of benefit include progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity or other disorders of the basal ganglia which result in abnormal movement or posture. The present invention may also be effective in treating Parkinson's with on-off phenomena; Parkinson's with freezing (end of dose deterioration); and Parkinson's with prominent dyskinesias.

[0121] The compounds of formula (I) may be used or administered in combination with one or more additional drugs useful in the treatment of movement disorders, such as L-DOPA or a dopamine agonist, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.

[0122] Other disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors may be beneficial include acute and chronic pain; for example neuropathic pain, cancer pain, trigeminal neuralgia, migraine and other conditions associated with cephalic pain, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, phantom limb pain, spinal cord injury pain, central pain, post-herpetic pain and IIfV pain; affective disorders including mood disorders such as bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease; central and peripheral nervous system degenerative disorders including corticobasal degeneration, demyelinating disease (multiple sclerosis, disseminated sclerosis), Freidrich's ataxia, motoneurone disease (amyotrophic lateral sclerosis, progressive bulbar atrophy), multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy (diabetic neuropathy, tabes dorsalis, druginduced neuropathy, vitamin deficiency), systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy, spasticity; schizophrenia and related pyshoses; cognitive disorders including dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senile dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome, dementia pugilans; attention disorders such as attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood, and hyperactive child syndrome; central nervous system injury including traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injury, raised intracranial pressure, cerebral oedema, hydrocephalus, spinal cord injury; cerebral ischaemia including transient ischaemic attack, stroke (thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke, lacunar stroke) subarachnoid haemorrhage, cerebral vasospasm, neuroprotection for stroke, peri-natal asphyxia, drowning, cardiac arrest, subdural haematoma; myocardial ischaemia; muscle ischaemia; sleep disorders such as hypersomnia and narcolepsy; eye disorders such as retinal ischaemia-reperfusion injury and diabetic neuropathy; cardiovascular disorders such as claudication and hypotension; and diabetes and its complications.

[0123] According to a ftrther aspect of the present invention there is provided use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment or prevention of movement disorders in a subject.

[0124] According to a furter aspect of the invention there is provided a method of treating or preventing movement disorders comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) invention or a pharmaceutically acceptable salt or prodrug thereof.

[0125] According to a further aspect of the invention there is provided use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection in a subject.

[0126] According to a further aspect of the invention there is provided a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.

[0127] The medicament for or method of neuroprotection may be of use in the treatment of subjects who are suffering from or at risk from a neurodegenerative disorder, such as a movement disorder.

[0128] According to a further aspect of the invention, there is provided for use in therapy a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

[0129] The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.

[0130] According to a ftutber aspect of the present invention, there is provided a compound of formula (I), per se, other than compounds wherein R1 is H and R3 is selected from methyl, more preferably other than compounds wherein R1 is H and R3 is selected from unsubstituted lower alkyl, more preferably other than compounds wherein R1 is H and R3 is selected from unsubstituted allyl, and more preferably other than compounds wherein R1 is H.

[0131] According to a further aspect of the present invention, there is provided a compound of formula (I), per se, other than compounds wherein R3 is methyl, preferably other than compounds wherein R3 is unsubstituted lower alkyl and more preferably other than compounds wherein R3 is unsubstituted alkyl.

[0132] According to a frrther aspect of the invention there is provided a method of preparing the novel compounds of formula (1). Compounds of formula (1) may be prepared according to conventional synthetic methods. For example compounds of formula (1) where R1 is NH2 may be synthesised by standard methods such as those illustrated in Reaction Scheme 1. 3

[0133] Compounds of formula (4) where R3 is alkyl (including arylalkyl, heteroarylalkyl and (CR9R10)nCO2R5) may be prepared from compounds of formula (3) by standard methods such as reaction with an appropriate alkyl halide, or substituted alkyl halide in the presence of a suitable base such as sodium hydride.

[0134] Compounds of formula (4) where R3 is (CR9R10)nCONR5R6 or (CR0R10)nCONR4NR5R6 may be prepared from compounds of formula (4) where R3 is (CR9R10)nCO2R5 by standard methods such as direct reaction with an appropriate amine or hydrazine or by initial hydrolysis of the ester group CO2R5 to a carboxylic acid followed by reaction with an appropriate amine or hydrazine in the presence of a standard coupling reagent such as DCC.

[0135] Compounds of formula (4) where R3 is (CR9R10)nC(═NR4)NR5R6 may be prepared from compounds of formula (4) where R3 is(CR9R10)nCN by standard methods such as treatment with an appropriate amine in the presence of trimethyl aluminium.

[0136] Compounds of formula (4) where R3 is(CR9R10)nCN may be prepared from compounds of formula (3) by standard methods such as treatment with an appropriate substituted alkyl halide in the presence of a suitable base such as sodium hydride.

[0137] Compounds of formula (4) where R3 is CONR5R6 or CONR4NR5R6 may be prepared from compounds of formula (3) by standard methods such as treatment with an appropriate isocyanate (R5NCO or R6NCO) or carbamoyl chloride (R5R6NCOCl or R5R6NR4NCOCl).

[0138] Compounds of formula (4) where R3 is COR5, CO2R7 or SO2R7 may be prepared from compounds of formula (3) by standard methods such as treatment with an appropriate acid chloride (R5COCl), chloroformate (ClCO2R7) or sulphonyl chloride (R7SO2Cl) in the presence of a suitable base such as triethylamine.

[0139] Compounds of formula (3) may be prepared from the known chloro compound of formula (2) by standard methods such as aryl or heteroaryl coupling reactions. Suitable aryl or heteroaryl coupling reactions would include reaction with an appropriate aryl or heteroarylboronic acid derivative, an aryl or heteroaryl trialkylstannane derivative or an aryl or heteroarylzinc halide derivative in the presence of a suitable catalyst such as a palladium complex.

[0140] Compounds of formula (3) may also be prepared from compounds of formula (7) by standard methods such as treatment with isoamyl nitrite. Compounds of formula (7) are either known in the literature or may be prepared from compounds of formula (6) by standard methods such as reduction with hydrogen in the presence of a suitable catalyst such as Pd. Compounds of formula (6) are either known in the literature or may be prepared from the known compound of formula (5) by standard methods such as aryl or heteroaryl coupling reactions as described above.

[0141] Compounds of formula (1) where R1 is NR5R6 may be prepared from compounds of formula (4) by standard methods such as reductive amination with an appropriate aldehyde or ketone, or by treatment with an appropriate alkyl halide in the presence of a suitable base.

[0142] Compounds of formula (1) where R1 is NR4CONR5R6, wherein R4 is H, may be prepared from compounds of formula (4) by standard methods such as treatment with an appropriate isocyanate R5NCO or R6NCO) or carbamoyl chloride R5R6NCOCl). Compounds of formula (1) where R1 is NR4CONR5R6, wherein R4 is alkyl, may be prepared as described above having first performed an additional alkylation step as described above.

[0143] Compounds of formula (I) where R1 is NR4COR5, NR4CO2R7 or NR4SO2R7, wherein R4 is H, may be prepared from compounds of formula (4) by standard methods such as treatment with an appropriate acid chloride (R5COCl), chloroformate (ClCO2R7) or sulphonyl chloride (R7SO2Cl) in the presence of a suitable base. Compounds of formula (I) where R1 is NR4COR5, NR4CO2R7 or NR4SO2R7, wherein R4 is alkyl may be prepared as described above having first performed an additional alkylation step as described above.

[0144] Compounds of formula (I) where R1 is NH2 may also be synthesised by standard methods such as those illustrated in Reaction Scheme 2. 4

[0145] Compounds of formula (4) where R3 is alkyl (including arylalkyl, heteroarylalkyl and (CR9R10)nCO2R5) may be prepared from compounds of formula (10) by standard methods such as aryl or heteroaryl coupling reactions as described above. Compounds of formula (10) where R3 is alkyl are either known in the literature or may be prepared by methods analogous to those described in the literature. For example compounds of formula (10) where R3 is alkyl may be prepared from compounds of formula (9) where R3 is alkyl by standard methods such as treatment with isoamyl nitrite. Compounds of formula (9) where R3 is alkyl are either known in the literature or may be prepared by methods analogous to those described in the literature such as the treatment of the known compound of formula (8) with an appropriate amine in a suitable solvent preferably at elevated temperature.

[0146] Compounds of formula (1) where R1 is NH2 may also be synthesised by standard methods such as those illustrated in Reaction Scheme 3. 5

[0147] Compounds of formula (4) where R3 is alkyl (including arylalkyl, heteroarylalkyl and (CR9R10)nCO2R5) may be prepared from compounds of formula (15) where R3 is alkyl by standard methods such as treatment with isoamyl nitrite. Compounds of formula (15) where R3 is alkyl may be prepared from compounds of formula (14) where R3 is alkyl by standard methods such as reduction with hydrogen in the presence of a suitable catalyst such as Pd. Compounds of formula (14) where R3 is alkyl are either known in the literature or may be prepared from compounds of formula (13), where X is a suitable leaving group such as a tosylate or triflate group, by standard methods such as treatment with a suitable amine in the presence of a suitable base such as triethylamine. Compounds of formula (13) where X is a suitable leaving group are either known in the literature or may be prepared from compounds of formula (12) by standard methods such as treatment with tosyl chloride or triflic anhydride in the prence of a suitable base such as triethylamine or 2,6-dimethylpyridine. Compounds of formula (12) are either known in the literature or may be prepared from the known compound of formula (11) by standard methods such as aryl or heteroaryl coupling reactions as described above.

[0148] Other compounds of formula (1) may be prepared by standard methods such as those illustrated in Reaction Scheme 4. 6

[0149] Compounds of formula (1) where R1 is H, alkyl or aryl may be prepared from compounds of formula (16) where R1 is H, alkyl or aryl by standard methods such as aryl or heteroaryl coupling reactions as described above. Compounds of formula (16) where R1 is H, alkyl or aryl are either known in the literature or may be prepared by methods analogous to those described in the literature.

[0150] Compounds of formula (1) where R1 is alkoxy, aryloxy, alkylthio, arylthio, CN or NRs may be prepared from compounds of formula (1) where R1 is halogen by standard methods such as nucleophilic displacement using an appropriate nucleophilic reagent such as an alcohol, thiol, cyanide or amine (NR5R6) in the presence of a suitable base if required. Compounds of formula (1) where R1 is halogen may be prepared from compounds of formula (16) where R1 is halogen as described above. Compounds of formula (16) where R1 is halogen are either known in the literature or may be prepared by methods analogous to those described in the literature.

[0151] Compounds of formula (I) where R1 is NR4CONR5R6, NR4COR5, NR4CO2R7 or NR4SO2R7, wherein R4 is alkyl or aryl, may be prepared from compounds of formula (1) where R1 is NR5R6,wherein R5 is H and R6 is alkyl or aryl, by the methods described above.

[0152] In certain cases it may be advantageous to prepare a compound of formula (1) where R3 is selected to perform the function of a protecting group, for example a suitable protecting group would be a benzyl group or substituted benzyl group such as a 3,4-dimethoxybenzyl group. Compounds of this nature may prepared as described above and the protecting group R3 may be removed by standard methods such as treatment with, for example, TFA to give a compound of formula (1) where R3 is H. Compounds of formula (1) where R3 is H may then be used to prepare other compounds of formula (1), where R3 is as previously defined, by the methods described above.

[0153] In the compounds of formula (1) the groups R1, R2 and R3 may be further substituted as defined above and it will be appreciated by those skilled in the art that suitable substituent groups may be introduced directly according to the methods described above or alternatively may be introduced by further functionalisation of substituent groups which themselves are introduced directly. For example where the group R1, R2 or R3 contains a nitro substituent this may be reduced by standard methods to an amino group. The resulting amino group may then be further transformed by a variety of standard methods known to those skilled in the art to an alternative functional group such as an amide, urea, carbamate, sulphonamide or alkylamine.

[0154] According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining a compound of formula (I) with a pharmaceutically acceptable carrier or excipient.

[0155] The pharmaceutical compositions employed in the present invention comprise a compound of the present invention, or pharmaceutically acceptable salts or prodrugs thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients known to those skilled in the art. The term, “pharmaceutically acceptable salts”, refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic acids and organic acids.

[0156] Where the compounds of formula (I) are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, and sulfuric acids, and most particularly preferred is the hydrochloride salt.

[0157] Any suitable route of administration may be employed for providing the patient with an effective dosage of a compound of the present invention. For example, oral, rectal, parenteral (intravenous, intramuscular), transdermal, subcutaneous, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like. The most suitable route in any given case will depend on the severity of the condition being treated. The most preferred route of administration of the present invention is the oral route. The compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

[0158] In practical use, the compounds can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (e.g. intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations such as, for example, powders, capsules, and tablets, with the solid oral preparations being preferred over the liquid preparations. The most preferred solid oral preparation is tablets.

[0159] Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques.

[0160] In addition to the common dosage forms set out above, the compounds may also be administered by controlled release means and/or delivery devices such as those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719; 4,687,660; and 4,769,027, the disclosures of which are hereby incorporated by reference.

[0161] Pharmaceutical compositions employed in the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, an oil-in-water emulsion, or a water-inoil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

[0162] For example, a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0163] The invention is further defined by reference to the following examples. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practised without departing from the purpose and interest of this invention.

EXAMPLES

Synthetic Examples

[0164] The invention is illustrated with reference to the following Examples, as set out in Table 1. 1 TABLE 1 Example Structure Compound Name 1 7 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 2 8 N,N-bis(2-fluorobenzyl)-3-(2-fluorobenzyl)-7- (2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine- 5-amine 3 9 3-(2-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 4 10 7-(2-furyl)-3-(3-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 5 11 3-(3-aminobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 6 12 methyl 3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- yl)methylbenzoate 7 13 3-(3,5-dimethoxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 8 14 3-(5-chloro-2-thienyl)methyl-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 9 15 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- yl)methyl)phenyl-(1-methyl-1H-imidazol-4- yl)sulphonamide 10 16 5-amino-N-benzyl-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylcarboxamide 11 17 7-(2-furyl)-3-(3-methoxybenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 12 18 7-(2-furyl)-3-(2-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 13 19 3-(2-aminobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 14 20 ethyl 5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[45-d]pyrimidin-3-ylacetate 15 21 3-(3-cyanobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 16 22 7-(2-furyl)-3-(3-(3-pyridyl)propyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 17 23 7-(2-furyl)-3-(3-trifluoromethylbenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 18 24 7-(2-furyl)-3-(3-hydroxybenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 19 25 7-(5-methyl-2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 20 26 3-(2-fluorobenzyl)-7-(5-methyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 21 27 7-(1H-pyrazol-3-yl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 22 28 3-(2-fluorobenzyl)-7-(5-thiazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 23 29 7-(2-furyl)-3-(3-methylbenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 24 30 7-(2-furyl)-3-(2-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 25 31 7-(2-furyl)-3-(3-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 26 32 (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetic acid 27 33 3-(3-chlorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 28 34 3-(2-fluorobenzyl)-7-(1H-pyrazol-3-yl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 29 35 7-(2-furyl)-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 30 36 (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetamide 31 37 (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-(3-chlorophenyl)acetamide 32 38 7-(2-furyl)-3-(6-methoxy-2-pyridylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 33 39 7-(2-furyl)-3-(2-thienylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 34 40 3-(2-fluorobenzyl)-7-(2-thiazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 35 41 3-(2-fluorobenzyl)-7-(2-thienyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 36 42 3-(3-aminobenzyl)-7-(5-methyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 37 43 7-(2-furyl)-3-(6-methyl-2-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 38 44 3-(2-fluorobenzyl)-7-(5-methyl-2-thiazolyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 39 45 tert-butyl N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)benzyl)carbamate 40 46 3-(2,5-dimethoxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 41 47 3-(2,6-difluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 42 48 3-(2-fluorobenzyl)-7-(4-methyl-2-thiazolyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 43 49 7-(2-thienyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 44 50 6-chloro-N-(7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridine- 3-carboxamide 45 51 3-(3-nitrobenzyl)-7-(5-thiazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 46 52 3-(3-aminomethylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 47 53 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N,N-dimethylbenzamide 48 54 3-(3-aminobenzyl)-7-(2-thienyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 49 55 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N-methylbenzamide 50 56 3-(3-aminobenzyl)-7-(5-thiazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 51 57 3-(2-fluoro-5-methoxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 52 58 (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-(2-pyridyl)acetamide 53 59 (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-(2-pyridylmethyl)acetamide 54 60 (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-phenylacetamide 55 61 3-(3,5-dinitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 56 62 7-(5-methyl-2-furyl)-3-(3-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 57 63 3-(2,3-difluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 58 64 3-(2,4-difluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 59 65 7-(5-methyl-2-furyl)-3-(6-methyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 60 66 3-(2,6-difluorobenzyl)-7-(5-methyl-2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 61 67 7-(5-methyl-2-furyl)-3-(2-thienylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 62 68 3-(3-chlorobenzyl)-7-(5-methyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 63 69 7-(2-furyl)-3-(4-methoxy-2-pyridylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 64 70 7-(2-furyl)-3-(2-methylbenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 65 71 3-(2,5-difluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 66 72 7-(2-furyl)-3-(2-methoxy-5-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 67 73 3-(5-amino-7-(5-methyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)- N-methylbenzamide 68 74 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)benzyl)acetamide 69 75 3-(2-fluorobenzyl)-7-(5-oxazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 70 76 3-(4-chloro-2-pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 71 77 3-(6-fluoro-2-pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 72 78 3-(2-methoxybenzyl)-7-(5-methyl-2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 73 79 tert-butyl N-(3-(5-amino-7-(5-methyl-2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)benzyl)carbamate 74 80 3-(2-aminobenzyl)-7-(5-methyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride 75 81 3-(3,5-diaminobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 76 82 3-(3-aminomethylbenzyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine hydrochloride 77 83 7-(2-furyl)-3-(2-methoxybenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 78 84 3-(2-fluoro-5-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 79 85 3-(5-amino-2-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 80 86 3-(2-fluorobenzyl)-7-(1H-triazol-4-yl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 81 87 3-(6-chloro-2-pyridylmethyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 82 88 7-(5-methyl-2-furyl)-3-(6-phenyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 83 89 3-(3-aminobenzyl)-7-(2-thiazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 84 90 3-(5-amino-2-fluorobenzyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine hydrochloride 85 91 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)benzyl)-3-methylbutanamide 86 92 7-(5-methyl-2-furyl)-3-(4-nitro-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 87 93 3-(4-hydroxylamino-2-pyridylmethyl)-7-(5- methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 88 94 7-(2-furyl)-3-(2-methyl-3-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 89 95 3-(3-amino-2-methylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 90 96 3-(3-amino-4-methylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 91 97 3-(3,5-dimethylisoxazol-4-ylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 92 98 7-(2-furyl)-3-(3-methyl-2-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 93 99 3-cyclohexylmethyl-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 94 100 7-(2-furyl)-3-(3-methyl-4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 95 101 7-(2-furyl)-3-(3-methyl-2-pyridylmethy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 96 102 7-(2-furyl)-3-(5-methyl-2-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 97 103 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 98 104 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidin-3-ylmethyl)benzoic acid 99 105 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidin-3-ylmethyl)benzamide 100 106 7-(2-furyl)-3-(2-methylthiazol-4-ylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 101 107 3-(3-aminomethylbenzyl)-7-(1H-pyrazol-3- yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 102 108 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N-isopropyl-N- methylbenzamide 103 109 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N-isopropylbenzamide 104 110 3-(2-amino-5-methylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 105 111 3-(4-cyano-2-pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 106 112 7-(2-furyl)-3-(5-methyl-2-pyrazinylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 107 113 7-(2-furyl)-3-(8-quinolinylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 108 114 7-(2-furyl)-3-(2-phenylthiazol-4-ylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 109 115 7-(4-methyl-2-thiazolyl)-3-(3-nitrobenzyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 110 116 3-(4-chloro-3-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 111 117 3-[1,2,5-benzoxadiazol-5-yl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 112 118 7-(2-furyl)-3-(6-methoxymethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 113 119 3-benzyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 114 120 3-(3-amino-4-chlorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 115 121 7-(2-furyl)-3-(4-nitro-2-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 116 122 7-(2-furyl)-3-(4-hydroxylamino-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 117 123 7-(2-furyl)-3-(6-methyl-4-nitro-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 118 124 7-(2-furyl)-3-(4-hydroxylamino-6-methyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 119 125 3-(4-chloro-2-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 120 126 3-(2-amino-4-chlorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 121 127 3-(4-cyanobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 122 128 3-(3,4-dimethoxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine trifluoroacetate salt 123 129 7-(5-methyl-2-furyl)-3-(3-methyl-4- nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 124 130 3-(4-amino-3-methylbenzyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 125 131 7-(2-furyl)-3-(5-methyl-3-oxazolyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 126 132 7-(2-furyl)-3-(3-methyl-4-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 127 133 3-(1,2,5-benzothiadiazol-4-ylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 128 134 7-(2-furyl)-3-(2-pyrazinylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 129 135 3-(4-fluoro-3-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 130 136 3-(3-nitrobenzyl)-7-phenyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 131 137 7-(2-furyl)-3-(4-methyl-2-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 132 138 tert-butyl N-(2-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)- 4-pyridylmethyl)carbamate 133 139 7-(2-furyl)-3-(3-methoxy-4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 134 140 7-(2-furyl)-3-(4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 135 141 3-(6-ethyl-2-pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 136 142 3-(2-ethyl-4-pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 137 143 tert-butyl 7-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)indole-1-carboxylate 138 144 tert-butyl 4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)indole-1-carboxylate 139 145 7-(2-furyl)-3-(4-indolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 140 146 tert-butyl N-(4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)benzyl)carbamate 141 147 3-(4-aminobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 142 148 tert-butyl 5-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)indole-1-carboxylate 143 149 tert-butyl N-(4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)- 2-fluorophenyl)carbamate 144 150 3-(4-aminomethylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 145 151 7-(5-ethyl-2-furyl)-3-(3-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 146 152 tert-butyl 6-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)indole-1-carboxylate 147 153 3-(4-amino-3-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 148 154 tert-butyl (4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)- 3,5-difluorophenyl)carbonate 149 155 3-(2,6-difluoro-4-hydroxybenzyl)-7-(2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 150 156 3-(3-aminobenzyl)-7-(5-ethyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 151 157 3-(3-aminobenzyl)-7-phenyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 152 158 7-(2-furyl)-3-(6-indolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 153 159 7-(2-furyl)-3-(5-indolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 154 160 7-(2-furyl)-3-(7-indolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 155 161 3-(5-fluoro-2-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 156 162 3-(2,6-difluoro-4-methoxybenzyl)-7-(2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 157 163 tert-butyl N-(2-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)benzyl)carbamate 158 164 3-(1H-benzothiazol-5-ylmethyl)-7-(2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 159 165 7-(2-furyl)-3-(2-methoxy-4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 160 166 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)phenylacetamide 161 167 3-(2-aminomethylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 162 168 3-(3-(N,N-dimethylamino)benzyl)-7-(2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 163 169 3-(4-difluoromethoxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 164 170 7-(2-furyl)-3-(6-phthalimidomethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 165 171 3-(3-amino-4-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 166 172 3-(2,3-dihydrobenzofuran-5-ylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 167 173 3-(5-bromo-2-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 168 174 7-(2-furyl)-3-(2,3,5-trifluorobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 169 175 3-(2-fluoro-5-iodobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 170 176 7-(2-furyl)-3-(2-furylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 171 177 3-(2-amino-5-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 172 178 tert-butyl (5-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)- 2-nitrophenyl)carbonate 173 179 3-(4-amino-3-hydroxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 174 180 3-(4-amino-3-fluorobenzyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 175 181 3-(3-aminobenzyl)-7-(1H-pyrazol-3-yl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 176 182 7-(2-furyl)-3-(3-hydroxy-4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 177 183 N-(6-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2- pyridylmethyl)acetamide 178 184 N-(2-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)benzyl)acetamide 179 185 7-(2-furyl)-3-(3-thienylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 180 186 3-(3-amino-2-methylbenzyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 181 187 7-(2-furyl)-3-(3-methyl-2-thienyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 182 188 3-(6-allyloxymethyl-2-pyridylmethyl)-N,N- diallyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 183 189 3-(6-methoxymethyl-2-pyridylmethyl)-7-(5- methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 184 190 3-(4-aminobenzyl)-7-(5-methyl-2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 185 191 3-(6-allyloxymethyl-2-pyridylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- amine 186 192 3-(6-allyloxymethyl-2-pyridylmethyl)-7-(5- methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 187 193 7-(2-furyl)-3-(3-isopropyl-4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 188 194 7-(2-furyl)-3-(quinolin-2-ylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 189 195 7-(2-furyl)-3-(4-(N-methylamino)benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 190 196 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(6-methyl-2- pyridyl)propanone 191 197 3-(3-aminobenzyl)-7-(1H-pyrrol-2-yl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 192 198 3-(3-nitrobenzyl)-7-(2-pyridyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 193 199 N-(4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)phenyl)acetamide 194 200 7-(2-furyl)-3-(4-nitro-2-(2- trimethylsilylethoxy)methoxybenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 195 201 3-(3-ethyl-4-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 196 202 7-(2-furyl)-3-(2-(2-thienylethyl))-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 197 203 7-(2-furyl)-3-(6-isopropyl-2-pyridylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 198 204 7-(2-furyl)-3-(1-(2H-tetrahyropyran-2- yl)indazol-5-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 199 205 3-(4,6-diisopropyl-2-pyridylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 200 206 7-(2-furyl)-3-(5-indazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 201 207 7-(2-furyl)-3-(2-hydroxy-4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 202 208 7-(2-furyl)-3-(6-vinyl-2-pyridylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 203 209 tert-butyl 5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-carboxylate 204 210 tert-butyl 3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)indole-1-carboxylate 205 211 6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)pyridine-2-carboxaldehyde 206 212 tert-butyl 2-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)indole-1-carboxylate 207 213 3-(2-indolylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 208 214 3-(5-ethyl-2-thienylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 209 215 7-(2-furyl)-3-(3,4-methylenedioxybenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 210 216 3-(4-amino-3-ethylbenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 211 217 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-phenylethanone 212 218 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- methyl)phenyl)thiophene-2-carboxamide 213 219 7-(2-furyl)-3-(6-hydroxymethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride 214 220 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- methyl)phenyl)-3,3-dimethylbutanamide 215 221 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- methyl)phenyl)cyclopropanecarboxamide 216 222 7-(2-furyl)-3-(6-n-propyl-2-pyridylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 217 223 7-(2-furyl)-3-(6-isobutyloxymethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 218 224 3-(6-bromomethyl-2-pyridylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 219 225 3-(4-amino-3-isopropylbenzyl)-7-(2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 220 226 3-(6-cyanomethyl-2-pyridylmethyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 221 227 3-(4-hydroxybenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 222 228 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(4-nitrophenyl)ethanone 223 229 4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylacetyl)-benzonitrile 224 230 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)phenyl)propanesulphonamide 225 231 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)phenyl)-5-chloro-2- thiophenesulphonamide 226 232 7-(2-furyl)-3-(6-(N-methylamino)methyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride 227 233 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(4-(N,N- diethylamino)phenyl)ethanone 228 234 7-(2-furyl)-3-(6-isopropyl-3-pyridylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 229 235 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(4-methoxyphenyl)ethanone 230 236 tert-butyl 7-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)- 5-chloroindole-1-carboxylate 231 237 3-(5-chloro-7-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 232 238 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)phenyl)-3,5-dimethylisoxazol-4- ylsulphonamide 233 239 3-(6-(N,N-dimethylamino)methyl-2- pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 234 240 7-(2-furyl)-3-(6-methylthiomethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 235 241 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(2-nitrophenyl)ethanone 236 242 N-(3-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- ylmethyl)phenyl)-1,2-dimethyl-1H-imidazol- 4-ylsulphonamide 237 243 N,N-bis(6-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2- pyridylmethyl)methanesulphonamide 238 244 7-(2-furyl)-3-(6-methylsulphonylmethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 239 245 N-(6-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2- pyridylmethyl)-N-methyl methanesulphonamide 240 246 3-(3-aminobenzyl)-7-(4,5-dimethyl-2- thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 241 247 3-(4-amino-2-fluorobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 242 248 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-indanone 243 249 7-(2-furyl)-3-(5-methyl-7-indolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 244 250 N-(4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2- methylphenyl)formamide 245 251 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-phenylpropanone 246 252 3-(7-fluoro-5-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 247 253 7-(2-furyl)-3-(6-isopropoxymethyl-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 248 254 3-(6-ethyl-2-pyridylmethyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 249 255 3-(4-chloro-5-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 250 256 3-(7-bromo-5-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 251 257 3-(6-chloro-5-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 252 258 3-(3-(4-fluorobenzylamino)benzyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 253 259 3-(6-ethoxy-2-pyridylmethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 254 260 3-(6-ethoxy-2-pyridylmethyl)-7-(5-methyl-2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 255 261 3-(3-(2-pyridylmethylamino)benzyl)-7-(2- furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 256 262 7-(2-furyl)-3-(1-(4- trifluoromethylphenyl)ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 257 263 3-(6-fluoro-5-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 258 264 3-(5-fluoro-2-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 259 265 3-(3,5-dimethyl-4-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 260 266 3-(1-(3-fluorophenyl)ethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 261 267 3-(7-chloro-5-indolyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 262 268 3-(4-amino-3,5-dimethylbenzyl)-7-(2-furyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 263 269 3-(1-(3-aminophenyl)ethyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 264 270 7-(2-furyl)-3-(6-(2-methoxyethyl)-2- pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 265 271 7-(2-furyl)-3-(1-(5,6-dimethyl-2- pyridyl)propyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 266 272 3-(3-nitrobenzyl)-7-(1H-pyrazol-3-yl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride 267 273 7-(5-methyl-2-furyl)-3-(2-methyl-3- nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 268 274 7-(5-methyl-2-furyl)-3-(4-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 269 275 tert-butyl N-(4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3- ylmethyl)phenyl)-N-methylcarbamate 270 276 tert-butyl 2-(5-amino-3-(3-nitrobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-7-yl)pyrrole-1- carboxylate 271 277 7-(4,5-dimethylthiazol-2-yl)-3-(3- nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 272 278 3-(2-fluoro-4-nitrobenzyl)-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-5-amine 273 279 tert-butyl 7-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)- 5-methylindole-1-carboxylate 274 280 ethyl N-(4-(5-amino-7-(2-furyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)- 2-methylphenyl)carbamate

[0165] The general synthetic methods used for the preparation of these Examples are set out below as Methods A to BH. Table 2 sets out the Method used for each Example, together with analytical data.

[0166] HPLC is carried out using the following conditions: Column. Waters Xterra RP 18 (50×4.6 mm); Particle size 5 &mgr;M; Mobile phase MeOH: 10 mM aq NH4OAc (pH 7 buffer); Gradient 50:50 isocratic for 1 min. then linear gradient 50:50 to 80:20 over 5 min. then 80:20 isocratic for 3 min.; Flow rate 2.0 mL/min.; Detection wavelength &lgr;=230 nM. Retention times are provided.

[0167] Method A

[0168] 7-(2-Furyl)-1H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 1)

[0169] A solution of 7-chloro-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (570 mg, 3.34 mmol) in N-methyl-2-pyrrolidinone (4 mL) was treated with PdCl2(PPh3)2 (117 mg, 0.17 mmol) and 2-(tributylstannyl)furan (1.05 mL, 1 mmol), stirred at 80° C. for 5 h, diluted with EtOAc, filtered through a silica pad and concentrated in vacuo. The residue was triturated with diethyl ether and the title compound isolated as a yellow solid (438 mg, 65%).

[0170] Method B

[0171] 3-(2-Fluorobenzyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 3)

[0172] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (101 mg, 0.5 mmol) in DMF (2 mL), at 0° C., was treated with NaH (20 mg, 60%, 0.5 mmol), stirred for 20 mins then treated with 2-fluorobenzyl bromide (60 &mgr;L, 0.5 mmol). The reaction mixture was allowed to warm to room temperature, stirred for 1 h, quenched with water, extracted with EtOAc, dried (MgSO4) and concentrated in vacuo. The crude product was purified by chromatography (EtOAc:Heptane, 1:4—EtOAc:Heptane, 2:1) to give N,N-bis(2-fluorobenzyl)-3-(2-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (Example 2) (28 mg, 11%) as a yellow solid and the title compound (34 mg, 22%) as a yellow solid.

[0173] Method C

[0174] 3-(3-Aminobenzyl)7(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimiidine-5-Amine (Example 5)

[0175] A solution of 7-(2-furyl)-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine (152 mg, 0.45 mmol) in EtOH (2 mL) at 50° C. was treated with a solution of SnCl2 (305 mg, 1.35 miol) in conc. HCl (0.7 mL), stirred for 2 h, cooled, diluted with water, basified to pH 10 (5-M, NaOH) and filtered to give the titlecompound (127 mg, 92%) as a white solid.

[0176] Method D

[0177] N-(3-(5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Yl)Methyl)Phenyl-(1-Methyl-1H-Imidazol-4-Yl)Sulphonamide (Example 9)

[0178] A solution of 3-(3-aminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (125 mg, 0.41 mmol) in DMF (2 mL) was treated with Et3N (85 SAL, 0.61 mmol) and 1-methylimidazole-4-sulphonyl chloride (74 mg, 0.41 mmol), stirred at room temperature overnight, poured into water, extracted with EtOAc, dried (MgSO4) and concentrated in vacuo. The crude product was purified by chromatography [SiO2; EtOAc:MeOH (1:10)] to give the title compound (26 mg, 14%) as a cream solid.

[0179] Method E

[0180] 5-Amino-N-benzyl-7-(2Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Ylcarboxamide (Example 10)

[0181] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (202 mg, 1.0 mmol) in DMF (3 mL) was treated with benzyl isocyanate (123 &mgr;L, 1.0 mmol) and a catalytic amount of DMAP, stirred at room temperature overnight, diluted with EtOAc and filtered to give the tide compound (62 mg, 19%) as a peach coloured solid.

[0182] Method F

[0183] Ethyl 5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Ylacetate (Example 14)

[0184] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (101 mg, 0.5 mmol) in DMF (4 mL) was treated with 4-(NN-dimethylamino)pyridine (5 mg, 0.04 mmol) and ethyl bromoacetate (55 &mgr;L, 0.5 mmol), stirred at room temperature for 16 h and purified directly by chromatography [SiO2; EtOAc:Heptane (1:2)] to give the title compound (50 mg, 35%) as a white solid.

[0185] Method G

[0186] 7-2-Furyl)-3-(3-Hydroxybenzyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine5-Amine (Example 18)

[0187] A solution of 7-(2-furyl)-3-(3-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine (119 mg, 0.37 mmol) in dichloromethane (20 mL) at 0° C. was treated with boron tribromide (1-M in dichloromethane, 8.8 mL, 8.8 mmol) portion-wise over 3 days, concentrated in vacuo and isolated by filtration to give the title compound (114 mg, 100%) as a yellow solid.

[0188] Method H

[0189] 6-(5-Methyl-2-Furyl)-5-Nitropyrimidine-2,4-Diamine

[0190] A solution of 6-chloro-5-nitropyrimidine-2,4-diamine (10 g, 60% pure, 32 mmol) in THF (300 mL) was treated with saturated aq NaHCO3 (75 mL), 5-methylfuran-2-boronic acid (7.33 g, 0.058 mol) and Pd(PPh3)4 (1 g, 0.865 mmol) and refluxed with vigorous stirring under argon overnight. The mixture was cooled to room temperature, diluted with EtOAc (400 mL) and water (300 mL), filtered to remove insoluble material and the filtrate was extracted with EtOAc (2×100 mL). The combined organic phase was dried (MgSO4), concentrated in vacuo and the resulting solid triturated with dichloromethane and filtered to give the title compound (6 g, 72%) as a yellow solid; mp 196.3-196.9° C.; IR &ngr;max (Nujol)/cm−4 3442, 3169, 2930, 1629, 1463, 1377, 1027, and 790; NMR &dgr;H (400 MHz, DMSO) 7.40 (2H, br s), 7.09 (2H, br s), 6.87 (1H, dd, J 0.5, 3.2 Hz), 6.26 (2H, dd, J 1.0, 3.3 Hz) and 2.28 (3H, s).

[0191] Method I

[0192] 6-(5-Methyl-2-Furyl)Pyrimidine-2,4,5-Triamine

[0193] A suspension of 6-(5-methyl-2-firyl)-5-nitroprdine-2,4-diamine (6.6 g, 29.6 mmol) and 10% Pd/C (0.66 g) in. MeOH (100 mL) was heated at 40° C. under an atmosphere of H2 for 3 h, cooled to room temperature, filtered through Celite, and concentrated in vacuo to give the title compound (5.8 g, 99%) as an off-white solid; IR &ngr;max (DR)/cm−1 3333, 2237, 1634, 1458, 1237, 1025, 963 and 828; NMR &dgr;H (400 MIz, DMSO) 6.77 (1H, dd, J 0.5, 3.2 Hz), 6.21-6.17 (3H, m), 5.14 (2H, s), 4.21 (2H, s), and 2.35 (3H, s).

[0194] Method J

[0195] 7-(5-Methyl-2-Furyl)-1H-[1,2,3]Triazolo[4,5-Dl]Primidine-5-Amine (Example 19)

[0196] A solution of 6-(5-methyl-2-furyl)pyrimidine-2,4,5-triarnine (5.8 g, 30.1 mmol) in dioxane (116 mL) was treated with isoamyl nitrite (4.1 mL, 30.5 mmol), heated at 80° C. for 3.5 h, cooled to room temperature and the resulting precipitate was filtered, washed with dioxane (10 mL) and heptane (2×15 mL) then triturated with heptane and filtered to give the title compound (4.7 g, 77%) as a sandy solid.

[0197] Method K

[0198] 7-(1H-Pyrazol-3-Yl)-1H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 21)

[0199] A solution of 7-(1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazol-3-yl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (120 mg, 0.361 mmol) in MeOH (2 nmL) was treated with HC1 (4-M in dioxan, 1 mL), stirred for 2 h, filtered and the resulting solid washed with Et2O to give the title compound (76 mg, 100%) as a yellow solid.

[0200] Method L

[0201] (2-Amino-6-(2-Furyl)-5-Nitropyrinidin-4-Yl) 4-Methylbenzenesulphonate

[0202] A suspension of 2-amino-6-(2-furyl)-5-nitropyrimidine4(1H)-one (1.00 g, 4.50 mmol) in dichloromethane (50 mL) was treated with triethylamine (0.941 mL, 6.75 mmol) and p-toluenesulfonyl chloride (944 mg, 4.95 mmol), stirred for 1 h, diluted with dichloromethane (50 mL), washed with 2-M HCl (20 mL), dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (2:1)] to give the title compound (410 mg, 24%) as a yellow solid; NMR &dgr;H (400 Z, CDCl3) 7.95 (2H, d, J 8.5 Hz), 7.59-7.57 (1H, m), 7.39 (2H, d, J 8.5 Hz), 7.23-7.21 (1H, m), 6.59-5.39 (2H, br s), 2.48 (3H, s); Retention time 5.68 min.

[0203] Method M

[0204] 6-(2-Furyl)-5-Nitro-N4-(2-Pyridylmethyl)Pyrilidine-2,4-Diamine

[0205] A solution of (2-amino-6-(2-furyl)-5-nitropyrimidin-4-yl) 4-methylbenzenesulphonate (478 mg, 1.27 mmol) in dimethoxyethane (15 mL) was treated with triethylarnine (0.531 mL, 3.81 mmol) and 2-pyridinemethylamine (0.393 mL, 3.81 mmol), stirred for 16 h, poured into water (100 mL) and the resulting solid was filtered to give the title compound (275 mg, 69%) as a yellow solid; NMR &dgr;H (400 MHz, CDCl3) 8.70-8.58 (2H, m), 7.70-7.66 (1H, m), 7.55-7.54 (1H, m), 7.28 (1H, d, J 8.0 Hz), 7.24-7.20 (1H, m), 7.07-7.06 (1H, m), 6.54-6.52 (1H, m), 5.26 (2H, br s) and 4.83 (2H, d, J 5.0 Hz); Retention tim 1.44 min.

[0206] Method N

[0207] 7-(2-Furyl)-3-(2-Pyridylmethyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrnidine-5-Amine (Example 24)

[0208] A solution of 6-(2-frryl)-5-nitro-N4-(2-pyridylmethyl)pyrimidine-2,4diamine (270 mg, 0.864 mmol) and 10% Pd/C (92 mg, 0.086 mmol) in EtOH (30 mL) and EtOAc (10 mL) was stirred under an hydrogen atmosphere for 1 h, filtered through Celite and concentrated in vacuo. The resulting yellow oil was dissolved in in dioxane (25 mL), treated with isoamyl nitrite (0.109 mL, 0.815 mmol), stirred at 100° C. for 6 h, cooled to room temperature, filtered through Celite, concentrated in vacuo and triturated with Et2O to give the title compound (110 mg, 46%) as a yellow solid.

[0209] Method O

[0210] (5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Yl)Acetic Acid (Example 26)

[0211] A solution of ethyl 5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylacetate (547 mg, 1.89 mmol) in MeOH (5 mL) was treated with aqueous NaOH (2 mL, 2-M, 4 rnmol), refluxed for 10 min, cooled, acidified with aqueous HCl (1-M), filtered and dried to give the title compound (417 mg, 85%) as a white solid.

[0212] Method P

[0213] (5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Yl)-N-(3-Chlorophenyl)Acetamn (Example 31)

[0214] A suspension of (5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetic acid (140 mg, 0.5 mmol) in DMP (1 mL) was treated with carbonyl dlimidazole (81 mg, 0.5 mmol), stirred at room temperature for 1 h, treated with 3-chloroaniline (53 &mgr;L, 0.5 rnmol) and the mixture heated to 50° C. for 16 h. The reaction mixture was cooled, diluted with water (3 mL) and filtered to give the title compound (94 mg, 48%) as a cream solid.

[0215] Method Q

[0216] 3-(2-Fluorobenzyl)-7-(2-Thiazolyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 34)

[0217] A stirred solution of thiazole (0.10 mL, 1.43 mmol) in dry THEF (5 mL) at −78° C., under argon was treated with n-BuLi (0.9 mL, 1.6-M in hexanes, 1.43 mmol), stirred for 30 min, treated with a solution of ZnCl2 (1.8 mL, 1-M in Et2O, 1.80 mmol) and allowed to warm gradually to room temperature. The mixture was treated with 7-chloro-3-(2-fluorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (200 mg, 0.714 mmol) and Pd(PPh3)4 (50 mg), refluxed for 2 h and partitioned between saturated NH4Cl (20 mL) and EtOAc (20 mL). The organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; iso-hexane:EtOAc (1:1)) to give the title compound (70 mg, 30%) as a cream solid.

[0218] Method R

[0219] N-(2-Amino-6-(2-Furyl)-5-Nitropyrimidine-4-Yl)-6-Chloropyridine-3-Carboxainide

[0220] A solution of 6-(2-furyl)-5-nitropyrimidine-2,44diamnine (500 mg, 2.26 mmol) in pyridine (10 mL) was treated with 6-chloronicotinoyl chloride (438 mg, 2.49 mmol), stirred for 16 h at 80° C., cooled to room temperature, poured into water (100 mL) and extracted with EtOAc (2×25 mL) and the combined organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (3:2)] to give the title compound (430 mg, 82%) as a yellow solid; NMR &dgr;H (400 MH, DMSO) 11.14 (1H, s), 8.86 (1H, d, J 2.5 Hz), 8.27 (1H, dd, J 8.5, 2.5 Hz), 7.93 (1H, m), 7.77 (2H, br s), 7.65 (1H, d, J 7.5 Hz), 7.09 (1H, d, J 4.5 Hz), 6.72-6.70 (1H, m); Retention time 2.41 min.

[0221] Method T

[0222] 6Chloro-N-(7-(2-Furyl)-1H,2,3]Triazolo[4,5-D]Pyrimidin-5-Yl)Pyridine-3-Carboxamide (Example 44)

[0223] A solution of N-(2-amino-6-(2-frryl)-5-nitropyrimidine-4-yl)-6-chloropyridine-3-carboxamide (153 mg, 0.423 mmol) and 10% Pd/C (82 mg, 42.3 &mgr;mol) in EtOH (20 nal.) and EtOAc (5 mL) was stirred under an hydrogen atmosphere for 3 h, filtered through Celite and concentrated in vacuo to give N-(2,5-diamino-6-(2-furyl)pyrimidin4-yl)-6-chloropyridine-3-carboxamide as a yellow oil. A solution of this product in EtOH (5 mL) and 2-M HCl (5 mL) at 0° C. was treated dropwise with an ice-cold solution of sodium nitrite (87 mg, 1.27 mmol) in water (2 mL). The mixture was stirred at 0° C. for 1 h, stirred at room temperature for 1 h, neutralised with 5-M NaOH, stirred for 16 h and the resulting solid was filtered to give title compound (40 mg, 28%) as a brown solid.

[0224] Method U

[0225] 6-Chloro-N-(3-Nitrobenzyl)Pyrimidine-2,4,5-Triamine

[0226] A mixture of 4,6-dichloropyrimidine-2,5-diamine (700 mg, 3.91 mmol), 3-nitrobenzylamine hydrochloride (885 mg, 4.69 mmol) and triethylamine (1.6 mL, 11.7 mmol) in n-BuOH (20 nmL) was refluxed for 17 h, concentrated in vacuo and the residue partitioned between EtOAc (10 mL) and H2O (5 mL). The organic phase was dried (MgSO4) and concentrated in vacuo to give the title compound as an orange solid (906 mg, 76%) which was used in the next reaction without further purification; NMR &dgr;H (400 MHz, CDCl3) 8.16 (1H, s), 8.10 (1H, d, J 8.0 Hz), 7.80 (1H, d, J 7.5 Hz), 7.62 (1H, t, J 7.5 Hz), 7.25 (1H, t, J 6.0 Hz), 5.69 (2H, s), 4.67 (2H, d, J 6.0 Hz) and 3.93 (2H, br s).

[0227] Method V

[0228] 3-Chloromethyl-N,N-Dimethylbenzamide

[0229] A solution of 3-(chloromethyl)benzoyl chloride (426 &mgr;L, 3 rumol) and Et3N (626 &mgr;L, 4.5 mmol) in THF (5 mL) was treated with dimethylamine (1.5 mL, 2-M in TBF, 3 mmol), stirred at room temperature for 1 h, poured into water, extracted with EtOAc, dried (MgSO4) and concentrated in vacuo to give the title compound (580 mg, 98%) as a colourless oil; NMR &dgr;H (400 MHz, CDCl3) 7.46-7.34 (4H, m), 4.59 (2H, s), 3H, s) and 2.98 (3H, s); Anal. Calcd for C12H12N6O2•0.2 H2O: C, 49.38; H, 4.28, N, 28.79

[0230] Found: C, 49.25; H, 4.09; N, 28.47.

[0231] Method W

[0232] 7-(2-Furyl)-3(2-Methoxy5-Nitrobenzyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 66)

[0233] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrmidine-5-amine (606 mg, 3 mmol) in DMF (5 mL) at 0° C., was treated with CsCO3 (977 mg, 3 mrnol), stirred for 1 h, treated with 2-methoxy-5-nitrobenzyl bromide (738 mg, 3 mmol) and stirred at room temperature for 1 h. The reaction mixture was diluted with water (10 mL), filtered and the resulting solid purified by chromatography [SiO2; EtOAc:Heptane (2:1)] to give the title compound (279 mg, 25%) as a yellow solid.

[0234] Method X

[0235] 3-(2-Fluorobenzyl)-7-(5-Oxazolyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 69)

[0236] A stirred solution of oxazole (138 mg, 2.0 mmol) in dry TBF (10 mL) at −78° C., under argon was treated with n-BuLi (1.25 mL, 1.6-M in hexanes, 2.0 mmol), stirred for 30 min, treated with a solution of ZnCl2 (2.0 mL, 1-M in Et2O, 2.0 mmol)) and allowed to warm gradually to room temperature. The mixture was treated with 7-chloro-3-(2-fluorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (280 mg, 1.0 mmol) and Pd(PPh3)4 (100 mg), refluxed for 4 h and partitioned between saturated NH4Cl solution (10 mL) and EtOAc (10 mL). The organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; iso-hexane:EtOAc (1:1), then neat EtOAc] to give the title compound (6 mg, 2%) as a beige solid.

[0237] Method Y

[0238] 3-(2-Fluorobenzyl)-7-(1H-Triazol-4-Yl)-3H-[1,2,3]Triazolo[4,5-D]Pyriniie-5-Amine (Example 80)

[0239] A mixture of 7-chloro-3-(2-fluorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (145 mg, 0.50 mmol), tributyl 1-(2-(trimethylsilyl)ethoxymethyl)-1H-triazol-5-ylstannane (336 mg, 0.75 mmol) and Pd(PPh3)2Ck2 (35 mg, 0.05 mmol) in DMF (2 mL) was shaken at 80° C. for 17 h then purified directly by chromatography [SiO2; iso-hexane:EtOAc (2:1)] to give 3-(2-fluorobenzyl)-7-(1-(2-trimethylsilyl)ethoxymethyl)-1H-triazol-5-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine as a colourless oil. This material was dissolved in MeOH (1 mL), treated with a solution of HCl (0.5 mL, 4-M in dioxane), stirred for 17 h, concentrated in vacuo and the residue triturated with Et2O to give the title compound (16 mg, 10%) as an off-white solid.

[0240] Method Z

[0241] 3-(4-Hydroxylamino-2Pyridyhuethyl)7-(5-Methyl-2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 87)

[0242] A solution of 7-(5-methyl-2-furyl)-3-(4-nitro-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (60 mg, 0.17 mmol) in EtOH (40 mL), MeOH (20 mL) and water (15 mL) was treated with ammonium chloride (280 mg, 5.23 mmol) and zinc (138 mg, 2.05 miol), stirred for 1 h, filtered through Celite, concentrated in vacuo to ˜20 mL, diluted with brine (20 mL), extracted with EtOAc (3×20 mL) and the combined organic phase dried (MgSO4) and concentrated in vacuo to give the title compound (40 mg, 73%) as a yellow solid.

[0243] Method AA

[0244] 3-(3-Aminomethylbenzyl)-7-(1H-Pyrazol-3-Yl)-3H-[1,2,3]Triazolo[4,5D]Pyrimidine5-Amine (Example 101)

[0245] A stirred solution of the 7-(1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazol-5-yl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (330 mg, 1 mmol) in dry DMF (5 mL) was treated with NaH (40 mg, 60% in oil, 1 mmol), stirred for 15 min, treated with tert-butyl N-(3-(bromomethyl)benzyl)carbamate (300 mg, 1 mmol) and stirred for 1 h. The mixture was partitioned between EtOAc (20 mL) and H2O (20 mL), the organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; iso-hexane:EtOAc (1:1)]. The resulting yellow syrup was dissolved in MeOH (3 mL), treated with HCl (2 mL, 4M in dioxane), stired for 17 h and the resulting solid filtered to give the title compound (258 mg, 80%) as a cream solid.

[0246] Method AB

[0247] 2-Bromomethyl-6-(Methoxymethyl)Pyridine

[0248] A solution of 6-methoxymethyl-2-pyridinemethanol (860 mg, 5.64 mmol) and triphenylphosphine (1.78 g, 6.77 mmol) in dichloromethane (40 mL) at 0° C. was treated portion wise with CBr4 (2.80 g, 8.43 mmol), stirred for 1. h, concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (3:1)] to give the title compound (1.20 g, 99%) as a colourless oil; NMR &dgr;H (400 MHz, CDCl3) 7.71 (1H, t, J 8.0 Hz), 7.35 (2H, d, J 8.0 Hz), 4.58 (2H, s) and 4.54 (2H, s).

[0249] The following novel compounds were also synthesised by Method AB from the appropriate alcohol.

[0250] 2-Bromomethyl-4-Methylpyridine

[0251] NMR &dgr;H (400 MHz, CDCl3) 8.43 (1H, d, J 5.0 Hz), 7.26-7.25 (1H, m), 7.03 (1H, d, J 5.0 Hz), 4.51 (2H, s) and 2.36 (3H, s).

[0252] 2-Bromomethyl-6-Ethylpyridine

[0253] NMR &dgr;H (400 z, CDCl3) 7.60 (1H, t, J 7.5 Hz), 7.26 (1H, d, J 7.5 Hz), 7.08 (1H, d, J 7.5 Hz), 4.53 (2H, s), 2.82 (2H, q, J 7.5 Hz) and 1.30 (3H, t, J 7.5 Hz).

[0254] 4-Bromomethyl-2-Ethylpyridine

[0255] NMR &dgr;H (400 MHz, CDCl3) 8.51 (1H, d, J 5.0-Hz), 7.17-7.16 (1H, m), 7.13-7.11 (1H, m), 4.37 (2H, s), 2.84 (2H, q, J 7.5 Hz) and 1.32 (3H, t, J 7.5 Hz).

[0256] Tert-Butyl (4-Bromomethyl-3,5-Difluorophenyl) Carbonate

[0257] NMR &dgr;H (400 MHz, CDCl3) 6.80 (2H, m), 4.49 (2H, s) and 1.56 (91H, s).

[0258] 2-Fluoro-5-Iodobenzyl Bromide

[0259] NMR &dgr;H (400 MHz, DMSO) 7.94-7.91 (1H, dd, J2.5, 7.5 Hz), 7.76-7.71 (1H, m), 7.12-7.06 (1H, dd, J 8.5, 10.0 Hz) and 4.66-4.64 (2H, s).

[0260] 2-Allyloxymethyl-6-Bromomethylpyridine

[0261] NMR &dgr;H (400 MHz, CDCl3) 7.71 (1H, t, J 7.5 Hz), 7.40 (1H, d, J 7.5 Hz), 7.34 (1H, d, J 7.5 Hz), 6.03-5.93 (111, m), 5.37-5.32 (1H, m), 5.26-5.22 (1H, m), 4.64 (2H, s), 4.54 (2H, s) and 4.14-4.12 (2H1, m).

[0262] 4-Nitro2-(2-Trimethylsflylethoxy)Methoxybenzyl Br Mide

[0263] NMR &dgr;H (400 z, CDCl3) 7.99 (1H, d, J 2.0 Hz), 7.84 (1H, dd, J 8.4, 2.0 Hz), 7.49 (1H, d, J 8.4 Hz), 5.41 (2H, s), 4.55 (2H, s), 3.82 (2H, m), 0.96 (2H, m) and 0.01 (9H, s).

[0264] 2-Bromomethyl-4,6-Diisopropylpyridine

[0265] NMR &dgr;H (400 MHz, CDCl3) 7.12 (1H, s), 6.93 (1H, s), 4.52 (2H, s), 3.03 (1H, sept. J 7.0 Hz), 2.87 (1H, sept, J 7.0 Hz), 1.29 (6H, d, J 7.0 Hz) and 1.25 (6H, d, J 7.0 Hz).

[0266] 2-Bromomethyl-6-Isopropylpyridine

[0267] NMR &dgr;H (400 MHz, CDCl3) 7.63-7.59 (1H, m), 7.27-7.25 (1H, m), 7.10-7.08 (1H, m), 4.54 (2H, s), 3.06 (1H, sept, J 7.0 Hz) and 1.30 (6H, d, J 7.0 Hz).

[0268] 2-Bromomethyl-6-Vinylpyridine

[0269] NMR &dgr;H (400 MHz, CDCl3) 7.66 (1H, t, J 7.5 Hz), 7.34-7.28 (2H, m), 6.81 (bH, dd, J 10.5, 17.5 Hz), 6.22 (1H, dd, J 1.0, 17.5 Hz), 5.51 (1H, dd, J 1.0, 10.5 Hz) and 4.55 (2H, s).

[0270] 2-Bromomethyl-5-Ethylthiophene

[0271] NMR &dgr;H (400 MHz, DMSO) 6.85-6.82 (1X, d, J 3.5 Hz), 6.71-6.68 (1H, d, J 3.5 Hz), 4.59-4.55 (2H, s), 2.81-2.75 (2H, m) and 1.25-1.20 (3H, m).

[0272] 2-Bromomethyl-6-N-Propylpyridine

[0273] NMR &dgr;H (400 MHz, CDCl3) 7.59 (1H, t, J 7.5 Hz), 7.26 (1H, d, J 7.5 Hz), 7.06 (1H, d, J 7.5 Hz), 4.53 (211, s), 2.76 (2H, t, J 7.5 Hz), 1.74 (2H, t, J 7.5 Hz) and 0.97 (3H, t, J 7.5 Hz).

[0274] 2-Bromomethyl-6-Isobutyloxymethylpyridine

[0275] NMR &dgr;H (400 MHz, CDCl3) 7.71 (1H, t, J 7.5 Hz), 7.41 (1H, d, J 7.5 Hz), 7.33 (1H, d, J 7.5 Hz), 4.62 (2H1, s), 4.53 (2H, s), 3.33 (2H, d, J 6.5 Hz), 1.91-2.01 (1H, m) and 0.96 (6H, d, J 6.5 Hz).

[0276] 5-Bromomethyl-2-Isopropylpyridine

[0277] NMR &dgr;H (400 MHz, CDCl3) 8.54 (1H, m), 7.65 (1H, dd, J 2.5, 8.0 Hz), 7.16 (1H, d, J 8.0 Hz), 4.47 (2H, s), 3.07 (1H, sept, J 7.0 Hz) and 1.30 (6X, d, J 7.0 Hz).

[0278] 2-Bromomethyl-6-Isobutyloxymethylpyridine

[0279] NMR &dgr;H (400 MHz, CDCl3) 7.71-7.67 (1H, m), 7.42-7.40 (1H, m), 7.33-7.31 (1H, m), 4.63 (2H, S), 4.53 (2H, s), 3.75 (1H, sept, J 6.0 Hz) and 1.25 (6H, d, J 6.0 Hz).

[0280] Method AC

[0281] 2-Bromomethyl-4-Nitropyridine

[0282] A solution of 2-methylnitropyridine (1.79 g, 13.0 mmol) in CC14 (30 mL) was treated with N-bromosuccinimide (2.31 g, 13.0 mmol) and benzoyl peroxide (420 mg, 1.30 mmol), stirred at 80° C. for 16 h, cooled to room temperature, filtered through Celite, concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (15:1)] to give the title compound (700 mg, 25%) as a colourless oil; NMR 8H (400 IKL, CDCl3) 8.89 (1H, d, J 5.0 Hz), 8.19 (1H, d, J 2.0 Hz), 7.96 (1H, dd, J 5.0, 2.0 Hz) and 4.66 (2H, s).

[0283] The following novel compounds were also synthesised by bromination of the appropriate arylalkyl compounds using Method AC.

[0284] 2-Bromomethyl-6-Methyl-4-Nitropyridine

[0285] NMR &dgr;H (400 MHz, CDCl3) 7.99-7.98 (1H, m), 7.79 (1H, d, J 2.0 Hz), 4.60 (2H, s) and 2.71 (3H, s).

[0286] Tert-Butyl 7-Bromomethylindole-1-Carboxylate

[0287] NMR &dgr;H (400 MHz, CDCl3) 7.57 (1H, d, J 4.0 Hz), 7.55 (1H, dd, J 8.0, 1.5 Hz), 7.27 (1H, d, J 7.5 Hz), 7.19 (1H, t, J 7.5 Hz), 6.58 (1H, d, J 3.5 Hz), 5.24 (2H, s) and 1.68 (9H, s).

[0288] Tert-Butyl 5-Bromomethylindole-1-Carboxylate

[0289] NMR &dgr;H (400 MHz, CDCl3) 8.11 (1H, br d, J 8.5 Hz), 6.72 (1H, d, J 3.5 Hz), 7.59 (1H, d, J 1.5 Hz), 7.35 (1H, dd, J 8.5, 1.5 Hz), 6.54 (1H, d, J 4.0 Hz), 4.64 (2H, s) and 1.67 (9H, s).

[0290] Tert-Butyl 7-Bromomethyl-5-Chloroindole-1-Carboxylate

[0291] NMR &dgr;H (400 MHz, CDCl3) 7.58 (1H, d, J 3.5 Hz), 7.51 (1H, d, J 2.0 Hz), 7.27 (1H, m), 6.52 (1H, d, J3.5 Hz), 5.15 (2H, s), and 1.67 (9H, s).

[0292] Tert-Butyl 7-Bromomethyl-5-Methylindole-1-Carboxylate

[0293] NMR &dgr;H (400 MHz, CDCl3) 7.53 (1H, d, J 4.0 Hz), 7.32 (1H, s), 7.09 (1H, s), 6.49 (1H, d, J 3.5 Hz), 5.21 (2H, s), 2.41 (3H, s) and 1.66 (9H, s).

[0294] Tert-Butyl 5-Bromomethyl-7-Fluoroindole-1-Carboxylate

[0295] NMR &dgr;H (CDCl3) 7.65 (1H, d, J 4.0 Hz), 7.35 (1H, d, J 1.5 Hz), 7.07 (1H, dd, J 13.0, 1.5 Hz), 6.56 (1H, dd, J 3.5, 1.5 Hz), 4.56 (2H, s) and 1.65 (9H, s).

[0296] Tert-Butyl 5-Bromomethyl-4-Chloroindole-1-Carboxylate

[0297] NMR &dgr;H (400 MHz, CDCl3) 8.03 (1H, d, J 8.5 Hz), 7.63 (1H, d, J 4.0 Hz), 7.36 (1H, d, 8.5 Hz), 6.71 (1H, d, J 3.5 Hz), 4.75 (2H, s) and 1.67 (9H, s).

[0298] Tert-Butyl 7-Bromo-5-Bromomethylindole-1-Carboxylate

[0299] NMR &dgr;H (400 MHz, CDCl3) 7.57 (1H, s), 7.56-7.52 (2H, m), 6.54 (1H, d, J 3.5 Hz), 4.56 (2H, s) and 1.66 (9H, s).

[0300] Tert-Butyl 5-Bromomethyl-6-Chloroindolel-Carboxylate

[0301] NMR &dgr;H (400 MHz, CDCl3) 8.23 (1H, br s), 7.60 (1H, s), 7.58 (1H, d, J 3.5 Hz), 6.51 (1H, d, J4.5 Hz), 4.71 (2H, s) and 1.67 (9H, s).

[0302] Tert-Butyl 5-Bromomethyl-6-Fluoroindole-1-Carboxylate

[0303] NMR &dgr;H (400 MHz, CDCl3) 7.88 (1H, br, d, J 11.0 Hz), 7.57 (1H, d, J 4.0 Hz), 7.54 (1H, d, J 7.0 Hz), 6.52 (1H, d, J 4.5 Hz), 4.64 (2H, s) and 1.67 (9H, s).

[0304] Tert-Butyl 2-Bromomethyl-5-Fluoroindole-1-Carboxylate

[0305] NMR &dgr;H (400 MHz, CDCl3) 8.12 (1H, dd, J 9.0, 4.5 Hz), 7.15 (1H, dd, J 8.5, 2.5 Hz), 7.04 (1H, dt, J 9.0, 2.5 Hz), 6.66 (1H, s), 4.90 (2H, s) and 1.72 (9H, s).

[0306] Tert-Butyl 5-Bromomethyl-7-Chloroindole-1-Carboxylate

[0307] NMR &dgr;H (400 MHz, CDCl3) 7.56 (1H, d, J 4.0 Hz), 7.49 (1H, d, J 2.0 Hz), 7.37 (1H, s), 6.54 (1H, d, J 3.5 Hz), 4.56 (2H, s) and 1.65 (9H, s).

[0308] 2-(1-Bromopropyl)-5,6-Dimethylpyridine

[0309] NMR &dgr;H (400 MHz, CDCl3) 7.39 (1H, d, J 8.0 Hz), 7.18 (1H, d, J 8.0 Hz), 4.93 (1H, t, J 7.5 Hz), 2.49 (3H, s), 2.27 (3H, s), 2.29-2.24 (2H, m) and 1.02 (3H, t, J 7.0 Hz); MIZ 228 (M+H)+.

[0310] The following novel compound was synthesised by bromination of 2-(1-methoxypropyl)-6-methylpyridine using Method AC.

[0311] 2-Bromo-1-(6-Methylpyridin-2-Yl)Propanone

[0312] NMR &dgr;H (400 MHz, CDCl3) 7.91 (1H, d, J 7.5 Hz), 7.74 (1H, t, J 7.5 Hz), 7.35 (1H, d, J 7.5 Hz), 6.13 (1H, q, J7.0 Hz), 2.62 (3H, s) and 1.89 (3H, d, J7.0 Hz).

[0313] Method AD

[0314] Tert-Butyl 7-Methylindole-1-Carboxylate

[0315] A stirred solution of 7-methylindole (1.18g, 9 mmol) in dry ThF (50 mL) was treated with NaH (360 mg, 60% in oil, 9 mmol), stirred for 10 min, treated with di-tert-butyl dicarbonate (2.3 mL, 9.3 mmol), stirred for 1 h, treated with 4-(N,N-dimethylamino)pyridine (catalytic amount) and stirred for 1 h. The mixture was partitioned between EtOAc (50 mL) and saturated NH4Cl solution (30 mL) and the organic phase was dried (MgSO4), concentrated in vacuo, and purified by chromatography [SiO2; iso-hexane:EtOAc (5:1)] to give the title compound (2.35 g, 100%) as an orange oil; NMR &dgr;H (400 MHz, CDCl3) 7.51 (1H, d, J 4.0 Hz), 7.37 (1H, d, J 7.5 Hz), 7.13 (1H, t, J 7.5 Hz), 7.08 (1H, d, 7.5 Hz), 6.51 (1H, d, J 4.0 Hz), 2.64 (3H, s) and 1.63 (9H, s).

[0316] The following novel compounds were synthesised from the appropriate indoles using Method AD.

[0317] Tert-Butyl 5-Chloro-7-Methylindole-1-Carboxylate

[0318] NMR &dgr;H (400 MHz, CDCl3) 7.52 (1H, d, J 4.0 Hz), 7.35 (1H, d, J 2.0 Hz), 7.07 (1H, d, J 1.5 Hz), 6.46 (1H, d, J 3.5 Hz), 2.61 (3H, s), and 1.63 (9H, s).

[0319] Tert-Butyl 5,7-Dinethylind Le-1-Carboxylate

[0320] NMR &dgr;H (CDCl3) 7.48 (1H, d, J 4.0 Hz) 7.16 (1H, s), 6.92 (1H, s), 6.44 (1H, d, J 4.0 Hz), 2.60 (3H, s) 2.38 (3H, s) and 1.62 (9H, s).

[0321] Tert-Butyl 7-Fluoro-5-Methylindole-1-Carboxylate

[0322] NMR &dgr;H (CDCl3) 7.59 (1H, d, J4.0 Hz), 7.10 (IH, s), 6.84 (1H, d, J 13.5 Hz), 6.50-6.47 (1H, m), 2.40 (3H, s) and 1.64 (9H, s).

[0323] Tert-Butyl 4-Chloro-5-Methylindole-1-Carboxylate

[0324] NMR &dgr;H (400 MHz, CDCl3) 7.92 (1H, d, J 8.0 Hz), 7.57 (1H, d, J 3.5 Hz), 7.15 (1H, d, J 8.5 Hz), 6.66 (1H, d, J 3.5 Hz), 2.46 (3H, s) and 1.66 (9H1 s).

[0325] Tert-Butyl 7-Bromo-5-Methylindole-1-Carboxylate

[0326] NMR &dgr;H (400 MHz, CDCl3) 7.47 (1H, d, J 3.5 Hz), 7.35 (1H, s), 7.26 (1H, s), 6.44 (1H, d, J4.0 Hz), 2.38 (3H, s) and 1.64 (9H, s).

[0327] Tert-Butyl 6-Chloro-5-Methylindole-1-Carboxylate

[0328] NMR &dgr;H (400 MHz, CDCl3) 8.17 (1H, br s), 7.53 (1H, d, J 3.5 Hz), 7.38 (1H, s), 6.46 (1H, d, J 3.0 Hz), 2.44 (3H, s), 1.67 (9H, s).

[0329] Tert-Butyl 6-Fluoro-5-Methylindole-1-Carboxylate

[0330] NMR &dgr;H (400 MHz, CDCl3) 7.79 (1H, br d, J 10.5 Hz), 7.51 (1H, d, J 3.5 Hz), 7.30 (1H, d, J 7.5 Hz), 6.46 (1H, d, J 3.5 Hz), 2.34 (3H, s) and 1.66 (9H, s).

[0331] Tert-Butyl 5-Fluoro-2-Methylindole-1-Carboxylate

[0332] NMR &dgr;H (400 MHz, CDCl3) 8.04 (1H, dd, J 9.0, 4.5 Hz), 7.07 (1H, dd J 9.0, 2.5 Hz), 6.92 (1H, dt, J 9.5, 3.0 Hz), 6.27 (1H, s), 2.58 (3H, d, J 1.5 Hz) and 1.67 (9H, s).

[0333] Tert-Butyl 7-Chloro-5-Methylindole-1-Carboxylate

[0334] NMR &dgr;H (400 MHz, CDCl3) 7.50 (1H, d, J 3.5 Hz), 7.22 (1H, s), 7.14 (1H, s), 6.46 (1H, d, J 4.0 Hz), 2.38 (3H, s) and 1.64 (9H, s).

[0335] The following novel compound was synthesised from 2,6-difluoro-4-hydroxybenzyl alcohol using Method AD.

[0336] Tert-Butyl (3,5-Difluoro-4-Hydroxymethylphenyl) Carbonate

[0337] IR &ngr;max (DR)/cm−1 3388, 2983, 1775, 1605, 1446, 1396, 1373, 1289, 1146, 1072, 967 and 882; NMR &dgr;H (400 MHz, CDCl3) 6.79 (2H, m), 4.75 (2H, d, J 6.5 Hz), 1.84 (1H, t, J 6.5 Hz) and 1.56 (9H, s).

[0338] Method AE

[0339] 2,6-Difluoro-4-Hydroxybenzyl Alcohol

[0340] A mixture of 3,5difluorophenol (25 g, 0.19 mol) and KOH (85%, 12.7 g, 0.19 mol) was treated dropwise with water (50 mL), stirred at 60° C. for 1 h, treated dropwise with formaldehyde solution (37%, 15.6 mL, 0.19 mol) and water (50 mL) and stirred overnight at 40° C. The mixture was cooled, acidified with 6-M HCl, filtered and the resulting solid washed with water and dried to give the title compound (15 g, 49%) as a white solid: NMR &dgr;H (400 MHz, DMSO) 10.28 (1H, s), 6.43 (2H, m), 4.99 (1H, t, J 5.6 Hz) and 4.37 (2H,d,J5.6Hz).

[0341] Method AF

[0342] 7-(2-Furyl)-3-(6-Indolylmethyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 152)

[0343] A mixture of tert-butyl 6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl (135 mg, 4.08 mmol), and NaOMe (22 mg, 4.08 mmol) in MeOH (10 mL) was refluxed for 1 h, treated with NaOMe (110 mg, 20.4 mmol), refluxed for a further 4 h then stirred at room temperature for 17 h. The mixture was concentrated in vacuo to half volume and the resulting precipitate was filtered and washed with H2O to give the title compound (90 mg, 96%) as a cream solid.

[0344] Method AG

[0345] 3-(2,6-Difluoro-4-Methoxybeny)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 156)

[0346] A solution of 3-(2,6-difluoro-4-hydroxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride (130 mg, 0.34 mmol) in DUF (5 mL) at 0° C., was treated with CsCO3 (223 mg, 0.68 nmmol), stirred for 10 min, treated with methyl iodide (21 &mgr;L, 0.34 mmol) and stirred at room temperature for 30 min. The reaction mixture was diluted with water (10 mL) and filtered to give the title compound (122 mg, 100%) as a white solid.

[0347] Method AH

[0348] 2-Fluoro-5-Iodobenzyl Alcohol

[0349] A solution of 2-fluoro-5-iodobenzaldehyde (1.173 g, 4.692 mmol) in isopropanol (25 mL) was treated with sodium borohydride (0.379 g, 10.02 mmol), stirred at room temperature for 18 h, poured into water (125 mL), and extracted with isopropyl ether (2×25 mL). The combined organic phase was dried (Na2SO4), and concentrated in vacuo to give the title compound (1.187 g, 99%) as a pale yellow solid; NMR &dgr;H (400 MHz, CDCl3) 7.77 (1H, m), 7.57 (1H, m), 6.82 (1H, t, J 8.8 Hz), 4.73 (2H, d, J 6.1 Hz), and 1.79 (1H, t, J 6.1 Hz).

[0350] Method AI

[0351] 3-(Tert-Butoxycarbonyloxy)-4-Nitrobenzoic Acid

[0352] A solution of 3-hydroxy4nitrobenzoic acid (1.83 g, 10 mmol) in THF (10 mL) was treated with Et3N (3.4 mL, 24 mmol) and di-tert-butyl dicarbonate (2.40 mL, 11 mmol) and stirred at room temperature for 16 h. The reaction mixture was poured into 10% citric acid solution (20 mL), extracted with EtOAc (2 x 10 mL), dried (MgSO4) and concentrated in vacuo to give the title compound (2.36 g, 83%) as a cream solid; IR &ngr;max (Nujol)/cm−1 2985, 1772, 1717 and 1592; NMR &dgr;H (400 MHz, DMSO) 13.85 (1H, s), 8.26 (1H, d, J 8.5 Hz), 8.04 (1H, dd, J 8.5, 2.0 Hz), 7.98 (1H, d, J 2.0 Hz) and 1.49 (9H, s).

[0353] Method AJ

[0354] Tert-Butyl (5-Bromomethyl-2-Nitrophenyl) Carbonate

[0355] A solution of 3-(tert-butoxycarbonyloxy)Anitrobenzoic acid (2.26 g, 8 mmol) and N-methylmorpholine (1.85 mL, 16.8 mmol) in THP (20 mL) at 0° C., was treated with isobutylchloroformate (1.09 mL, 8.4 mmol) and stirred for l h. The reaction mixture was added to a cooled (−78° C.) solution of NABIL (605 mg, 16 mmol) in MeOH (16 nmL) and stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc (20 mL), washed with saturated NaHCO3 (10 mL) and 10% citric acid solution (10 mL), dried (MgSO4) and concentrated in vacuo to give tert-butyl (5-hydroxymethyl-2-nitrophenyl) carbonate (1.36 g, 86%) as a cream solid. This material was brominated directly using Method AB to give the title compound (961 mg, 58%) as a yellow oil: NMR &dgr;H (400 MHz, CDCl3) 8.09 (1H, d, J 8.4 Hz), 7.41 (1H, dd, J 8.4, 2.0 Hz), 7.34 (1H, d, J 2.0 Hz), 4.47 (2H, s) and 1.58 (9H, s).

[0356] Method AK

[0357] 3-(3-Nitrobenzyl)-7-(1H-Pyrazol-3-Yl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine Hydrochloride (Example 266)

[0358] A soluition of 7-chloro-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (306 mg, 1 mmol), 1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazol-5-ylboronic acid (2 mmol), Pd(PPh3)4 (100 mg) and saturated NaHCO3 (5 mL) in THF (20 mL) was refluxed for 2 h, diluted with water (20 mL), extracted with EtOAc(2 x 20 mL), dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; CH2Cl2 :EtOAc (6:1)] to give 3-(3-nitrobenzyl)-7-(1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazol-5-yl)-3-H[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (156 mg, 34%) as a pale yellow syrup.

[0359] A solution of 3-(3-nitrobenzyl)-7-(1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazol-5-yl)3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (156 mg, 0.34 mmol) in MeOH (2 mTL) was treated with 4-M HCl in dioxane (4 mL) stirred at room temperature for 2 h, concentrated in vacuo, triturated with Et20 and filtered to give the title compound (110 mg, 97%) as a yellow solid.

[0360] Method AL

[0361] 3-(6-Acetamidomethyl-2-Pyridylmethyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5D]Pyrimidine-5-Amine (Example 177)

[0362] A suspension of 7-(2-furyl)-3-(6-phthalimidomethyl-2-pyridylmethyl)-3-H[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (210 mg, 0.465 mmol) in EtOH (50 mL) was treated with ethylenediamine (62 &mgr;l, 0.929 mmol), stirred for 3 h at 90° C. and the resulting clear solution, cooled to room temperature and concentrated in vacuo to give 3-(6aminomethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine. A solution of this material in pyridine (10 mL) at 0° C. was treated with acetyl chloride (109 ml, 1.53 mmol), stirred for 10 min, poured into water (70 mL), extracted with EtOAc (3×20 mL) and the combined organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; EtOAc] to give the title compound (110 mg, 65%) as a beige solid.

[0363] Method AM

[0364] 3-(6-Allyloxymethyl-2-Pyridylmethyl)-N,N-Diallyl-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 182)

[0365] A solution of 7-(2-furyl)-3-(6-hydroxymethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (120 mg, 0.377 mmol) in DMF (5 mL) at 0° C. was treated with sodium hydride (30 mg, 0.743 mmol), stirred for 15 min, treated with allyl bromide (96 &mgr;l, 1.11 mmol), stirred at room temperature for 16 h, concentrated in vacuo to ˜2 mL and purified by chromatography [SiO2; isohexane:EtOAc (3:1)] to give the title compound (50 mg, 30%) as a yellow solid.

[0366] Method AN

[0367] 6-Allyloxymethyl-2-Pyridinemethanol

[0368] A solution of 2,6-pyridinedimethanol (5.0 g, 35.9 mmol) in DMP (30 mL) at 0° C. was treated with sodium hydride (1.44 g, 35.9 mmol), stirred for 30 min, treated with allyl bromide (3.42 ml, 39.5 mmol), stirred for 16 h at room temperature, poured into water (150 mL), extracted with EtOAc (3×30 mL) and the combined organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (3:1 to 1:1)] to give the title compound (1.56 g, 24%) as a colourless oil: NMR &dgr;H (400 MD, CDCl3) 7.69 (1H, t, J 7.5 Hz), 7.37 (1H, d, J 7.5 Hz), 7.13 (1H, d, J 7.5 Hz), 6.04-5.93 (1H, m), 5.38-5.21 (2H, m), 4.74 (2H, d, J 5.0 Hz), 4.65 (2H, s), 4.15-4.09 (2H, m) and 3.76 (1H, t, J 5.0 Hz).

[0369] The following novel compounds were synthesised from the appropriate alcohols by Method AN

[0370] 2-(1-Methoxypropyl)-6-Methylpyridine

[0371] NMR &dgr;H (400 MHz, CDCl3) 7.58 (1H, t, J 8.0 Hz), 7.18 (1H, d, J 8.0 Hz), 7.04 (1H, d, J 8.0 Hz), 4.17 (1H, dd, J 5.5, 7.5 Hz), 3.30 (3H, s), 2.55 (3H, s), 1.84-1.69 (2H, m) and 0.93 (3H, t, J 7.5 Hz).

[0372] 6-Isobutyloxymethylpyridine-2-Methanol

[0373] NMR &dgr;H (400 MHz, CDCl3) 7.69 (1H, t, J 7.5 Hz), 7.37 (1H, d, J 7.5 Hz), 7.13 (1H, d, J 7.5 Hz), 4.74 (2H, s), 4.63 (2H, s), 3.94 (1H, br s), 3.33 (2H, d, J 6.5 Hz), 1.91-2.01 (1H, m) and 0.96 (6H, d, J 6.5 Hz).

[0374] 6-Isobutyloxymethylpyridine-2-Methanol

[0375] NMR &dgr;H (400 MHz, CDCl3) 7.70-7.66 (1H, m), 7.39 (1H, d, J 7.5 Hz), 7.11 (1H, d, J 8.0 Hz), 4.74 (2H, s), 4.64 (2H, s), 3.75 (1H, sept, J 6.0 Hz) and 1.25 (6H, d, J 6.0 Hz).

[0376] Method AO

[0377] 3-Isopropyl-4-Nitrobenzyl Bromide

[0378] A solution of 4-nitrobenzyl bromide (432 mg, 2 mmol) in ThF (5 mL) at −70° C., was treated dropwise with isopropylmagnesium chloride (1 mL, 2-M in Et2O, 2 mmol), stirred for 1 h, treated with DDQ (499 mg, 2.2 mmol) and stirred at room temperature for 16 h. The reaction mixture was poured into water (10 mL), extracted with EtOAc (2×10 mL), dried (MgSO4), concentrated in vacuo and filtered. The resulting solid was purified by chromatography [SiO2; EtOAc:Heptane (1:4)] to give the title compound (183 mg, 35%) as a pale yellow solid which was used in the next reaction without further purification.

[0379] The following novel compound was also synthesised from 4-nitrobenzyl bromide using Method AO

[0380] 3-Ethyl-4-Nitrobenzyl Bromide

[0381] NMR &dgr;H (400 MHz, CDCl3) 7.87 (1H, d, J 8.3 Hz), 7.37 (1H, s), 7.35 (1H, d, J 8.3 Hz), 4.47 (2H, s), 2.92 (2H, q, J 7.5 Hz) and 1.30 (3H, t, J 7.5 Hz).

[0382] Method AP

[0383] 2-(Trimethylsilyl)Ethoxymethyl 4-Nitro-2-((2-Trimethylsilyl)Ethoxymethoxy)Benzoic Acid

[0384] A solution of 2-hydroxy-4-nitrobenzoic acid (1.83 g, 10 mmol) in TPF (20 mL), was treated with NN-diisopropylethylamine (3.92 mL, 22 mmol) and 2-(trimethylsilyl)ethoxymethyl chloride (3.46 mL, 20 mmol) and stirred for 16 h then purified directly by chromatography [SiO2:EtOAc:heptane (1:4)] to give the title compound (5.82 mg, quantitative) as white solid which was used in the next reaction without further purification; NMR &dgr;H (400 MHz, CDCl3) 8.09-8.07 (1H, m), 7.87-7.85 (2H, m), 5.50 (2H, s), 5.35 (2H, s), 3.78 (4H, t, J 8.5 Hz), 1.00-0.88 (4H, m), 0.00 (9H, s) and 0.03 (9H, s).

[0385] Method AQ

[0386] 2-(2-Trimethylsilyl)Ethoxymethoxy-4-Nitrobenzyl Alcohol

[0387] A solution of 2-(trimethylsilyl)ethoxymethyl 4-nitro-2-(2-(trimethylsilyl)ethoxymethoxy)benzoic acid (2.91 mg, 5 mmol) in Et2O (10 mL) at 0° C., was treated with LiAIH4 (190 mg, 22 mmol) and stirred for 30 min. The reaction mixture was poured into water (20 mL), extracted with EtOAc (2×10 mL), dried (MgSO4) and concentrated in vacuo to give the title compound (1.35 g, 91%) as a slightly impure colourless oil; NMR &dgr;H (400 MHz, CDCl3) 7.96-7.99 (1H, m), 7.90 (1H, dd, J 8.5, 2.0 Hz), 7.55 (1H, d, J 8.5 Hz), 5.35 (2H, s), 4.78 (2H, s), 3.80-3.74 (2H, m), 0.99-0.94 (2H, m) and 0.00 (9H, s).

[0388] Method AR

[0389] 4,6-Diisopropyl-2-Pyridinemethanol

[0390] A solution of 2-pyridinemethanol (5.00 g, 45.8 mmol), conc. sulfuric acid (2.44 ml, 45.8 mmol), iron(II) sulfate heptahydrate (1.53 g, 5.50 mmol) and isopropyl iodide (13.7 ml, 137 mmol) in DMSO (150 mL) was treated dropwise with hydrogen peroxide (27.5wt% in H20, 17.0 mL, 137 mmol), with ice-bath cooling to maintain the internal temperature at 25-30° C. A further portion of iron(II) sulfate heptahydrate (1.53 g, 5.50 mmol) was added, the mixture was allowed to cool to room temperature over 1 h, poured into water (500 mL), basified to pH 9 with 5-M NaOH, extracted with dichloromethane (3×100 mL) and the combined organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (3:2)] to give 4,6-diisopropyl-2-pyridinemethanol (500 mg, 6%) as a colourless oil; NMR &dgr;H (400 MHz, CDCl3) 6.90 (1H, s), 6.85 (1H, s), 4.69 (2H, br s), 4.35 (1H, br s), 3.03 (1H, sept, J 7.0 Hz), 2.87 (1H, sept, J 7.0 MHz), 1.30 (6H, d, J 7.0 Hz) and 1.25 (6H, d, J 7.0 Hz), and 6-isopropyl-2-pyridinemethanol (900 mg, 13%) as a colourless oil.

[0391] The following novel compound was also synthesised from 2-pyridinemethanol by Method AR.

[0392] 6-N-Propyl-2-Pyridinemethanol

[0393] NMR &dgr;H (400 MHz, CDCl3) 7.58 (1H, t, J 7.5 Hz), 7.03 (2H, t, J 7.5 Hz), 4.72 (2H, s), 4.15 (1H, br s), 2.77 (2H, t, J 7.5 Hz), 1.77 (2H, sept, J 7.5 Hz) and 0.97 (3H, t, J 7.5 Hz).

[0394] Method AS

[0395] Tert-Butyl 5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-3-Carboxylate (Example 203)

[0396] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (300 mg, 1.49 mmol) in DMF (5 mL), at 0° C., was treated with 60% sodium hydride in mineral oil (60 mg, 1.49 mmol), stirred for 30 minutes, treated with tert-butyl 4-(bromomethyl)phenylcarbonate (471 mg, 1.64 mmol), stirred at room temperature for 16 h, and purified by chromatography [SiO2; EtOAc:heptane, (1:2)] to give the title compound (55 mg, 12%) as a beige solid.

[0397] Method AT

[0398] 2-(5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Yl)-1-Phenylethanone (Example 211)

[0399] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (101 mg, 0.5 mmol) in DMP (2 mL) was treated with 2-bromoacetophenone (100 mg, 0.5 mmol) and triethylamine (105 &mgr;L, 0.75 mmol), stirred at room temperature for 3 days, diluted with water (100 mL) and filtered. The resulting solid was purified by chromatography [SiO2; Hexane: EtOAc, (3:1 to 1:1)] to give the title compound (20 mg, 13%) as a yellow solid.

[0400] Method AU

[0401] 7.(2-Furyl)-3-(6-Hydroxymethyl2-Pyridylmethyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine Hydrochloride (Example 213)

[0402] A solution of 6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)pyridine-2-carboxaldehyde (62 mg, 0.193 mmol) in MeOH (20 mL) was treated with acetic acid (5 mL), dimethylamine (2-M in MeOH, 1.93 mL, 3.86 mmol) and sodium cyanoborohydride (242 mg, 3.86 mmol), stirred for 16 h and concentrated in vacuo. The residue was treated with saturated NaHCO3 solution (20 mL), extracted with EtOAc (3×10 mL) and the combined organic phase dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; EtOAc] to give the free base as a yellow solid. The solid was suspended in MeOH (1 mL), treated with HCl (4-M in dioxane, 0.25 mL), stirred for 10 min, concentrated in vacuo and triturated with Et2O to give the title compound (22 mg, 29%) as a yellow solid.

[0403] Method AV

[0404] 3-(6-Cyanomethyl-2-Pyridylmethyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 220)

[0405] A solution of 3-(6-bromomethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (200 mg, 0.517 mmol) and sodium cyanide (51 mg, 1.03 mmol) in DMP (5 mL) was stirred at 60° C. for 16 h, poured into water (40 mL), extracted with EtOAc (3×8 mL), the combined organic phase dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2;isohexane:EtOAc (1:1)] to give title compound (50 mg, 26%) as a yellow solid.

[0406] Method AW

[0407] 3-(4-Hydroxybenzyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 221)

[0408] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine—amine (400 mg, 1.98 mmol) in DMP (3 mL), at 0° C., was treated with 60% sodium hydride in mineral oil (80 mg, 1.98 mmol), stirred for 30 min, treated with 4-(2-(trimethylsilyl)ethoxymethoxy)benzyl bromide (1.23 g, 3.96 mmol), stirred at room temperature for 48 h and purified by chromatography [SiO2; EtOAc:heptane, (1:2)]. The resulting yellow solid was dissolved in MeOH:DMP (1:2), passed through an ion exchange cartridge (Isolute SPE SCX-2), concentrated in vacuo, and washed with water and ether to give the title compound (41 mg, 7%) as a pale yellow solid.

[0409] Method AX

[0410] N-(3(5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Ylmethyl)Phenyl)Propanesulphonamide (Example 224)

[0411] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (153 mg, 0.5 mmol) in pyridine (2 mL) at 0° C. was treated with propanesulfonyl chloride (62 &mgr;L, 0.55 mmol) and shaken at room temperature for 16 h. The mixture was poured into water (50 mL), extracted with EtOAc (2×10 mL), washed with 10% citric acid (10 mL) and the combined organic phase dried (MgSO4) and concentrated in vacuo to give the title compound (111 mg, 54%) as a cream solid.

[0412] Method AY

[0413] 7-(2-Furyl)-3-(6-(N-Methylanino)Methyl-2-Pyridylmethyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 226)

[0414] A solution of N-methyl-2,2,2-trifluoroacetamide (197 mg, 1.55 mmol) in DMP (5 mL) at 0° C. was treated with sodium hydride (60% dispersion in mineral oil; 62 mg, 1.55 mmol), stirred for 15 min, treated with 3-(6-bromomethyl-2-pyridylmethyl)-7-(2-furyl)-3-H[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (120 mg, 0.310 mmol), stirred at 50° C. for 1 h, cooled to room temperature, poured into water (20 mL), extracted with EtOAc (3×10 mL) and the combined organic phase dried (MgSO4) and concentrated in vacuo to give N-(6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyimidin-3-ylmethyl)-2-pyridylmethyl)-N-methyltrifluoroacetamide. A solution of this product in MeOH (20 mL) was treated with a solution of sodium (71 mg, 3.10 mmol) in MeOH (10 rL), stirred for 16 h, concentrated in vacuo, treated with EtOAc (20 mL), filtered through Celite and concentrated in vacuo. The resulting solid was suspended in MeOH (2 mL), treated with HCl (4-M in dioxane, 1.0 mL), stirred for 10 min, concentrated in vacuo and triturated with Et2O to give the title compound (80 mg, 58%) as a yellow solid.

[0415] Method AZ

[0416] 3-(1H-Benzotriazol-5-ylmethyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 158)

[0417] A mixture of 5-methyl-1H-benzotriazole (666 mg, 5 mmol) in THF (20 mli) was treated with NaH (60% dispersion, 200 mg, 5 mmol), stirred at room temperature for 10 min, treated with di-tert-butyl dicarbonate (115 mg, 5 mmol) and stirred overnight. The mixture was treated with saturated NaHCO3 solution (10 mL), extracted with EtOAc (2×10 mL), dried MgSO4), filtered through a plug of SiO2 and concentrated in vacuo to give tert-butyl 5-methylbenzotriazole-1-carboxylate (as a mixture with the 6-methyl regioisomer) (1.08 g, 92%) as a colourless oil.

[0418] A solution of tet-butyl 5-methyl-1H-benzotriazole-l-carboxylate (as a mixture with the 6-methyl regioisomer) (1.08 g, 4.63 mmol), benzoyl peroxide (112 mg, 0.46 mmol) and N-bromosuccinnimide (0.76 g, 4.63 mmol) in CC14 (25 mL) was refluxed overnight, cooled, filtered, concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (10:1)] to give tert-butyl 5-(bromomethyl)-1H-benzotriazole-l-carboxylate (666 mg, 46%) (as a mixture with the 6-bromomethyl regioisomer) as a colourless oil.

[0419] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (404 mg, 2 mmol) in DMF (4 mL) was treated with NaH (60% dispersion, 80 mg, 2 mnmol), stirred at room temperature for 10 min, treated with a solution of tert-butyl 5-(bromomethyl)1H-benzotriazole-1-carboxylate (as a mixture with the 6-bromomethyl regioisomer) (624 mg, 2 mmol) in DMF (2 mL) and stirred overnight. The mixture was concentrated in vacuo and purified by chromatography [SiO2, isohexane:EtOAc (2:1)] to give tert-butyl 5-(5-amino-7-(2-furyl)-3H-triazolo[4,5-d]pyrimidin-3-yl)methyl-1H-benzotriazol-1-carboxylate (135 mg, 24%) (as a mixture with the 6-substituted regioisomer) as a white solid.

[0420] A solution of tert-butyl 5-(5-amino-7-(2-furyl)-3H-triazolo[4,5-d]pyrimidin-3-yl)methyl-1H-benzotriazol-1-carboxylate (as a mixture withthe 6-substituted regioisomer) (135 mg, 0.31 mmol) in MeOH (5 mL) and TBF (5 mL) was treated with 40% aqueous dimethylamine (0.176 mL, 1.56 mmol), refluxed for 25 min, concentrated in vacuo and the resulting solid triturated with ether, filtered, triturated with MeOH, filtered and dried to give the title compound (31 mg, 30%) as a yellow solid.

[0421] Method BA

[0422] Ethyl 4-((5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-3-Yl)Methyl)-2-Methylphenylcarbamate (Example 274)

[0423] A suspension of 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (260 mg, 0.812 mmol) in pyridine (5 mL) at room temperature was treated dropwise with ethyl chloroformate (0.155 mL, 1.62 mmol), stirred for 30 min, poured into water (30 mL), extracted with EtOAc (2×10 mL) and the combined organic phase was dried (MgSO4) and concentrated in vacuo to give the title compound (318 mg, 100%) as a beige solid.

[0424] Method BB

[0425] N-(4-(5-Amino-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidin-3-Ylmethyl)-2-Methylphenyl)Formamide (Example 244)

[0426] A mixture of ethyl 4-((5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl)methyl (318 mg, 0.81 mmol) and LiMH4 (62 mg, 1.62 mmol) in dry THF (30 mL) was refluxed overnight, cooled to room temperature, treated with 13% aqueous NaOH solution (0.1 mL) then water (0.3 mL), stirred for 30 min, filtered through Celite and concentrated in vacuo. The resulting solid was triturated with THF and filtered to give the title compound (20 mg, 7%) as a yellow solid.

[0427] Method BC

[0428] 7-Fluoro-5-Methylindole

[0429] A solution of chloral hydrate (7.3 g, 44 mmol), sodium sulphate decahydrate (52 g, 160 mmol) and H2O (100 mL) was added slowly to a stird solution of 2-fluoro4-methylamine (5.0 g, 40 mmol), hydroxylamine hydrochloride (11.1 g, 160 mmol) and conc. HCl (3 mL) in H2O (50 mTL). The reaction mixture was refluxed for 1 h, stirred at room temperature for 5 h, filtered and the resulting solid crystallised from MeOH/H2O to yield brown crystals (1.53 g). This material was added in small portions with stirring to conc. sulphuric acid (20 mL) at 70° C., stirred for 1 h, then added slowly with rapid stirring to ice/H2O (200 mL), extracted twice with EtOAc (2×25 mL) and the combined organic phase dried (MgSO4) and concentrated in vacuo to give 7-fluoro-5-methylisatin (1.68 g, 24 %) as a dark red gum.

[0430] A solution of 7-fluoro-5-methylisatin (1.68 g, 9.43 mmol) in dry TlF (50 mL) was added slowly to an ice cold, stirred suspension of LiAlH4 (1.18 g, 31 mmol) in dry TBF (50 mL), refluxed for 2 h, cooled to room temperature then treated sequentially with H2O (1.2 mL), 15% NaOH (1.2 mL) and H2O (3 mL). The solution was filtered through a pad of Celite, washing the filter cake thoroughly with TFH, the deep blue filtrate was concentrated in vacuo and purified by chromatography [SiO2; iso-Hexane:EtOAc (9:1)] to give the title compound (480 mg, 41%) as a pale blue oil; NMR 5H (CDCl3) 8.19 (1H, br s), 7.21-7.16 (2H, m), 6.74 (1H, d, J 12.0 Hz), 6.51-6.46 (1H, m) and 2.42 (3H, s).

[0431] Method BE

[0432] 3-(7-Fluoro-5-Indolyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 246)

[0433] A stirred suspension of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyriridine-5-amine (303 mg, 1.5 mmol) in DMF (2 mL) was treated with NaH (60% dispersion in oil, 60 mg, 1.5 mmol), stirred for 10 min, treated slowly with a solution of tert-butyl 5-bromomethyl-7-fluoroindole-1-carboxylate (460 mg, 1.5 mmol) in DMF (1 mL), stirred for 2 h then the mixture was purified directly by chromatography [SiO2; iso-hexarie:EtOAc (2:1)] to give the BOC protected product (180 mg, 0.417 mmol) as a pale green solid. This material was dissolved in MeOH (5 mL), treated with sodium methoxide (113 mg, 2 mmol), refluxed for 4 h, cooled to room temperature, diluted with H2O and filtered to give the title compound (118 mg, 81%) as a cream solid.

[0434] Method BF

[0435] 3-(3(4-Fluorobenzylanno)Benzyl)-7-(2-Furyl)-3H-[1,2,3]Triazolo[4,5-D]Pyrimidine-5-Amine (Example 252)

[0436] A suspension of 3-(3-aminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (200 mg, 0.65 mmol) and 4A molecular sieves in ThF (10 mL) was treated with 4-fluorobenzaldehyde (0.04 mL, 0.37 mmol), heated to 40° C. for 3 h, cooled to room temperature, treated sodium triacetoxyborohydride (400 mg, 1.89 mmol) and acetic acid (0.1 mL) and stirred for 15 minutes. The reaction was quenched by addition of sat. NaHCO3 (5 mL), extracted with EtOAc (2×5 mL) and the combined organic phase dried (MgSO4), concentrated in vacuo and purified by chromatography [(SiO2; EtOAc:Heptane (1:2)] to give the title compound (60 mg, 44%) as a white solid.

[0437] Method BG

[0438] 2-(2-Methoxyethyl)-6-(Triphenylmethoxy)Methylpyridine

[0439] A stirred solution of (methoxymethyl)triphenylphosphonium chloride (2.79 g, 8.13 mmol) in THP (50 mL) at 0° C. was treated dropwise with n-BuLi (1.6-M in hexanes, 5.08 mL, 8.13 mmol), stiered for 1 h, treated with a solution of 6-(triphenylmethoxy)methylpyridine-2-carboxaldehyde (1.54 g, 4.06 mmol) in THF (15 mL) and allowed to warm to room temperature overnight. The reaction was treated with saturated NH4Cl solution (5 mL), diluted with water (50 mL), extracted with EtOAc (2×50 mL) and the combined organic phase diluted with iso-hexane (50 mL), dried (MgSO4), filtered through silica and concentrated in vacuo to give 2-(2-methoxyethenyl)-6-(triphenylmethoxy)methylpyridine (1.58 g) as a yellow oil. A solution of this crude alkene and 10% Pd/C (216 mg, 0.203 mmol) in EtOAc (50 mL) was stirred under a hydrogen atmosphere for 16 h, filtered through Celite and concentrated in vacuo to give the title compound (1.08 g, 65%) as a yellow oil; NMR SH (400 M , CDCl3) 7.67-7.64 (1H, m), 7.52-7.49 (6H, m), 7.32-7.21 (10H, m), 7.09-7.07 (1H, m), 4.34 (2H, s), 3.69 (2H, t, J 6.5 Hz), 3.32 (3H, s) and 2.98 (2H, t, J 6.5 Hz); M/Z 410 (M+H)+.

[0440] Method BH

[0441] 2-Bromomethyl-6-(2-Methoxyethyl)Pyridine

[0442] A solution of 2-(2-methoxyethyl)-6-(triphenylmethoxy)methylpyridine (1.08 g, 2.64 mmol) in 4-M HCl in dioxan (10 mL, 40.0 mmol) was stirred for .4 h and concentrated in vacuo. The residue was partitioned between dichloromethane (15 mL) and saturated NaHCO3 solution (15 mL), the aqueous phase was extracted with dichloromethane (10 mL) and the combined organic phase was dried (MgSO4) and concentrated in vacuo to give 6-(2-methoxyethyl)pyridine-2-methanol. A solution of this product in dichloromethane (40 mL) at 0° C. was treated with triphenylphosphine (830 mg, 3.16 mmol) followed portion wise by carbon tetrabromide (1.31 g, 3.96 rnmol), stirred for 1 h, concentrated in vacuo and purified by chromatography [SiO2; isohexane:EtOAc (4:1)] to give the title compound (303 m g, 50%) as a yellow oil; NMR &dgr;H (400 MHZ, CDCl3) 7.60 (1H, t, J 7.5 Hz), 7.28 (1H, d, J 7.5 Hz), 7.13 (1H, d, J 7.5 Hz), 4.53 (2H, s), 3.76 (2H, t, J 6.5 Hz), 3.35 (3H, s) and 3.05 (2H, t, J 6.5 Hz).

[0443] Experimental Data for Examples 1-274 are Provided in Table 2.

[0444] HPLC is carried out using the following conditions: Column. Waters Xterra RP 18 (50×4.6 mm); Particle size 5 &mgr;M; Mobile phase MeOH: 10 mM aq NH4OAc (pH 7 buffer); Gradient 50:50 isocratic for 1 min. then linear gradient 50:50 to 80:20 over 5 min. then 80:20 isocratic for 3 min.; Flow rate 2.0 mL/min.; Detection wavelength &lgr;=230 nM. Retention times are provided in Table 2. 2 TABLE 2 Example Method Yield(%) Physical Data 1 A 65 IR &ngr;max(Nujol)/cm−1 3403, 3329, 3134, 2925, 1656, 1634, 1582, 1565, 1463 and 1377; NMR &dgr;H(400MHz, DMSO) 6.83-6.87(1H, m), 7.12(2H, s), 7.89(1H, d, J 3.1Hz), 8.09-8.10(1H, m), 15.52(1H, s); M/Z 203(M+H)+. 2 B 11 IR &ngr;max(Nujol)/cm−1 2924, 2854, 1612, 1587, 1526, 1489, 1456, 1372, 1221 and 753; NMR &dgr;H(400MHz, DMSO) 4.98(2H, s), 5.14(2H, s), 5.71(2H, s), 6.85-6.87 (1H, m), 7.00-7.14(3H, m), 7.14-7.46(9H, m), 7.89(1H, d, J 3.5Hz), 8.16(1H, d<J 1.0Hz); Anal. Calcd for C29H21F3N6O. 0.25 H2O: C, 65.59; H, 4.08; N, 15.83. Found: C, 65.46; H, 4.03; N, 15.76. 3 B 22 IR &ngr;max(Nujol)/cm−1 3480, 3312, 3195, 3118, 2925, 2854, 1652, 1609, 1581, 1487, 1456, 1436, 1027 and 759; NMR &dgr;H(400MHz, DMSO) 5.60(2H, s), 6.84-6.86 (1H, m), 7.15-7.29(3H, m), 7.32-7.43(3H, m), 7.89(1H, d, J 2.9Hz), 8.12(1H, s). 4 B 9 mp 221.0-221.1° C.; IR &ngr;max(Nujol)/cm−1 3470, 3310, 3191, 3144, 2924, 2854, 1642, 1610, 1521, 1463 and 1354; NMR &dgr;H(400MHz, DMSO) 5.85(2H, s), 6.87(1H, s), 7.37(2H, s), 7.63-7.73(2H, m), 7.91(1H, d, J 2.8Hz), 8.13(1H, s), 8.18(1H, s), 8.20(1H, s). Anal. Calcd for C15H11N7O3: C, 50.57; H, 3.11; N, 27.52. Found: C, 50.99; H, 3.23; N, 27.21. 5 C 92 mp 259.8-259.9° C.; IR &ngr;max(Nujol)/cm−1 3452, 3367, 3318, 3185, 3142, 2922, 1651, 1602, 1514, 1463 and 1377; NMR &dgr;H(400MHz, DMSO) 5.09(2H, s), 5.49(2H, s), 6.35(1H, s), 6.41(1H, d, J 7.5Hz), 6.45(1H, d, J 8.0Hz), 6.85-6.86 (1H, m), 6.96(1H, t, J 8.0Hz), 7.30(2H, s), 7.90(1H, d, J 3.5Hz), 8.11 (1H, s). Anal. Calcd for C15H13N7O: C, 56.63; H, 4.50; N, 30.82. Found: C, 56.82; H, 4.25; N, 30.57. 6 B 21 IR &ngr;max(Nujol)/cm−1 3405, 3328, 3211, 3155, 2925, 2854, 1719, 1603, 1577, 1463, 1023 and 731; NMR &dgr;H(400MHz, DMSO) 3.84(3H, s), 5.76(2H, s), 6.85-6.87 (1H, m), 7.33-7.38(2H, s), 7.50-7.59(2H, m), 7.89-7.92(3H, s), 8.12-8.13 (1H, m); Anal. Calcd for C17H14N6O3.0.25 H2O: C, 57.54; H, 4.12; N, 23.68. Found: C, 57.42; H, 3.75; N, 23.37. 7 B 27 IR &ngr;max(Nujol)/cm−1 3506, 3309, 3189, 3131, 2925, 2854, 1635, 1606, 1580, 1502, 1417, 1204, 1025 and 762; NMR &dgr;H(400MHz, DMSO) 3.70(6H, s), 5.58 (2H, s), 6.44(3H, s), 6.84-6.87(1H, m), 7.34(2H, s), 7.90(1H, d, J 3.5Hz), 8.11-8.12(1H, m); Anal. Calcd for C17H216N6O3.0.5 H2O: C, 56.50; H, 4.74; N, 23.26. Found: C, 56.44; H, 4.56; N, 22.98. 8 B 21 IR &ngr;max(Nujol)/cm−1 3488, 3314, 3146, 2922, 2853, 1667, 1608, 1583, 1463 and 1378; NMR &dgr;H(400MHz, DMSO) 5.79(2H, s), 6.84-6.87(1H, m), 7.01(1H, d, J 4.0Hz), 7.05(1H, d, J 4.0Hz), 7.38(2H, s), 7.89(1H, d, J 3.5Hz), 8.11-8.13 (1H, m). 9 D 14 IR &ngr;max(Nujol)/cm−1 3458, 3299, 3174, 3111, 2923, 1625, 1605, 1463 and 1377; NMR &dgr;H(400MHz, DMSO) 3.61(3H, s), 5.58(2H, s), 6.84-6.94(3H, m), 7.06-7.11 (1H, d, J 8.5Hz), 7.19(1H, t, J 8.0Hz), 7.34(2H, s), 7.64-7.67(2H, m), 7.91(1H, d, J 3.0Hz), 8.12(1H, s), 10.21(1H, s); Anal. Calcd for C29H21F3N6O.0.25 H2O: C, 65.59; H, 4.08; N, 15.83. Found: C, 65.46; H, 4.03; N, 15.76. 10 E 18 IR &ngr;max(Nujol)/cm−1 3404, 3313, 3202, 3122, 2923, 2854, 1724, 1639, 1609, 1557, 1456, 1407 and 1379; NMR &dgr;H(400MHz, DMSO) 4.60(2H, d, J 6.0Hz), 6.86-6.89(1H, m), 7.25-7.32(1H, m), 7.33-7.44(4H, m), 7.67(2H, s), 7.91 (1H, d, J 3.5Hz), 8.14-8.16(1H, m), 9.25(1H, t, J 6.0Hz). 11 B 40 IR &ngr;max(Nujol)/cm−1 3327, 3207, 2924, 2854, 1650, 1602, 1583, 1566, 1513 and 1487; NMR &dgr;H(400MHz, DMSO) 3.72(3H, s), 5.63(2H, s), 6.80(1H, d, J 7.5Hz), 6.85-6.89(3H, m), 7.26(1H, t, J 7.5Hz), 7.33(2H, s), 7.90(1H, d, J 3.5Hz), 8.11(1H, s); Anal. Calcd for C16H14N6O2.0.25 H2O: C, 58.80; H, 4.47; N, 25.71. Found: C, 58.90; H, 4.40; N, 25.75. 12 B 21 IR &ngr;max(Nujol)/cm−1 3374, 3311, 3202, 1636, 1606, 1586, 1530, 1511, 1465, 1439, 1377 and 1343: NMR &dgr;H(400MHz, DMSO) 6.03(2H, s), 6.86-6.89(1H, m), 6.98(1H, d, J 7.5Hz), 7.36(2H, s), 7.60-7.73(2H, m), 7.92(1H, d, J 3.5Hz), 8.14(1H, s), 8.2(1H, d, J 8.0Hz); Anal. Calcd for C15H11N7O3.0.35 H2O: C, 52.43; H, 3.43; N, 28.54. Found: C, 52.51; H, 3.33; N, 28.21. 13 C 67 IR &ngr;max(Nujol)/cm−1 3489, 3313, 3191, 1638, 1603, 1505, 1460 and 1378; NMR &dgr;H(400MHz, DMSO) 5.27(2H, s), 5.47(2H, s), 6.50(1H, t, J 7.5Hz), 6.67-6.78 (2H, m), 6.86(1H, s), 7.01(1H, t, J 7.0Hz), 7.36(2H, s), 7.90(1H, d, J 3.0Hz), 8.12(1H, s). 14 F 35 IR &ngr;max(Nujol)/cm−1 3447, 3327, 3205, 2922, 2853, 1725, 1652, 1611 and 1458; NMR &dgr;H(400MHz, DMSO) 8.13(1H, d, J 1.0Hz), 7.90(1H, d, J 3.5Hz), 7.38 (2H, s), 6.87-6.85(1H, m), 5.40(2H, s), 4.18(2H, q, J 7.0Hz) and 1.21(3H, t, J 7.0Hz); Anal. Calcd for C12H12N6O2+0.2 H2O: C, 49.38; H, 4.28, N, 28.79. Found: C, 49.25; H, 4.09; N, 28.47. 15 B 15 IR &ngr;max(Nujol)/cm−1 3490, 3307, 3189, 2230, 1959, 1728, 1642, 1611, 1583, 1565, 1463, 1377, 1283, 1234, 1030 and 761; NMR &dgr;H(400MHz, DMSO) 5.75 (2H, s), 6.82-6.89(1H, m), 7.35(2H, s), 7.57-7.59(2H, m), 7.79-7.81(2H, m), 7.91(1H, d, J 3.5Hz), 8.12(1H, s). 16 B 6 IR &ngr;max(Nujol)/cm−1 3309, 3184, 2726, 1639, 1608, 1585, 1456, 1377, 1026, 1002, 953 and 750; NMR &dgr;H(4.00MHz, DMSO) 2.22(2H, quin, J 7.0Hz), 2.67 (2H, t, J 7.0Hz), 4.45(2H, t, J 7.0Hz), 6.83-6.88(1H, m), 7.23-7.35(3H, m), 7.66(1H, dt, J 8.0, 2.0Hz), 7.89(1H, dd, J 3.5, 1.0Hz), 8.10-8.13(1H, m); Anal. calcd for C16H15N7O.0.6 H2O: C, 57.86; H, 4.92; N, 29.52. Found: C, 57.58; H, 4.53; N, 29.66. 17 B 7 IR &ngr;max(Nujol)/cm−1 3379, 3336, 3208, 1655, 1604, 1513, 1456, 1325, 11687, 1124, 1025 and 755; NMR &dgr;H(400MHz, DMSO) 5.79(2H, s), 6.83-6.88(1H, m), 7.36(2H, s), 7.53(1H, d, J 7.5Hz), 7.60(1H, t, J 7.5Hz), 7.67-7.76(2H, m), 7.91(1H, d, J 3.5Hz), 8.13(1H, s); Anal. Calcd. for C16H11F3N6O: C, 53.34; H, 3.08; N, 23.31. Found: C, 53.38; H, 3.18; N, 23.15. 18 G 100 IR &ngr;max(Nujol)/cm−1 3451, 3206, 2361, 2261, 1655, 1604, 1459, 1378, 1195, 1028 and 774; NMR &dgr;H(400MHz, DMSO) 5.57(2H, s), 6.57-6.63(1H, m), 6.65-6.74(2H, m), 6.83-6.88(1H, m), 7.14(1H, t, J 7.5Hz), 7.91(1H, d, J 3.0Hz), 8.12(1H, d, J 1.0Hz). 19 J 77 mp 291.8-292.0° C.; IR &ngr;max(DR)/cm−1 3436, 3178, 1651, 1615, 1398, 1226, 1029 and 977; NMR &dgr;H(400MHz, DMSO) 15.5-15.3(1H, br s), 7.84(1H, d, J 3.5Hz), 7.07(2H, br s), 6.48(1H, dd, J 3.5, J 1.0Hz), 2.44(3H, s). 20 B 47 mp 213.5.-213.7° C.; IR &ngr;max(DR)/cm−1 3300, 3218, 3098, 2957, 2927, 2744, 2368, 1645, 1602, 1570, 1537, 1508, 1490, 1438, 1328 and 1233; NMR &dgr;H(400MHz, DMSO) 7.86(1H, d, J 3.0Hz), 7.43-736(1H, m), 7.31(2H, br s), 7.28-7.15 (3H, m), 6.50(1H, dd, J 1.0, J 3.5Hz), 5.68(2H, s) and 2.45(3H, s). 21 K 99 IR &ngr;max(DR)/cm−1 3151, 2360, 1654, 1182, 998, 824, 681, and 572; NMR &dgr;H (400MHz, DMSO) 10.28(1H, d, J 2.0Hz) and 9.73(1H, d, J 2.5Hz) 22 A 8 IR &ngr;max(DR)/cm−1 3479, 3289, 3169, 1597, 1502, 1226, 1119, 999, 880 and 757; NMR &dgr;H(400MHz, DMSO) 9.43(1H, s), 9.25(1H, s), 7.48-7.34(3H, m) 7.30-7.22 (2H, m), 7.21-7.15(1H, m) and 5.72(2H, s). 23 B 20 mp 187.3-187.7° C.; IR &ngr;max(DR)/cm−1 3993, 3489, 3319, 3197, 2951, 2725, 2353, 1954, 1719, 1633, 1604, 1503, 1420, 1232, 1032 and 740; NMR &dgr;H(400MHz, DMSO) 2.27(3H, s) 5.62(2H, s), 6.82-6.88(1H, m), 7.02-7.16(3H, m), 7.24(1H, t, J 7.5Hz), 7.33(2H, s), 7.90(1H, d, J 3.5Hz) 8.12(1H, s). 24 N 46 mp 196.9-197.1° C.; IR &ngr;max(DR)/cm−1 3448, 3321, 3200, 1649, 1616, 1509, 1488; NMR &dgr;H(400MHz, DMSO) 8.49-8.47(1H, m), 8.12-8.11(1H, m), 7.91 (1H, d, J 3.5Hz), 7.81-7.77(1H, m), 7.34-7.30(1H, m), 7.27(2H, br s), 7.24 (1H, d, J 8.0Hz), 6.86-6.85(1H, m), 5.77(2H, s). 25 N 50 IR &ngr;max(DR)/cm−1 3326, 3211, 2956, 2856, 1641, 1612, 1507, 1491; NMR &dgr;H (400MHz, CDCl3) 8.77-8.76(1H, m), 8.58-8.56(1H, m), 8.08(1H, d, J 3.5Hz), 7.78(1H, m), 7.75-7.72(1H, m), 7.29-7.25(1H, m), 6.71-6.69(1H, m), 5.68(2H, s), 5.37(2H, br s); Anal. Calcd for C14H11N7O.0.2 H2O.0.4 C4H3O2: C, 56.41; H, 4.43, N, 29.52. Found: C, 56.10; H, 4.33; N, 29.52. 26 O 85 mp 291.0-291.1° C.; IR &ngr;max(Nujol)/cm−1 3401, 3317, 3205, 2995, 1714, 1646, 1615, 1587, 1483 and 1247; NMR &dgr;H(400MHz, DMSO) 13.58-13.31(1H, s), 8.12(1H, s), 7.91(1H, d, J 3.5Hz), 7.36(2H, s), 6.87-6.86(1H, m) and 5.29 (2H, s); Anal. Calcd for C10H8N6O3.0.6 H2O: C, 44.32; H, 3.42, N, 31.01. Found: C, 44.26; H, 3.07; N, 30.74. 27 B 19 mp 209.9-210.1° C.; IR &ngr;max(DR)/cm−1 3504, 3312, 3201, 2948, 1611, 1503, 1435, 1279, 1220, 1025 and 755; NMR &dgr;H(400MHz, DMSO) 5.69(2H, s), 6.82-6.87 (1H, m), 7.19-7.25(1H, m), 7.33(2H, s), 7.37-7.40(3H, m), 7.90(1H, d, J 3.5Hz), 8.10-8.13(1H, m). Anal. Calcd for C15H11N6OCl.0.2 H2O: C, 54.54; H, 3.48; N, 25.44. Found: C, 54.69; H, 3.33; N, 25.09. 28 K 40 IR &ngr;max(DR)/cm−1 3282, 2852, 1630, 1368, 1120, 871 and 618; NMR &dgr;H(400MHz, DMSO) 7.94(1H, d, J 2.5Hz), 7.45-7.36(2H, m), 7.29-7.22(2H, m), 7.21-7.16(1H, m) and 5.71(2H, s). 29 B 8 IR &ngr;max(DR)/cm−1 3999, 3483, 3438, 3310, 3207, 2950, 2732, 2452, 1846, 1657, 1486, 1312, 1030 and 754; NMR &dgr;H(400MHz, DMSO) 4.02(3H, s), 6.81-6.88 (1H, m), 7.25(2H, s), 7.88(1H, d, J 3.5Hz), 8.09-8.11(1H, m). 30 P 39 IR &ngr;max(Nujol)/cm−1 3500-3200, 2946, 2835, 1700 and 1523; NMR &dgr;H(400MHz, DMSO) 8.11(1H, s), 7.89(1H, d, J 3.5Hz), 7.69(1H, s), 7.34(1H, s), 7.26(2H, s), 6.87-6.84(1H, m) and 5.08(2H, s). 31 P 48 IR &ngr;max(Nujol)/cm−1 3457, 3313, 1666, 1617, 1523 and 1442; NMR &dgr;H(400MHz, DMSO) 10.68(1H, s), 8.12(1H, s), 7.91(1H, d, J 3.5Hz), 7.75(1H, s), 7.45(1H, d, J 8.0Hz), 7.37(1H, t, J 8.0Hz), 7.30(2H, s), 7.15(1H, d, J 8.0Hz), 6.88-6.84(1H, m and 5.39(2H, s); Anal. Calcd for C16H12N7O2Cl.0.8 H2O: C, 50.02; H, 3.57, N, 25.27. Found: C, 50.15; H, 3.48; N, 25.12. 32 N 76 mp 191.4-192.0° C.; IR &ngr;max(DR)/cm−1 3511, 3306, 3194, 2955, 1638, 1476; NMR &dgr;H(400MHz, DMSO) 8.12-8.11(1H, m), 7.91(1H, dd, J 3.5, 1.0Hz), 7.66(1H, dd, J 8.0, 7.0Hz), 7.27(2H, br s), 6.87-6.85(1H, m), 6.73-6.70(2H, m), 5.69(2H, s), 3.68(3H, s); Anal. Calcd for C15H13N7O2.0.2 C4H8O2: C, 55.66; H, 4.32, N, 28.76. Found: C, 55.88; H, 4.17; N, 28.59. 33 B 11 mp 204.1-204.2° C.; IR &ngr;max(DR)/cm−1 3490, 3321, 3200, 2923, 2711, 2490, 1749, 1605, 1502, 1376, 1272, 1034 and 761; NMR &dgr;H(400MHz, DMSO) 5.83 (2H, s), 6.83-6.86(1H, m), 7.01(1H, dd, J 5.0, 3.5Hz), 7.16(1H, dd, J 3.5, 1.0Hz), 7.34(2H, s), 7.48(1H, dd, J 5.0, 1.5Hz), 7.89(1H, d, J 3.5Hz), 8.09-8.12 (1H, m). 34 Q 30 mp 225-230° C.; IR &ngr;max(DR)/cm−1 3520, 3344, 1734, 1611, 1438, 1240, 996, 833 and 761; NMR &dgr;H(400MHz, DMSO) 8.26(1H, d, J 3.0Hz), 8.15(1H, d, J 3.0Hz), 7.50-7.44(2H, br s), 7.42-7.36(1H, m), 7.29-7.21(1H, m), 7.21-7.15 (1H, m) and 5.73(2H, s). 35 H 51 mp 174.0-174.2° C.; IR &ngr;max(DR)/cm−1 3473, 3317, 3188, 2740, 1736, 1648, 1243, 1004 and 752; NMR &dgr;H(400MHz, DMSO) 8.68(1H, dd, J 4.0, 1.5Hz), 7.99(1H, dd, J 5.0, 1.0Hz), 7.43-7.35(2H, m), 7.31-7.16(5H, m) and 5.71 (2H, s). 36 C 50 mp 231.7-234.0° C.; IR &ngr;max(DR)/cm−1 3498, 3404, 3309, 2931, 1607, 1539, 1498, 1317, 1101 and 1027; NMR &dgr;H(400MHz, DMSO) 7.86(1H, dd, J 0.5, 3.5Hz), 7.24(2H, br s), 6.96(1H, t, J 7.8Hz), 6.50(1H, dd, J 1.0, 3.5Hz), 6.48-6.43 (1H, m), 6.43-6.38(1H, m), 6.36(1H, t, J 1.7Hz), 5.46(2H, s), 5.07(2H, br s) and 2.43(3H, s). 37 N 60 mp 200.8-218.9° C.; NMR &dgr;H(400MHz, DMSO) 8.12-8.11(1H, m), 7.91 (1H, d, J 3.5Hz), 7.64(1H, t, J 7.5Hz), 7.29(2H, br s), 7.18(1H, d, J 7.5Hz), 6.90(1H, d, J 7.5Hz), 6.86-6.85(1H, m), 5.70(2H, s) and 2.42(3H, s). 38 Q 35 mp 242.0-242.1° C.; IR &ngr;max(DR)/cm−1 3513, 3294, 1570, 1234, 999 and 755; NMR &dgr;H(400MHz, DMSO) 7.96(1H, s), 7.46-7.34(3H, m), 7.30-7.13(3H, m), 5.72(2H, s) and 2.60(3H, s). 39 B 26 IR &ngr;max(Nujol)/cm−1 3464, 3340, 3189, 2966, 2748, 1692, 1643 and 1605; NMR &dgr;H(400MHz, DMSO) 8.11-8.09(1H, m), 7.90(1H, d, J 3.5Hz), 7.33-7.24 (4H, m), 7.19-7.12(2H, m), 7.09(1H, s), 6.86-6.84(1H, m), 5.64(2H, s), 4.07(2H, d, J 6.0Hz) and 1.33(9H, s). 40 B 12 IR &ngr;max(Nujol)/cm−1 3474, 3323, 3184, 3006, 2971, 2941, 2837, 1648, 1606 and 1496; NMR &dgr;H(400MHz, DMSO) 8.13-8.10(1H, m), 7.90(1H, d, J 3.5Hz), 7.32(2H, s), 6.98(1H, d, J 9.0Hz), 6.89-6.84(2H, m), 6.48(1H, d, J 3.0Hz), 5.57(2H, s), 3.76(3H, s) and 3.62(3H, s). 41 B 32 mp 213.8-213.9° C.; IR &ngr;max(DR)/cm−1 3996, 3654, 3507, 3320, 2930, 2562, 2621, 1944, 1837, 1676, 1428, 1230, 1095, 1026 and 797; NMR &dgr;H(400MHz, DMSO) 5.65(2H, s), 6.81-6.86(1H, m), 7.16(2H, t, J 8.5Hz), 7.31(2H, s), 7.44-7.56(1H, m), 7.86(1H, dd, J 3.5, 1.0Hz), 8.07-8.13(1H, m). Anal. Calcd for C15H10N6OF2: C, 54.88; H, 3.07; N, 25.59. Found: C, 54.57; H, 3.05; N, 25.23. 42 Q 29 mp 265.7-26.2° C.; IR &ngr;max(DR)/cm−1 3491, 3370, 3120, 1614, 1232, 972, 753 and 514; NMR &dgr;H(400MHz, DMSO) 7.72(1H, s), 7.51-7.43(2H, s), 7.42-7.35 (1H, m), 7.30-7.14(3H, m), 5.73(2H, s) and 2.55(3H, s). 43 H 65 mp 281.1-280.2° C.; IR &ngr;max(DR)/cm−1 3466, 3326, 1641, 1503, 1379, 1240, 1056, and 825; NMR &dgr;H(400MHz, DMSO) 15.5(1H, br s), 8.6(1H, dd, J 1.0, 4.0Hz), 7.96(1H, dd, J 1.0, 5.0Hz), 7.36(1H, dd, J 4.0, 5.0Hz) and 7.0(2H, br s). 44 S/T 28 IR &ngr;max(DR)/cm−1 3255, 1686, 1590, 1458; NMR &dgr;H(400MHz, DMSO) 11.24 (1H, s), 8.95-8.94(1H, m), 8.37-8.35(1H, m), 8.08-8.07(1H, m), 7.96-7.95 (1H, m), 7.68(1H, d, J 8.0Hz), 6.85-6.84(1H, m). 45 A 59 mp 190.4-190.8° C.; IR &ngr;max(DR)/cm−1 3322, 3162, 1665, 1576, 1351, 1119, 1000, 809 and 604; NMR &dgr;H(400MHz, DMSO) 9.44(1H, s), 9.26(1H, s), 8.24-8.16 (2H, m), 7.95(1H, s), 7.74-7.63(2H, m), 7.45(2H, br s) and 5.87(2H, s). 46 K 99 IR &ngr;max(Nujol)/cm−1 2967, 1651 and 1463; NMR &dgr;H(400MHz, DMSO) 8.35-8.24 (3H, s), 8.14-8.11(1H, m), 7.91(1H, d, J 3.5Hz), 7.47-7.39(2H, m), 7.36-7.31(2H, s), 6.88-6.84(1H, m), 5.67(2H, s) and 3.98(2H, q, J 5.5Hz); Anal. Calcd for C16H15N7O.2HCl.0.9 H2O: C, 46.82; H, 4.62, N, 23.89. Found: C, 47.10; H, 4.40; N, 23.84. 47 B 26 IR &ngr;max(Nujol)/cm−1 3375, 3194, 2929, 2753, 1732, 1657, 1515, 1400 and 1334; NMR &dgr;H(400MHz, DMSO) 8.14-8.11(1H, m), 7.90(1H, d, J 3.0Hz), 7.45-7.29 (6H, m), 6.88-6.84(1H, m), 5.71(2H, s), 2.95(3H, s) and 2.85(3H, s); Anal. Calcd for C18H17N7O2.0.5 H2O: C, 58.06; H, 4.87, N, 26.33. Found: C, 58.16; H, 4.65; N, 26.06. 48 C 49 mp 265.9-266.0° C.; IR &ngr;max(DR)/cm−1 3448, 3363, 3316, 3189, 1645, 1597, 1511, 1440 and 1103; NMR &dgr;H(400MHz, DMSO) 8.69(1H, dd, J 1.2, 3.7Hz), 7.95(1H, dd, J 1.2, 5.0Hz), 7.38(1H, dd, J 3.9, 5.0Hz), 7.26(2H, br s), 6.97 (1H, t, J 7.7Hz), 6.48-6.45(1H, m), 6.44-6.40(1H, m), 6.36(1H, t, J 1.7Hz), 5.5(2H, s) and 5.11(2H, br s). 49 B 8 IR &ngr;max(Nujol)/cm−1 3488, 3319, 2952, 1641, 1503 and 1420; NMR &dgr;H(400MHz, DMSO) 8.49-8.42(1H, m), 8.14(1H, d, J 1.0Hz), 7.91(1H, d, J 3.5Hz), 7.78-7.71(2H, m), 7.48-7.32(4H, m), 6.88-6.85(1H, m), 5.72(2H, s) and 2.75(3H, d, J 4.5Hz). 50 C 60 mp 228.2-228.3° C.; IR &ngr;max(DR)/cm−1 3441, 3318, 3197, 1738, 1648, 1515, 1122, 1006, 888 and 747; NMR &dgr;H(400MHz, DMSO) 9.45(1H, s), 9.27(1H, s), 7.44(2H, br s), 6.97(1H, t, J 8.0Hz), 6.49-6.39(2H, m), 6.35(1H, s), 5.52 (2H, s), and 5.13(2H, s). 51 N 70 mp 182.9-183.1° C.; IR &ngr;max(DR)/cm−1 3488, 3311, 3199, 2943, 1611, 1504; NMR &dgr;H(400MHz, DMSO) 8.10(1H, d, J 3.5Hz), 7.78(1H, m), 7.01(1H, t, J 9.0Hz), 6.79(1H, dt, J 9.0, 3.5Hz), 6.75-6.73(1H, m), 6.71-6.70(1H, m), 5.70(2H, s), 5.38(2H, br s), 3.71(3H, s); Anal. Calcd for C16H13N6O2F.0.1 H2O: C, 56.17; H, 3.89, N, 24.56. Found: C, 56.27; H, 3.85; N, 24.22. 52 P 70 mp 263.8-264.0° C.; IR &ngr;max(Nujol)/cm−1 3305, 3192, 1705, 1635 and 1442; NMR &dgr;H(400MHz, DMSO) 11.04(1H, s), 8.37(1H, d, J 4.0Hz), 8.15-8.11 (1H, m), 7.96(1H, d, J 7.0Hz), 7.91(1H, d, J 3.0Hz), 7.79(1H, dt, J 7.5, 2.0Hz), 7.32(2H, s), 7.18-7.11(1H, m), 6.88-6.85(1H, m) and 5.46(2H, s). 53 P 77 mp 256.1-256.4° C.; IR &ngr;max(Nujol)/cm−1 3454, 3311, 2993, 1664, 1488 and 1439; NMR &dgr;H(400MHz, DMSO) 8.86(1H, t, J 6.0Hz), 8.50(1H, d, J 4.5Hz), 8.12(1H, s), 7.90(1H, d, J 3.5Hz), 7.79(1H, dt, J 7.5, 1.5Hz), 7.41-7.25(4H, m), 6.88-6.84(1H, m) and 5.23(2H, s), 4.41(2H, d, J 6.0Hz); Anal. Calcd for C16H14N8O2.0.25 H2O: C, 54.16; H, 4.12, N, 31.58. Found: C, 54.01; H, 4.03; N, 31.44. 54 P 61 mp 292.2-292.3° C.; IR &ngr;max(Nujol)/cm−1 3433, 3323, 2975, 2941, 1673 and 1446; NMR &dgr;H(400MHz, DMSO) 10.50(1H, s), 8.13(1H, s), 7.92(1H, d, J 3.0Hz), 7.57(2H, d, J 7.5Hz), 7.37-7.27(4H, m), 7.08(1H, t, J 7.5Hz), 6.89-6.84 (1H, m) and 5.38(2H, s). 55 B 18 mp 264.5-264.8° C.; IR &ngr;max(DR)/cm−1 4007, 3489, 3308, 3190, 1649, 1552, 1433, 1349, 1227, 1082, 1030 and 729; NMR &dgr;H(400MHz, DMSO) 5.99(2H, s), 6.84-6.89(1H, m), 7.39(2H, s), 7.91(1H, d, J 3.5Hz), 8.11-8.15(1H, m), 8.59(2H, d, J 2.0Hz), 8.78(1H, t, J 2.0Hz). 56 B 30 IR &ngr;max(DR)/cm−1 3508, 3300, 3181, 1611, 1572, 1504, 1420, 1352, 1225 and 1030; NMR &dgr;H(400MHz, DMSO) 8.22-8.16(2H, m), 7.86(1H, d, J 3.2Hz), 7.63-7.72(2H, m), 7.35(2H, br s), 6.50(1H, dd, J 1.0, 3.5Hz), 5.82(2H, s) and 2.45(3H, s). 57 B mp 188.8-188.9° C.; IR &ngr;max(Nujol)/cm−1 3492, 3302, 3189, 2951, 1635 and 1505; NMR &dgr;H(400MHz, DMSO) 8.14-8.10(1H, m), 7.90(1H, d, J 3.0Hz), 7.47-7.32(3H, m), 7.20(1H, q, J 7.0Hz), 7.05(1H, t, J 7.0Hz), 6.88-6.83 (1H, m) and 5.75(2H, s). 58 B 15 mp 207.0-207.4° C.; IR &ngr;max(Nujol)/cm−1 3496, 3229, 3201, 3057, 2965, 2743, 1785 and 1615; NMR &dgr;H(400MHz, DMSO) 8.13-8.10(1H, m), 7.89(1H, d, J 3.5Hz), 7.40-7.27(4H, m), 7.08(1H, dt, J 8.5, 3.0Hz), 6.87-6.84(1H, m) and 5.66(2H, s). 59 B 30 mp 187.9-188.7° C. IR&ngr;max(DR)/cm−1 3338, 3202, 1659, 1607, 1567, 1523, 1457, 1424, 1321, 1204 and 1025; NMR &dgr;H(400MHz, DMSO) 7.88(1H, d, J 3.5Hz), 7.65(1H, t, J 7.5Hz), 7.29(2H, br s), 7.18(1H, d, J 7.5Hz), 6.89(1H, d, J 8.0Hz), 6.51(1H, d, J 3.0Hz), 5.69(2H, s), 2.46(3H, s) and 2.42(3H, s); Anal. Calcd for C16H15N7O.0.2 H2O: C, 59.14; H, 4.78, N, 30.17. Found: C, 59.37; H, 4.66; N, 29.86. 60 B 33 mp 209.7-209.8° C.; IR &ngr;max(DR)/cm−1 3404, 3330, 3226, 3109, 2961, 2926, 2742, 1637, 1601, 1508, and 1474; NMR &dgr;H(400MHz, DMSO) 7.83(1H, dd, J 0.5, 3.2Hz), 7.54-7.46(1H, m), 7.3(2H, br s), 7.16(2H, t, J 8.2Hz), 6.49(1H, dd, J 1.0, 3.5Hz), 5.63(2H, s) and 2.44(3H, s). 61 B 20 mp 193.8-194.1° C.; IR &ngr;max(DR)/cm−1 3336, 3218, 2980, 2753, 2432, 1734, 1654, 1611, 1438, 1381, 1331 and 1224; NMR &dgr;H(400MHz, DMSO) 7.86(1H, d, J 3.0Hz), 7.49(1H, dd, J 1.5, 5.0Hz), 7.3(2H, br s), 7.16(1H, dd, J 1.0, 3.5Hz), 7.0(1H, dd, J3.5, 5.0Hz), 6.50(1H, dd, J 1.0, 3.5Hz), 5.82(2H, s) and 2.45(3H, s). 62 B 40 mp 210.4-210.5° C.; IR &ngr;max(DR)/cm−1 3511, 3300, 3179, 2940, 2740, 2688, 1986, 1832, 1734, 1634, 1500 and 1436; NMR &dgr;H(400MHz, DMSO) 7.87(1H, d, J 3.5Hz), 7.40-7.37(3H, m), 7.30(2H, br s), 7.23-7.18(1H, m), 6.51 (1H, dd, J 1.0, 5.1Hz), 5.68(2H, s) and 2.45(3H, s). 63 N 41 mp 201.1-201.2° C.; IR &ngr;max(DR)/cm−1 3453, 3317, 3195, 1638, 1599, 1510, 1434; NMR &dgr;H(400MHz, DMSO) 8.28(1H, d, J 6.0Hz), 8.12-8.11(1H, m), 7.91(1H, d, J 3.5Hz), 7.29(2H, br s), 6.91(1H, dd, J 6.0, 2.5Hz), 6.87-6.85 (2H, m), 5.71(2H, s), 3.81(3H, s). 64 B 9 mp 218.0-218.1° C.; IR &ngr;max(DR)/cm−1 3999, 3376, 3209, 2916, 2747, 2326, 1957, 1782, 1610, 1515, 1278, 1023 and 763; NMR &dgr;H(400MHz, DMSO) 2.42 (3H, s), 5.64(2H, s), 6.86(1H, s), 6.91(1H, d, J 7.5Hz), 7.13(1H, t, J 7.0Hz), 7.17-7.26(2H, m), 7.32(2H, s), 7.90(1H, d, J 3.5Hz), 8.12(1H, s). 65 B 25 mp 208.1-208.2° C.; IR &ngr;max(Nujol)/cm−1 3347, 3199, 2981, 2932, 2764, 2719, 1660 and 1612; NMR &dgr;H(400MHz, DMSO) 8.14-8.11(1H, m), 7.90(1H, d, J 3.5Hz), 7.41-7.22(4H, m), 7.15-7.09(1H, m), 6.87-6.83(1H, m) and 5.69 (2H, s); Anal. Calcd for C15H10F2N6O.0.5 H2O: C, 53.42; H, 3.29, N, 24.92. Found: C, 53.72; H, 3.06; N, 24.77. 66 W 25 mp 243.4-243.9° C.; IR &ngr;max(Nujol)/cm−1 4008, 3483, 3316, 3196, 1734, 1599 and 1505; NMR &dgr;H(400MHz, DMSO) 8.32(1H, dd, J 9.0, 3.0Hz), 8.21(1H, d, J 3.0Hz), 8.12-8.10(1H, m), 7.68(1H, d, J 3.5Hz), 7.31(1H, d, J 9.0Hz), 7.00(2H, s), 6.85-6.82(1H, m), 5.94(2H, s) and 3.93(3H, s); Anal. Calcd for C16H13N7O4: C, 52.32; H, 3.57, N, 26.68. Found: C, 52.16; H, 3.56; N, 26.67. 67 B 32 mp 252.9-253.0° C.; IR &ngr;max(DR)/cm−1 3511, 33260, 2945, 1732, 1626, 1573, 1499, 1422, 1327 and 1222; NMR &dgr;H(400MHz, DMSO) 8.4(1H, d, J 4.5Hz), 7.87(1H, d, J 3.0Hz), 7.77-7.71(2H, m) 7.47-7.38(2H, m), 7.3(2H, br s), 6.50(1H, dd, J 1.0, 3.5Hz), 5.70(2H, s), 2.75(3H, d, J 4.5Hz) and 2.45(3H, s). 68 R 58 mp 228.1-229.3° C.; IR &ngr;max(Nujol)/cm−1 3508, 3263, 2990, 2946, 2837, 1646 and 1419; NMR &dgr;H(400MHz, DMSO) 8.29(1H, t, J 6.0Hz), 8.14-8.09(1H, m), 7.90(1H, d, J 3.5Hz), 7.33(2H, s), 7.29(1H, t, J 7.5Hz), 7.21-7.09(3H, m), 6.88-6.83(1H, m), 5.64(2H, s), 4.20(1H, d, J 6.0Hz) and 1.83(3H, s); Anal. Calcd for C18H17N7O2.0.25 H2O: C, 58.77; H, 4.79, N, 26.65. Found: C, 58.86; H, 4.54; N, 26.24. 69 X 2 NMR &dgr;H(400MHz, DMSO) 8.53(1H, s), 7.69(1H, s), 7.58(2H, br s), 7.45-7.36 (1H, m), 7.29-7.22(2H, m), 7.21-7.15(1H, m) and 5.73(2H, s); Retention time 1.14 min. 70 N 39 NMR &dgr;H(400MHz, DMSO) 8.45(1H, d, J 5.0, 1.0Hz), 8.13-8.12(1H, m), 7.91(1H, dd, J 3.5, 1.0Hz), 7.51-7.48(2H, m), 7.31(2H, br s), 6.87-6.85(1H, m), 5.80(2H, s); Retention time 1.75 min. 71 N 65 mp 228.7-228.9° C.; IR &ngr;max(DR)/cm−1 3408, 3326, 3210, 1648, 1614, 1511; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 8.02-7.96(1H, m), 7.92(1H, d, J 3.5Hz), 7.33(2H, br s), 7.20(1H, dd, J 7.5, 2.0Hz), 7.12(1H, dd, J 8.0, 2.0Hz), 6.87(1H, dd, J 3.5, 1.0Hz), 5.75(2H, s); Anal. Calcd for C14H11N7OF.0.2 H2O.0.1 C4H10O2: C, 53.66; H, 3.57, N, 30.42. Found: C, 53.68; H, 3.44; N, 30.24. 72 B 28 mp 195.4-196.5° C.; IR &ngr;max(DR)/cm−1 3328, 3210, 2956, 2836, 2740, 1736, 1648, 1608, 1438, 1322 and 1250; NMR &dgr;H(400MHz, DMSO) 7.87(1H, d, J 3.5Hz), 7.33-7.25(3H, m), 7.05(1H, d, J 7.5Hz), 6.88(1H, td, J 1.0, 7.5Hz), 6.87(1H, dd, J 2.0, 7.5Hz), 6.50(1H, dd, J 1.0, 3.5Hz), 5.58(2H, s), 3.83(3H, s) and 2.45(3H, s). 73 B 28 mp 178.7-179.3° C.; IR &ngr;max(DR)/cm−1 3468, 3346, 3172, 2988, 2747, 2130, 1943, 1696, 1610, 1418, 1330, and 1177; NMR &dgr;H(400MHz, DMSO) 7.86(1H, d, J 3.01Hz), 7.34-7.26(4H, m), 7.20-7.10(2H, m) 7.09(1H, s), 6.50(1H, dd, J 1.0, 3.5Hz), 5.63(2H, s), 4.2(2H, d, J 6.0Hz), 2.45(2H, s) and 1.34(9H, s). 74 C 40 mp 214.6-215.2° C.; IR &ngr;max(DR)/cm−1 2877, 1653, 1596, 1523, 1470, 1355, 1284, 1241, 1210 and 1109; NMR &dgr;H(400MHz, DMSO) 7.87(1H, d, J 3.0Hz), 7.16(1H, t, J 7.0Hz), 7.0-6.75(3H, m), 6.51(1H, d, J 3.0Hz), 5.58(2H, s) and 2.45(3H, s). 75 C 3 NMR &dgr;H(400MHz, DMSO) 4.74(4H, s), 5.33(2H, s), 5.62(2H, d, J 2.0Hz), 5.71(1H, t, J 2.0Hz), 6.83-6.88(1H, m), 7.29(2H, s), 7.91(1H, dd, J 3.5, 1.0Hz), 8.10-8.12(1H, m); Retention time 2.95 min. 76 K 100 IR &ngr;max(DR)/cm−1 3011, 1650, 1525, 1468, 1351, 1284 and 1210; NMR &dgr;H(400MHz, CD3OD) 8.36(1H, d, J 3.5Hz), 7.53-7.42(4H, m), 6.72(1H, dd, J 1.0Hz, 3.5Hz), 5.76(2H, s), 4.11(2H, s) and 2.61(3H, s). 77 W 25 mp 212.1-214.3° C.; IR &ngr;max(DR)/cm−1 4007, 3474, 3323, 3199, 2934, 2747, 2105, 1647, 1603, 1492, 1245, 1028 and 754; NMR &dgr;H(400MHz, DMSO) 3.82 (3H, s), 5.60(2H, s), 6.78-6.93(3H, m), 7.05(1H, d, J 8.5Hz), 7.24-7.38 (3H, m), 7.90(1H, d, J 3.0Hz), 8.12(1H, s). 78 B 21 IR &ngr;max(DR)/cm−1 4002, 3482, 3313, 3201, 2938, 2739, 2339, 2107, 1936, 1731, 1650, 1436, 1253, 1082 and 751; NMR &dgr;H(400MHz, DMSO) 5.82(2H, s), 6.84-6.88 (1H, m), 7.38(2H, s), 7.58(1H, t, J 9.0Hz), 7.90(1H, t, J 3.0Hz), 8.12 (1H, d, J 1.0Hz), 8.23-8.28(1H, m), 8.29-8.35(1H, m). 79 C 64 mp 308.2-308.3° C.; IR &ngr;max(DR)/cm−1 4013, 3456, 3322, 3193, 2958, 2745, 2103, 1861, 1653, 1516, 1237, 1026 and 777; NMR &dgr;H(400MHz, DMSO) 4.95 (2H, s), 5.56(2H, s), 6.15-6.20(1H, m), 6.44-6.51(1H, m), 6.84-6.93(2H, m), 7.34(2H, s), 7.91(1H, d, J 3.0Hz), 8.12(1H, d, J 1.0Hz). 80 Y 10 NMR &dgr;H(400MHz, DMSO) 8.84(1H, br s), 7.46-7.35(2H, m), 7.32-7.14 (4H, m) and 5.72(2H, s); Retention time 0.84 min. 81 B 47 mp 229.3-229.4° C.; IR &ngr;max(DR)/cm−1 3514, 3292, 3166, 1614, 1503; NMR &dgr;H (400MHz, DMSO) 7.88-7.84(2H, m), 7.47(1H, d, J 8.0Hz), 7.31(2H, br s), 7.22(1H, d, J 7.0Hz), 6.52-6.51(1H, m), 5.75(2H, s), 2.46(3H, s); Anal. Calcd for C15H12N7OCl.0.1 H2O: C, 52.44; H, 3.58, N, 28.54. Found: C, 52.62; H, 3.59; N, 28.20. 82 H 36 mp 205.0-205.3° C.; NMR &dgr;H(400MHz, DMSO) 7.97-7.85(5H, m), 7.46-7.41 (3H, m), 7.32(2H, br s), 7.13(1H, d, J 8.5Hz), 6.53-6.52(1H, m), 5.85 (2H, s), 2.46(3H, s). 83 C 19 mp 252.8-253.3° C.; NMR &dgr;H(400MHz, MeOD) 8.21(1H, d, J 3.0Hz), 7.98 (1H, d, 3.5Hz), 7.62-7.52(2H, m), 7.37-7.31(2H, m) and 5.81(2H, s); Retention time 0.83 min. 84 C 53 mp 235.8-236.5° C.; IR &ngr;max(DR)/cm−1 3309, 2836, 2033, 1823, 1651, 1505, 1468, 1354, 1250 and 1209; NMR &dgr;H(400MHz, CD3OD) 8.18(1H, d, J 4.0Hz), 7.47-7.37(3H, m), 6.61(1H, dd, J 1.0, 3.5Hz), 5.82(2H, s) and 2.57(3H, s). 85 R 72 mp 215.9-217.5° C.; IR &ngr;max(Nujol)/cm−1 3308, 2955, 2869, 1634, 1505 and 1435; NMR &dgr;H(400MHz, DMSO) 8.27(1H, t, J 5.5Hz), 8.13(1H, d, J 1.0Hz), 7.91(1H, d, J 3.5Hz), 7.36(2H, s), 7.31(1H, t, J 7.5Hz), 7.17(2H, t, J 7.5Hz), 7.09(1H, s), 6.89-6.84(1H, m), 5.64(2H, s), 4.21(2H, d, J 6.0Hz), 1.93(2H, s) and 0.79(6H, d, J 6.5Hz). 86 B 51 NMR &dgr;H(400MHz, DMSO) 8.84(1H, d, J 5.5Hz), 8.14(1H, d, J 2.0Hz), 8.08 (1H, dd, J 5.5, 1.0Hz), 7.89(1H, d, J 5.5Hz), 7.34(2H, br s), 6.53-6.52(1H, m), 5.98(2H, s), 2.46(3H, s); Retention time 1.85 min. 87 Z 73 NMR &dgr;H(400MHz, DMSO) 9.10(1H, s), 8.69(1H, s), 8.05(1H, d, J 5.5Hz), 7.89(1H, d, J 3.0Hz), 7.32(2H, br s), 6.59-6.57(1H, m), 6.53-6.51(1H, m), 6.37-6.36(1H, m), 5.60(2H, s), 2.46(3H, s); M/Z 339(M+H)+; Retention time 0.79 min. 88 B 11 mp 258.8-259.0° C.; IR &ngr;max(DR)/cm−1 4014, 3316, 3204, 2966, 2746, 2561, 2106, 1962, 1606, 1526, 1436, 1351, 1029 and 758; NMR &dgr;H(400MHz, DMSO) 2.46(3H, s), 5.79(2H, s), 6.86-6.88(1H, m), 7.23(1H, d, J 7.5Hz), 7.30-7.50 (3H, m), 7.81(1H, d, J 8.0Hz), 7.91(1H, d, J 3.5Hz), 8.13-8.15(1H, m). Anal. Calcd for C16H13N7O3: C, 54.70; H, 3.73; N, 27.89. Found: C, 54.70; H, 3.77; N, 27.48. 89 C 57 mp 247.1-247.2° C.; IR &ngr;max(DR)/cm−1 3322, 1740, 1600, 1240, 1167, 959 and 770; NMR &dgr;H(400MHz, DMSO) 2.10(3H, s), 4.93(2H, s), 5.56(2H, s), 6.11 (1H, d, J 6.5Hz), 6.58(1H, d, J 8.0Hz), 6.80(1H, t, J 7.5Hz), 6.85-6.87(1H, m), 7.35(2H, s), 7.90(1H, d, J 3.5Hz), 8.12-8.14(1H, m). 90 C 38 mp 268.5-269.1° C.; IR &ngr;max(DR)/cm−1 4010, 3451, 3317, 3182, 2957, 2749, 2104, 1844, 1652, 1608, 1487, 1335, 1025 and 764; NMR &dgr;H(400MHz, DMSO) 1.99(3H, s), 4.89(2H, s), 5.47(2H, s), 6.36-6.43(2H, m), 6.84-6.89(2H, m), 7.35(2H, s), 7.91(1H, d, J 3.5Hz) 8.12-8.14(1H, m). 91 B 15 mp 284.3-284.5° C.; IR &ngr;max(DR)/cm−1 3321, 3216, 1612, 1031, 765 and 552; NMR &dgr;H(400MHz, DMSO) 8.12(1H, d, J 1.0Hz), 7.88(1H, d, J 3.5Hz), 7.35 (2H, br s), 6.85(1H, dd, J 3.5, 1.5Hz), 5.44(2H, s), 2.52(3H, s) and 2.25(3H, s) 92 B 8 mp 267.9-268.5° C.; NMR &dgr;H(400MHz, DMSO) 2.32(3H, s), 5.69(2H, s), 6.85-6.89(1H, s), 7.04-7.10(1H, m), 7.33-7.54(4H, m), 7.90(1H, d, J 3.5Hz), 8.13-8.15(1H, m). 93 B 4 IR &ngr;max(Nujol)/cm−1 3316, 3193, 2926, 2851, 1637, 1508 and 1437; NMR &dgr;H (400MHz, DMSO) 8.11-8.09(1H, m), 7.89(1H, dd, J 3.5, 1.0Hz), 7.27(2H, s), 6.86-6.83(1H, m), 4.26(2H, d, J 7.5Hz), 2.04-1.90(1H, m), 1.72-1.50 (5H, m) and 1.25-0.95(5H, m). 94 B 15 mp 237.8-238.0° C.; NMR &dgr;H(400MHz, DMSO) 2.49(3H, s), 5.76(2H, s), 6.84-6.88(1H, m), 7.28(1H, dd, J 8.5, 1.5Hz), 7.30-7.42(3H, m), 7.91(1H, d, J 3.5Hz), 7.97(1H, d, J 8.5Hz), 8.11-8.14(1H, m). Anal. Calcd for C16H13N7O3.0.1 H2O: C, 54.42; H, 3.77; N, 27.77. Found: C, 54.73; H, 3.78; N, 27.40. 95 N 32 mp 249.8-250.0° C.; IR &ngr;max(DR)/cm−1 3437, 3317, 3210, 2964, 2865, 1610, 1508; NMR &dgr;H(400MHz, DMSO) 8.19-8.17(1H, m), 8.12(1H, m), 7.92-7.91 (1H, m), 7.66-7.63(1H, m), 7.24-7.20(3H, m), 6.86(1H, dd, J 3.5, 1.5Hz), 5.80(2H, s), 2.44(3H, s). 96 B 4 mp 226.6-226.9° C.; NMR &dgr;H(400MHz, DMSO) 2.32(3H, s), 5.98(2H, s), 6.84(1H, s), 6.85-6.90(1H, m), 7.35(2H, s), 7.43(1H, d, J 7.5Hz), 7.91(1H, d, J 7.5Hz), 8.07-8.15(2H, m). 97 C 63 mp 245.3-246.1° C.; IR &ngr;max(DR)/cm−1 4010, 3406, 3320, 3198, 2929, 2746, 1608, 1507, 1414, 1285, 1022 and 753; NMR &dgr;H(400MHz, DMSO) 2.00(3H, s), 4.86(2H, s), 5.42(2H, s), 6.54(1H, d, J 8.0Hz), 6.82-6.85(1H, m), 6.90 (1H, dd, J 8.0, 2.0Hz), 6.92-6.95(1H, m), 7.29(2H, s), 7.88(1H, d, J 3.5Hz), 8.09-8.12(1H, m). Anal. Calcd for C16H15N7O.0.2 H2O: C, 59.14; H, 4.78; N, 30.17. Found: C, 59.44; H, 4.74; N, 29.82. 98 O 98 IR &ngr;max(Nujol)/cm−1 3324, 3206, 1698, 1650 and 1611; NMR &dgr;H(400MHz, DMSO) 13.56-12.46(1H, s), 8.13-8.11(1H, s), 7.92-7.84(3H, m), 7.56-7.31 (3H, m), 6.87-6.85(1H, m) and 7.74(2H, s). 99 P 66 IR &ngr;max(Nujol)/cm−1 3324, 1644, 1491 and 1417; NMR &dgr;H(400MHz, DMSO) 8.12(1H, s), 7.98-7.93(1H, s), 7.91(1H, d, J 3.0Hz), 7.81(1H, d, J 6.5Hz), 7.77(1H, s), 7.47-7.29(5H, m), 6.86(1H, s) and 5.77-5.68(2H, m). 100 B 13 mp 285.7-285.9° C.; IR &ngr;max(DR)/cm−1 3345, 3197, 1664, 1613, 1116, 766 and 600; NMR &dgr;H(400MHz, DMSO) 8.13-8.02(1H, m) 7.90(1H, d, J 3.5Hz), 7.37-7.27(3H, m), 6.86(1H, dd, J 3.5, 2.0Hz), 5.67(2H, s) and 2.52(3H, s). 101 AA 32 mp 279.9-280.3° C.; NMR &dgr;H(400MHz, DMSO) 8.33(3H, br s), 7.93(1H, d, J 2.0Hz), 7.51-7.39(2H, m), 7.39-7.31(3H, m), 5.69(2H, s) and 3.98(2H, q, J 5.5Hz). 102 P 23 IR &ngr;max(Nujol)/cm−1 3480, 3322, 3202, 283, 1608 and 1506; NMR &dgr;H(400MHz, DMSO) 8.12(1H, s), 7.90(1H, d, J 3.5Hz), 7.47-7.25(5H, m), 6.87-6.84 (1H, m), 5.72(2H, s), 3.77-3.61(1H, s), 2.76(3H, s), 1.10(3H, s) and 0.99 (3H, s). 103 P 58 IR &ngr;max(Nujol)/cm−1 3298, 2972, 1635 and 1418; NMR &dgr;H(400MHz, DMSO) 8.21(1H, d, J 7.5Hz), 8.12(1H, s), 7.91(1H, d, J 3.0Hz), 7.82-7.74(2H, m), 7.48-7.29(4H, m), 6.86(1H, s), 5.71(2H, s), 4.13-4.01(1H, m) and 1.13(6H, d, J 6.5Hz). 104 C 10 mp 249.9-250.5° C.; NMR &dgr;H(400MHz, DMSO) 2.07(3H, s), 5.06(2H, s), 5.43(2H, s), 6.60-6.65(2H, m), 6.81-6.89(2H, m), 7.37(2H, s), 7.90(1H, dd, J 3.5, 1.0Hz), 8.12(1H, d, J 1.0Hz). Anal. Calcd for C16H15N7O.0.2H2O: C, 59.14; H, 4.78; N, 30.17. Found: C, 59.53; H, 4.75; N, 29.87. 105 B 16 mp 263.2-263.5° C.; IR &ngr;max(DR)/cm−1 3499, 3307, 3192, 2958, 2238, 1610, 1490; NMR &dgr;H(400MHz, DMSO) 8.73(1H, d, J 5.0Hz), 8.13-8.12(1H, m), 7.92-7.90(1H, m), 7.85-7.81(2H, m), 7.30(2H, br s), 6.87-6.86(1H, m), 5.87(2H, s). 106 B 16 mp 288.1-288.2° C.; IR &ngr;max(DR)/cm−1 3324, 3196, 1609, 1489, 1166, 1004, 798 and 550; NMR &dgr;H(400MHz, DMSO) 8.59(1H, s), 8.44(1H, s), 8.12(1H, s), 7.90(1H, d, J 3.5Hz), 7.31(2H, br s), 6.86(1H, dd, J 3.5, 1.5Hz), 5.81(2H, s) and 2.48(3H, s). 107 B 22 mp 276.4-277.4° C.; IR &ngr;max(DR)/cm−1 3443, 3324, 3202, 1610, 1324, 1229, 1030 and 788; NMR &dgr;H(400MHz, DMSO) 9.01(1H, dd, J 4.0, 2.0Hz), 8.45(1H, dd, J 8.5, 2.0Hz), 8.14-8.12(1H, m), 7.97(1H, d, J 8.0Hz), 7.93(1H, d, J 3.5Hz), 7.64(1H, 1H, dd, J 8.5, 4.0Hz), 7.52(1H, t, J 7.0Hz), 7.31(2H, br s), 7.15(1H, d, J 7.5Hz), 6.87(1H, dd, J 3.5, 2.0Hz) and 6.31(2H, s). 108 B 30 mp 215.0-215.3° C.; IR &ngr;max(DR)/cm−1 3325, 3198, 1612, 1246, 1026, 727 and 567; NMR &dgr;H(400MHz, DMSO) 8.14-8.12(1H, m), 7.91(1H, dd, J 3.5, 1.0Hz), 7.90-7.85(2H, m), 7.52(1H, s), 7.51-7.46(3H, m), 7.36(2H, br s), 6.86 (1H, dd, J 3.5, 1.5Hz), and 5.81(2H, s). 109 Q 23 mp 289.8-289.9° C.; IR &ngr;max(DR)/cm−1 3350, 2924, 2863, 1981, 1723, 1618, 1351, 1100, 974, 766 and 524; NMR &dgr;H(400MHz, DMSO) 8.23-8.16(2H, m), 7.77-7.62(3H, m), 7.49(2H, br s), 5.88(2H, s) and 2.56(3H, s). 110 B 31 mp 247.4-247.5° C.; IR &ngr;max(DR)/cm−1 3999, 3470, 3316, 3198, 2929, 2744, 2345, 2103, 1924, 1837, 1773, 1649, 1435, 1355, 1237, 1029 and 768; NMR &dgr;H (400MHz, DMSO) 5.79(2H, s), 6.85-6.87(1H, m), 7.36(2H, s), 7.56(1H, dd, J 8.5, 2.0Hz), 7.76(1H, d, J 8.0Hz), 7.91(1H, dd, J 3.5, 1.0Hz), 8.04(1H, d, J 2.0Hz), 8.12-8.13(1H, m). Anal. Calcd for C15H10N7O3Cl: C, 48.47; H, 2.71; N, 26.36. Found: C, 48.63; H, 2.80; N, 26.22. 111 B 14 mp 244.1-244.6° C.; NMR &dgr;H(400MHz, DMSO) 5.84(2H, s), 6.85-6.89 (1H, m), 7.37(2H, s), 7.54(1H, dd, J 9.5, 1.5Hz), 7.84(1H, t, J 1.0Hz), 7.92 (1H, d, J 3.5Hz), 8.08(1H, dd, J 9.0, 1.0Hz), 8.12-8.15(1H, m). Anal. Calcd for C15H10N8O2.0.75 C3H7NO: C, 53.25; H, 3.95; N, 31.50. Found: C, 53.08; H, 3.79; N, 31.38. 112 B 28 mp 190.4-191.4° C.; IR &ngr;max(DR)/cm−1 3482, 3308, 3194, 2940, 2880, 1610, 1508; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.92(1H, d, J 3.5Hz), 7.78(1H, t, J 8.0Hz), 7.35-7.32(3H, m), 7.04(1H, d, J 7.5Hz), 6.86(1H, dd, J 3.5, 2.0Hz), 5.75(2H, s), 4.43(2H, s), 3.33(3H, s). 113 B 39 IR &ngr;max(Nujol) cm−1 3499, 3316, 3193, 2946, 1651 and 1509; NMR &dgr;H(400MHz, DMSO) 8.13-8.10(1H, m), 7.90(1H, d, J3.5Hz), 7.39-7.26(7H, m), 6.87-6.84(1H, m) and 5.67(2H, s); Anal. Calcd for C15H12N6O.0.75 H2O: C, 58.91; H, 4.45, N, 27.48. Found: C, 58.84; H, 4.10; N, 27.32. 114 C 67 mp 256.7-257.1° C.; IR &ngr;max(DR)/cm−1 4003, 3452, 3324, 3203, 2950, 2746, 2102, 1733, 1654, 1516, 1420, 1305, 1221, 1106, 1024 and 761; NMR &dgr;H(400MHz, DMSO) 5.38(2H, s), 5.51(2H, s), 6.46(1H, dd, J 8.5, 2.5Hz), 6.58(1H, d, J 2.0Hz), 6.84-6.87(1H, m), 7.15(1H, d, J 8.0Hz), 7.32(2H, s), 7.91(1H, dd, J 3.5, 1.0Hz), 8.11-8.13(1H, m). Anal. Calcd for C15H12N7OCl.0.3 H2O: C, 51.90; H, 3.66; N, 28.24. Found: C, 52.12; H, 3.48; N, 27.86. 115 B 12 NMR &dgr;H(400MHz, DMSO) 8.84(1H, d, J 5.5Hz), 8.15-8.12(2H, m), 8.08-8.06 (1H, m), 7.92-7.91(1H, m), 7.32(2H, br s), 6.87(1H, dd, J 3.5, 1.5Hz), 5.99(2H, s); Retention time 1.28 min. 116 Z 87 NMR &dgr;H(400MHz, DMSO) 9.08(1H, br s), 8.66(1H, br s), 8.13-8.12(1H, m), 8.06-8.04(1H, m), 7.93-7.91(1H, m), 7.32(2H, br s), 6.87-6.86(1H, m), 6.60-6.58(1H, m), 6.38-6.37(1H, m), 5.61(2H, s); M/Z 325(M+H)+. 117 B 9 IR &ngr;max(DR)/cm−1 3491, 3310, 3198, 2976, 1612; NMR &dgr;H(400MHz, DMSO) 8.14-8.13(1H, m), 7.99-7.98(1H, m), 7.93-7.91(1H, m), 7.80-7.79(1H, m), 7.34(2H, br s), 6.88-6.86(1H, m), 5.90(2H, s), 2.57(3H, s). 118 Z 91 NMR &dgr;H(400MHz, DMSO) 13.45(1H, br s), 9.50(1H, br s), 8.15-8.14(1H, m), 7.92(1H, d, J 3.5Hz), 7.39(2H, br s), 6.87-6.86(1H, m), 6.56(1H, br s), 6.15(1H, br s), 5.67(2H, s), 2.39(3H, s); M/Z 339(M+H)+. 119 B 15 mp > 230° C.; IR &ngr;max(DR)/cm−1 3993, 3509, 3314, 3195, 2997, 2950, 2682, 2561, 2101, 1943, 1780, 1613, 1501, 1433, 1345, 1100, 1027, 889 and 780; NMR &dgr;H(400MHz, DMSO) 6.00(2H, s), 6.85-6.90(1H, m), 7.05(1H, d, J 8.5Hz), 7.37(2H, s), 7.78(1H, dd, J 8.5, 2.0Hz), 7.91(1H, d, J 3.5Hz), 8.14(1H, d, J 1.0Hz), 8.27(1H, d, J 2.5Hz). Anal. Calcd for C15H10N7O3Cl.0.3 H2O: C, 47.77; H, 2.83; N, 26.00. Found: C, 47.65; H, 2.71; N, 25.85. 120 C 19 mp 211.4-211.6° C.; IR &ngr;max(DR)/cm−1 4015, 3325, 3218, 2969, 2878, 2101, 1653, 1508, 1423, 1275, 1023, 834 and 761; NMR &dgr;H(400MHz, DMSO) 5.45 (2H, s), 5.60(2H, s), 6.51(1H, dd, J 8.0, 2.0Hz), 6.70-6.79(2H, m), 6.83-6.89 (1H, m), 7.38(2H, s), 7.90(1H, d, J 3.5Hz), 8.12(1H, s). 121 B 13 mp 292.3-292.4° C.; IR &ngr;max(DR)/cm−1 3324, 3207, 2098, 1602, 1527, 1352, 1024 and 813; NMR &dgr;H(400MHz, CDCl3) 8.10(1H, d, J 3.0Hz), 7.79(1H, d, J 1.5Hz), 7.64(2H, d, J 8.5Hz), 7.49(2H, d, J 8.5Hz), 6.71(1H, dd, J 3.5, 1.5Hz), 5.71(2H, s) and 5.38(2H, br s). 122 A 50 mp 227.5-228.5° C.; IR &ngr;max(DR)/cm−1, 3265, 1701, 1521, 1480, 1413, 1355, 1309, 1204 and 1147; NMR &dgr;H(400MHz, DMSO) 8.11(1H, d, J 1.0Hz), 7.9( 1H, d, J 3.5Hz), 7.3(2H, br s), 7.04(1H, d, J 2.0Hz), 6.90( 1H, d, J 8.0Hz), 6.85(1H, dd, J 1.5, 3.5Hz), 6.79(1H, dd, J 2.0, 8.0Hz), 5.57(2H, s), 3.71(3H, s,) and 3.72(3H, s). 123 B 35 mp 214.6-216.2° C.; IR &ngr;max(DR)/cm−1 3512, 3295, 3173, 2988, 2736, 2415, 1636, 1437, 1340 and 1228; NMR &dgr;H(400MHz, DMSO) 7.97(1H, d, J 8.5Hz), 7.87(1H, d, J 3.0Hz), 7.40(1H, d, J 1.0Hz), 7.31(2H, br s), 7.27(1H, dd, J 1.5, 8.0Hz), 6.51(1H, dd, J 1.0, 3.5Hz), 5.74(2H, s), 2.48(3H, s) and 2.46(3H, s). 124 C 65 mp 215.7-216.7° C.; IR &ngr;max(DR)/cm−1 3328, 2928, 2424, 2345, 1609 and 1263; NMR &dgr;H(400MHz, DMSO) 7.85(1H, d, J 3.5Hz), 7.26(2H, br s), 6.93(1H, d, J 1.5Hz), 6.89(1H, dd, J 2.0, 8.0Hz), 6.54(1H, d, J 8.0Hz), 6.49(1H, J 1.0, 3.5Hz), 5.40(2H, s), 4.89(2H, br s), 2.45(3H, s) and 2.27(3H, s). 125 B 29 mp 221.5-221.6° C.; IR &ngr;max(DR)/cm−1 3506, 3294, 3178, 2683, 1613, 1315, 1027 and 697; NMR &dgr;H(400MHz, DMSO) 8.13-8.11(1H, m), 7.90(1H, d, J 4.5Hz), 7.38(2H, br s), 6.86(1H, dd, J 3.5, 1.5Hz), 6.18-6.16(1H, m), 5.70 (2H, s) and 2.36(3H, s). 126 N 26 mp 229.6-230.3° C.; IR &ngr;max(DR)/cm−1 3317, 3198, 1602, 1499; NMR &dgr;H(400MHz, DMSO) 8.44-8.43(1H, m), 8.31(1H, d, J 5.0Hz), 8.14-8.13(1H, m), 7.92(1H, d, J 3.0Hz), 7.35(2H, br s), 6.88-6.86(1H, m), 6.70(1H, d, J 5.0Hz), 5.71(2H, s), 2.39(3H, s). 127 B 13 mp 275.0-273.3° C.; IR &ngr;max(DR)/cm−1 3449, 3310, 3202, 1605, 1487, 1420, 1023, 836, 760 and 551; NMR &dgr;H(400MHz, DMSO) 8.15-8.11(1H, m), 8.07 (1H, d, J 9.0Hz), 7.91(1H, d, J 3.5Hz), 7.68(1H, dd, J 9.0, 6.5Hz), 7.38-7.29 (3H, m), 6.86(1H, dd, J 3.5, 1.5Hz) and 6.15(2H, s). 128 B 16 mp 129.1-131.0° C.; IR &ngr;max(DR)/cm−1 3993, 3470, 3310, 3197, 1610, 1508, 1420, 1239, 1002 and 796; NMR &dgr;H(400MHz, DMSO) 8.74(1H, d, J 1.5Hz), 8.61(1H, d, J 2.5Hz), 8.57-8.54(1H, m), 8.13-8.11(1H, m), 7.91(1H, d, J 3.5Hz), 7.31(2H, br s), 6.86(1H, dd, J 3.5, 2.0Hz) and 5.88(2H, s). 129 B 20 mp 266.5-266.7° C.; IR &ngr;max(DR)/cm−1 4018, 3487, 3310, 3193, 2744, 1636, 1585, 1539, 1507, 1437, 1347, 1266, 1238 and 1196; NMR &dgr;H(400MHz, DMSO) 8.15(1H, dd, J 2.5, 7.5Hz), 8.12(1H, d, J 1.0Hz), 7.90( 1H, d, J 3.5Hz), 7.73-7.68(1H, m), 7.58(1H, dd, J 11.3, 8.8Hz), 7.36(2H, br s), 6.88(1H, dd, J 1.5, 3.5Hz) and 5.78(2H, s). 130 H 32 mp 149.0-149.6° C.; IR &ngr;max(DR)/cm−1 4072, 3332, 3198, 1654, 1604, 1348, 1237, 1111, 1012, 775, 691 and 570; NMR &dgr;H(400MHz, DMSO) 8.79-8.70 (2H, m), 8.25-8.14(2H, m), 7.77-7.58(5H, m), 7.38(2H, br s) and 5.87(2H, s). 131 B 22 mp 225.7-225.8° C.; NMR &dgr;H(400MHz, DMSO) 8.33(1H, d, J 4.5Hz), 8.13-8.12 (1H, m), 7.92-7.91(1H, m), 7.30(2H, br s), 7.15(1H, d, J 5.0Hz), 7.07-7.06 (1H, m), 6.86(1H, dd, J 1.5, 3.5Hz), 5.72(2H, s), 2.28(3H, s); Anal. Calcd for C15H13N7O.0.7 H2O: C, 56.31; H, 4.54, N, 30.65. Found: C, 56.57; H, 4.24; N, 30.33. 132 N 10 IR &ngr;max(DR)/cm−1 3332, 2977, 1694, 1608; NMR &dgr;H(400MHz, DMSO) 8.41 (1H, d, J 4.5Hz), 8.14-8.13(1H, m), 7.92(1H, d, J 3.5Hz), 7.43(1H, t, J 6.0Hz), 7.33(2H, br s), 7.16(1H, d, J 4.5Hz), 6.97-6.96(1H, m), 6.87(1H, dd, J 2.0, 3.5Hz), 5.76(2H, s), 4.10(2H, d, J 6.0Hz), 1.31(9H, s). 133 B 14 mp 209.7-209.9° C.; IR &ngr;max(Nujol)/cm−1 3506, 3311, 3196, 2996, 2951, 1637, 1518 and 1283; NMR &dgr;H(400MHz, DMSO) 8.15-8.12(1H, m), 7.91(1H, dd, J 3.5, 1.0Hz), 7.84(1H, d, J 8.0Hz), 7.43(1H, d, J 1.5Hz), 7.42-7.35(2H, s), 6.88-6.82(2H, m), 5.77(2H, s) and 3.91(3H, s). 134 B 14 mp 240.9-241.1° C. IR &ngr;max(DR)/cm−1 4010, 3629, 3499, 3313, 3196, 2946, 2733, 2447, 1943, 1638, 1528, 1420, 1351, 1222, 1025 and 960. NMR &dgr;H(400MHz, DMSO) 5.85(2H, s), 6.84-6.89(1H, m), 7.36(2H, s), 7.50(2H, dt, J 8.5, 2.0Hz), 7.92(1H, dd, J 3.5, 1.0Hz), 8.12-8.14(1H, m), 8.22(2H, dt, J 9.0, 2.0Hz). Anal. Calcd for C15H11N7O3.0.6H2O: C, 51.75; H, 3.53; N, 28.17. Found: C, 52.08; H, 3.22; N, 27.96. 135 B 18 mp 208.6-208.8° C.; IR &ngr;max(DR)/cm−1 3432, 3304, 3191, 2961, 1616, 1500, 1434; NMR &dgr;H(400MHz, DMSO) 8.14-8.13(1H, m), 7.93-7.91(1H, m), 7.67 (1H, t, J 7.5Hz), 7.35(2H, br s), 7.19(1H, d, J 7.5Hz), 6.90-6.86(2H, m), 5.73 (2H, s), 2.68(2H, q, J 7.5Hz), 1.14(3H, t, J 7.5Hz). 136 B 18 mp 172.7-173.2° C.; NMR &dgr;H(400MHz, DMSO) 8.42(1H, d, J 5.5Hz), 8.14 (1H, m), 7.92(1H, d, J 3.5Hz), 7.39(2H, br s), 7.11-7.10(1H, m), 6.97(1H, d, J 5.5Hz), 6.87(1H, dd, J 2.0, 3.5Hz), 5.70(2H, s), 2.71(2H, q, J 7.5Hz), 1.18 (3H, t, J 7.5Hz). 137 B 13 mp 176.3-176.5° C.; IR &ngr;max(DR)/cm−1 3452, 3326, 3209, 2973, 1734, 1611, 1328, 1026 and 774; NMR &dgr;H(400MHz, DMSO) 8.13(1H, d, J 2.5Hz), 7.90 (1H, d, J 3.5Hz), 7.72(1H, d, J 3.5Hz), 7.61(1H, d, J 8.5Hz), 7.34(2H, br s), 7.19(1H, t, J 8.0Hz), 6.86(1H, dd, J 3.5, 2.0Hz), 6.77(1H, d, J 4.0Hz), 6.75 (1H, d, J 7.5Hz), 6.07(2H, s) and 1.54(9H, s). 138 B 26 mp 58.5-62.6° C.; IR &ngr;max(DR)/cm−1 3430, 3315, 3210, 3973, 1718, 1165, 834 and 772; NMR &dgr;H(400MHz, DMSO) 8.13-8.11(1H, m), 8.03(1H, d, J 8.0Hz), 7.89(1H, d, J 3.5Hz), 7.73(1H, d, J 4.0Hz), 7.39(2H, br s), 7.30(1H, t, J 8.5Hz), 7.08(1H, d, J 7.0Hz), 6.91(1H, d, J 4.5Hz), 6.86(1H, dd, J 3.5, 1.5Hz), 5.90(2H, s) and 1.62(9H, s). 139 K 85 mp 192.3-193.5° C.; NMR &dgr;H(400MHz, DMSO) 11.27(1H, br s), 8.12(1H, d, J 2.5Hz), 7.90(1H, d, J 3.5Hz), 7.39-7.33(2H, m), 7.04(1H, t, J 8.0Hz), 6.87-6.83 (2H, m), 6.56-6.52(1H, m) and 5.86(2H, s). 140 B 20 mp 184.0-185.2° C.; IR &ngr;max(DR)/cm−1 3638, 3462, 3331, 3184, 2976, 1686, 1174, 1026 and 756; NMR &dgr;H(400MHz, DMSO) 8.13(1H, d, J 1.0Hz), 7.90 (1H, d, J 3.5Hz), 7.45-7.31(3H, m), 7.27-7.17(4H, m), 6.86(1H, dd, J 3.5, 2.0Hz), 5.64(2H, s), 4.08(2H, d, J 6.0Hz) and 1.37(9H, s). 141 C 45 mp 240.3-240.4° C. IR &ngr;max(DR)/cm−1 3320, 3198, 2929, 1610, 1505, 1438, 1280, 1233, 1028, 956 and 759; NMR &dgr;H(400MHz, DMSO) 5.85(2H, s), 6.84-6.89 (1H, m), 7.36(2H, s), 7.50(2H, dt, J 8.5, 2.0Hz), 7.92(1H, dd, J 3.5, 1.0Hz), 8.12-8.14(1H, m), 8.22(2H, dt, J 9.0Hz). 142 B 14 mp 189.0-189.1° C.; IR &ngr;max(DR)/cm−1 3506, 3304, 3180, 1735, 1609, 1167, 1029 and 766; NMR &dgr;H(400MHz, DMSO) 8.15-8.11(1H, m), 8.02(1H, d, J 8.5Hz), 7.91(1H, d, J 3.5Hz), 7.68(1H, d, J 3.5Hz), 7.53(1H, s), 7.37(2H, br s), 7.29(1H, dd, J 8.5, 1.5Hz), 6.86(1H, dd, J 3.5, 2.0Hz), 6.70(1H, d, J 3.5Hz), 5.75(2H, s) and 1.61(9H, s). 143 B 18 mp 167.0-167.3° C.; IR &ngr;max(DR)/cm−1 3650, 3485, 3320, 3194, 2978, 1726, 1168, 953 and 756; NMR &dgr;H(400MHz, DMSO) 9.00(1H, br s), 8.13(1H, s), 7.91(1H, d, J 3.5Hz), 7.57(1H, t, J 8.0Hz), 7.39(2H, br s), 7.16(1H, d, J 11.5Hz), 7.04(1H, d, J 8.5Hz), 6.86(1H, dd, J 3.5, 2.0Hz), 5.64(2H, br s) and 1.44 (9H, s). 144 K 56 mp > 300° C. dec; IR &ngr;max(DR)/cm−1 2903, 2030, 1606, 1464, 1033, 779 and 589; NMR &dgr;H(400MHz, DMSO) 8.30(2H, br s), 8.14(1H, s), 7.92(1H, d, J 3.5Hz), 7.46(2H, d, J 8.0Hz), 7.32(2H, d, J 8.0Hz), 6.92-6.84(1H, m), 5.69(2H, s) and 4.04-3.96(2H, m). 145 H 30 IR &ngr;max(DR)/cm−1 3511, 3292, 3164, 2971, 1609, 1525, 1437, 1354 and 1239; NMR &dgr;H(400MHz, DMSO) 8.19(2H, m), 7.90(1H, d, J 3.5Hz), 7.72-7.64 (2H, m), 7.36(2H, br s), 6.53(1H, d, J 3.5Hz), 5.83(2H, s), 2.80(2H, q, J 7.5Hz), and 1.27(3H, t, J 7.5Hz). 146 B 35 mp 180.0-180.5° C.; IR &ngr;max(DR)/cm−1 3325, 3206, 2976, 1734, 1604, 1341, 1024 and 768; NMR &dgr;H(400MHz, DMSO) 7.92(1H, d, J 3.0Hz), 7.84(1H, s), 7.67(1H, d, J 4.0Hz), 7.62(1H, d, J 8.0Hz), 7.37(2H, br s), 7.26(1H, d, J 8.0Hz), 6.87(1H, dd, J 3.5, 1.5Hz), 6.70(1H, d, J 3.5Hz), 5.80(2H, s) and 1.51 (9H, s). 147 K 57 mp > 200° C. dec; IR &ngr;max(DR)/cm−1 2816, 2004, 1660, 1507, 1427, 1277, 1030, 746 and 524; NMR &dgr;H(400MHz, DMSO) 8.15-8.12(1H, m), 7.91(1H, d, J 3.5Hz), 7.14(1H, d, J 12.0Hz), 7.06-6.94(2H, m), 6.86(1H, dd, J 3.5, 2.0Hz) and 5.57(2H, s). 148 B 43 Mp 259.8-259.9° C. IR &ngr;max(DR)/cm−1 3382, 3214, 2986, 2731, 2090, 1767, 1730, 1606, 1487, 1372, 1275, 1137, 1029, 873 and 771; NMR &dgr;H(400MHz, DMSO) 1.49(9H, s), 5.63(2H, s), 6.85-6.86(1H, m), 7.20-7.27(2H, m), 7.40 (2H, s), 7.87(1H, d, J 3.0Hz), 8.11-8.14(1H, m). 149 K 96 IR &ngr;max(Nujol)/cm−1 3375, 3061, 1653, 1509 and 1474; NMR &dgr;H(400MHz, DMSO) 11.15-10.13(1H, s), 8.43-7.36(3H, s), 8.14-8.12(1H, m), 7.89 (1H, dd, J 3.5, 1.0Hz), 6.87-6.84(1H, m), 6.59-6.51(2H, m) and 5.51(2H, s). 150 C 37 IR &ngr;max(DR)/cm−1 4043, 3461, 3312, 3198, 2970, 2748, 2438, 1923, 1650, 1514, 1497 and 1324; NMR &dgr;H(400MHz, DMSO) 7.9(1H, d, J 3.5Hz), 7.31(2H, br s), 6.97(1H, t, J 8.0Hz), 6.53(1H, d, J 3.5Hz), 6.45(1H, dd, J 1.5, 8.0Hz), 6.40(1H, d, J 7.5Hz), 6.34(1H, t, J 1.7Hz), 5.48(2H, s), 5.12(2H, s), 2.80(2H, q, J 7.5Hz) and 1.27(3H, t, J 7.5Hz). 151 C 48 mp 251.2-251.5° C.; IR &ngr;max(DR)/cm−1 3449, 3365, 3314, 3196, 2954, 2742, 1731, 1642, 1598, 1556, 1463 and 1407; NMR &dgr;H(400MHz, DMSO) 8.76-8.72 (2H, m), 7.67-7.62(3H, m), 7.36(2H, br s), 6.97(1H, t, J 8.0Hz), 6.46 (1H, dd, J 1.5, 8.0Hz), 6.43(1H, d, J 7.5Hz), 6.36(1H, t, J 1.7Hz), 5.52(2H, s) and 5.13(2H, s). 152 AF 86 mp 298.9-299.0° C.; IR &ngr;max(DR)/cm−1 3422, 3321, 3105, 3942, 1601, 1351, 1219, 1019 and 762; NMR &dgr;H(400MHz, DMSO) 11.09(1H, br s), 8.13(1H, s), 7.91(1H, d, J 3.0Hz), 7.51(1H, d, J 8.5Hz), 7.43-7.31(3H, m), 7.28(1H, s), 7.00(1H, d, J 8.0Hz), 6.89-6.83(1H, m), 6.39(1H, s) and 5.73(2H, br s). 153 AF 75 mp 226.8-227.4° C.; IR &ngr;max(DR)/cm−1 3475, 3320, 2739, 1645, 1506, 1223, 1008 and 778; NMR &dgr;H(400MHz, DMSO) 11.14(1H, br s), 8.14-8.10(1H, m), 7.90(1H, d, J 3.5Hz), 7.50(1H, s), 7.40-7.31(4H, m), 7.09(1H, dd, J 8.0, 1.5Hz), 6.85(1H, dd, J 3.5, 1.5Hz), 6.43-6.38(1H, m) and 5.70(2H, s). 154 AF 77 mp 295.3-295.5° C.; IR &ngr;max(DR)/cm−1 3215, 1610, 1005, 758, 650 and 565; NMR &dgr;H(400MHz, DMSO) 11.36(1H, br s), 8.15-8.11(1H, m), 7.91(1H, d, J 3.5Hz), 7.51(1H, d, J 8.0Hz), 7.46(1H, t, J 2.5Hz), 7.43(2H, br s), 6.92(1H, t, J 7.5Hz), 6.86(1H, dd, J 3.5, 2.0Hz), 6.71(1H, d, J 7.0Hz), 6.53-6.49(1H, m) and 5.93(2H, s). 155 B 35 mp 258.6-258.7° C.; IR &ngr;max(Nujol)/cm−1 3386, 3206, 1646, 1607 and 1481; NMR &dgr;H(400MHz, DMSO) 8.33(1H, dd, J 9.0, 4.5Hz), 8.15(1H, s), 7.92(1H, d, J 3.5Hz), 7.55-7.47(1H, m), 7.47-7.35(2H, s), 6.93-6.85(2H, m) and 6.03(2H, s). 156 AG 99 mp 274.2-274.3° C.; IR &ngr;max(Nujol)/cm−1 3482, 3305, 3197, 2963, 1606, 1499 and 1420; NMR &dgr;H(400MHz, DMSO) 8.12(1H, s), 7.87(1H, d, J 3.0Hz), 7.37 (2H, s), 6.86-6.77(3H, m), 5.55(2H, s) and 3.79(3H, s); Anal. Calcd for C16H12N6O2F2.0.5 H2O: C, 52.32; H, 3.57, N, 22.88. Found: C, 52.62; H, 3.31; N, 22.72. 157 B 24 mp 204.2-204.4° C.; NMR &dgr;H(400MHz, DMSO) 1.41(9H, s), 4.37,(2H, d, J 6.0Hz), 5.72(2H, s), 6.83(1H, d, J 6.0Hz), 6.85-6.88(1H, d, J 7.5Hz), 7.14-7.22 (1H, m), 7.30(2H, d, J 4.0Hz), 7.36(2H, s), 7.48(1H, t, J 6.0Hz), 7.91 (1H, d, J 3.5Hz), 8.12-8.14(1H, m). Anal. Calcd for C21H23N7O3: C, 59.85; H, 5.50; N, 23.25. Found: C, 59.69; H, 5.54; N, 22.74. 158 AZ mp > 300° C. dec; IR &ngr;max(DR)/cm−1 3212, 1607, 1438, 1212, 1029 and 770; NMR &dgr;H(400MHz, DMSO) 15.74(1H, br s), 8.13(1H, s), 7.91(1H, d, J 3.5Hz), 7.80(2H, br s), 7.54-7.30(3H, s), 6.86(1H, dd, J 4.0, 2.0Hz) and 5.85 (2H, s). 159 B 16 Mp 235.9-237.8° C.; NMR &dgr;H(400MHz, DMSO) 8.15-8.13(1H, m), 7.93-7.91 (1H, d, J 3.5Hz), 7.84-7.82(1H, d, J 2.5Hz), 7.80-7.76(1H, dd, J 2.5, 8.5Hz), 7.43-7.37(2H, s) 7.04-7.00(1H, d, J 8.5Hz), 6.89-6.86(1H, dd, J 2.0, 3.5Hz), 5.71-5.69(2H s), and 3.99-3.97(3H s). 160 B 28 mp 277.4-277.9° C.; NMR &dgr;H(400MHz, DMSO) 9.93(1H, s), 8.15-8.12(1H, m), 7.92(1H, d, J 3.5Hz), 7.55(1H, d, J 8.0Hz), 7.38(2H, s), 7.34(1H, s), 7.27 (1H, t, J 8.0Hz), 6.96(1H, d, J 7.5Hz), 6.88-6.85(1H, m), 5.63(2H, s) and 1.99(3H, s). 161 K 100 mp > 250° C. dec; IR &ngr;max(DR)/cm−1 3035, 1968, 1654, 1464, 1354, 1247, 1032 and 746; NMR &dgr;H(400MHz, DMSO) 4.39(2H, q, J 5.5Hz), 5.81(2H, s), 6.84-6.89 (1H, m), 7.13(1H, d, J 7.5Hz), 7.31-7.46(3H, m), 7.55(1H, d, J 7.5Hz), 7.90(1H, d, J 3.5Hz), 8.12-8.16(1H, m), 8.44(3H, s). Anal. Calcd for C16H15N7O.2 HCl.1.5 H2O: C, 45.62; H, 4.79; N, 23.27. Found: C, 45.63; H, 4.71; N, 23.14. 162 B 14 mp 195.1-195.2° C.; IR &ngr;max(DR)/cm−1 3490, 3375, 3310, 3199, 2895, 1734, 1609, 1507, 1421, 1228, 1026, 1001 and 760; NMR &dgr;H(400MHz, DMSO) 2.86 (6H, s), 5.58(2H, s), 6.48(1H, d, J 7.5Hz), 6.64(1H, dd, J 8.0, 2.0Hz), 6.72-6.75 (1H, m), 6.84-6.87(1H, m), 7.12(1H, t, J 7.5Hz), 7.35(2H, s), 7.90(1H, d, J 3.5Hz) and 8.10-8.14(1H, m). 163 B 20 IR &ngr;max(DR)/cm−1 3489, 3324, 3199, 2560, 1605, 1235, 1121, 1048 and 762; NMR &dgr;H(400MHz, DMSO) 8.12(1H, d, J 2.5Hz), 7.90(1H, d, J 3.5Hz), 7.44-7.32 (4H, m), 7.16(2H, d, J 9.0Hz), 6.86(1H, dd, J 3.5, 1.5Hz) and 5.67(2H, s). 164 B 16 mp 120.1-121.0° C.; IR &ngr;max(DR)/cm−1 3318, 1772, 1709, 1607, 1462, 1395; NMR &dgr;H(400MHz, DMSO) 8.15-8.14(1H, m), 7.81(1H, d, J 3.5Hz), 7.77 (1H, t, J 8.0Hz), 7.71-7.65(4H, m), 7.33(1H, d, J 8.0Hz), 7.21(2H, br s), 7.12 (1H, d, J 8.0Hz), 6.88(1H, dd, J 1.5, 3.5Hz), 5.68(2H, s), 4.80(2H, s). 165 C 60 mp 259.7-259.8° C.; IR &ngr;max(DR)/cm−1 3457, 3315, 3183, 2959, 2747, 1734, 1653, 1608, 1518, 1441, 1420 and 1386; NMR &dgr;H(400MHz, DMSO) 8.12(1H, d, J 1.0Hz), 7.90(1H, d, J 3.5Hz), 7.35(2H, br s), 6.93(1H, dd, J 8.0, 11.5Hz), 6.86(1H, dd, 1.5, J 3.5Hz), 6.58(1H, dd, J 2.0, J 8.5Hz) 6.47-6.39(1H, m), 5.49(2H, s) and 5.19(2H, s). 166 B 10 mp 210.3-211.2° C.; NMR &dgr;H(400MHz, DMSO) 8.15-8.10(1H, m), 7.89(1H, d, J 4.5Hz), 7.35(2H, br s), 7.18(1H, s), 7.08(1H, d, J 8.0Hz), 6.85(1H, dd, J 3.5, 1.5Hz), 6.72(1H, d, J 8.0Hz), 5.55(1H, s), 4.49(2H, t, J 8.5Hz) and 3.13 (2H, t, J 8.5Hz). 167 B 11 IR &ngr;max(Nujol)/cm−1 3486, 3319, and 1606; NMR &dgr;H(400MHz, DMSO) 8.15-8.10 (1H, m), 7.92-7.87(1H, d, J 3.5Hz), 7.64-7.56(1H, m), 7.54-7.47(1H, m), 7.46-7.35(2H, s), 7.32-7.22(1H, t, J 9.5Hz), 6.88-6.84(1H, dd, J 2.0, 3.5Hz), and 5.71-5.65(2H s); Anal. Calcd for C15H10N6OFBr.0.5 H2O: C, 45.25; H, 2.78; N, 21.11. Found: C, 45.10; H, 2.48; N, 20.69. 168 B 12 Mp 204.0-204.2° C.; IR &ngr;max(Nujol)/cm−1 3343 and 3208; NMR &dgr;H(400MHz, DMSO) 8.14-8.12(1H, m), 7.91-7.89(1H, dd, J 1.0, 3.5Hz), 7.62-7.53(1H, m), 7.45-7.37(2H, s), 7.05-6.97(1H, m), 6.88-6.85(1H, dd, J 2.0, 3.5Hz), and 5.76-5.74(2H, s). 169 B 11 IR &ngr;max(Nujol)/cm−1 3490 and 3321; NMR &dgr;H(400MHz, DMSO) 8.15-8.13 (1H, m), 7.91-7.89(1H, d, J 3.5Hz), 7.78-7.72(1H, m), 7.67-7.63(1H, dd, J 2.0, 7.0Hz), 7.46-7.38(2H, s), 7.15-7.08(1H, dd, J 9.0, 10.0Hz) 6.88-6.85 (1H, dd, J 2.0, 3.5Hz), and 5.67-5.64(2H, s). 170 B 18 IR &ngr;max(Nujol)/cm−1 3495 and 3304; NMR &dgr;H(400MHz, DMSO) 8.14-8.12 (1H, m), 7.90-7.88(1H, dd, J 1.0, 3.5Hz), 7.64-7.62(1H, dd, J 1.0, 2.0Hz), 7.43-7.37(2H, s), 6.87-6.84(1H, dd, J 1.5, 3.5Hz), 6.51-6.48(1H, dd, J 1.0, 3.5Hz), 6.46-6.44(1H, dd, J 2.0, 3.5Hz) and 5.67-5.65(2H, s). 171 C 59 mp 219.3° C.; IR &ngr;max(Nujol)/cm−1 3508, 3421, 3307, 3190, 2949, 1609 and 1506; NMR &dgr;H(400MHz, DMSO) 8.14(1H, s), 7.91(1H, d, J 3.5Hz), 7.43(2H, s), 6.92-6.85(2H, m), 6.72(1H, dd, J 8.5, 5.0Hz), 6.52(1H, dd, J 9.5, 3.0Hz), 5.47(2H, s) and 5.19(2H, s). 172 B 18 IR &ngr;max(Nujol)/cm−1 3490, 3304, 3182, 2986, 1779, 1762, 1603, 1345 and 1231; NMR &dgr;H(400MHz, DMSO) 8.16(1H, d, J 8.5Hz), 8.15-8.13(1H, m), 7.92 (1H, d, J 3.5Hz), 7.46(1H, d, J 2.0Hz), 7.45-7.36(2H, s), 7.32(1H, dd, J 8.5, 1.5Hz), 6.88-6.86(1H, m), 5.84(2H, s) and 1.47(9H, s). 173 C 78 mp 239.6-239.8° C.; IR &ngr;max(Nujol)/cm−1 3323, 2936, 2733, 1772, 1734, 1609, 1508 and 1282; NMR &dgr;H(400MHz, DMSO) 9.07(1H, s), 8.13-8.11(1H, m), 7.89(1H, d, J 3.5Hz), 7.34(2H, s), 6.87-6.84(1H, m), 6.59-6.50(3H, m), 5.41(2H, s) and 4.57(2H, s). 174 K 81 mp > 200° C.; dec; IR &ngr;max(DR)/cm−1 3144, 2570, 2004, 1654, 1458, 1369, 1280, 1037 and 760; NMR &dgr;H(400MHz, DMSO) 7.87(1H, d, J 3.5Hz), 7.13(1H, d, J 11.5Hz), 7.05-6.91(2H, m), 6.51(1H, dd, J 3.5, 1.0Hz), 5.55(2H, s) and 2.45 (3H, s). 175 C 17 mp 279.3-281.3° C.; IR &ngr;max(DR)/cm−1 3462, 3202, 2952, 1653, 1510, 1462, 1416, 1342, 1293 and 1261; NMR &dgr;H(400MHz, DMSO) 13.52(1H, br s), 7.97 (1H, br s), 7.31(1H, s), 7.25(2H, br s), 6.96(1H, t, J 7.5Hz), 6.46(1H, dd, J 1.0, 8.0Hz), 6.42(1H, d, J 7.0), 6.34(1H, s), 5.50(2H, s) and 5.13(2H, s). 176 K 51 IR &ngr;max(Nujol)/cm−1 3651, 3488, 3317, 1637, 1507 and 1331; NMR &dgr;H(400MHz, DMSO) 11.04(1H, s), 8.15-8.13(1H, m), 7.92(1H, dd, J 3.5, 1.0Hz), 7.87(1H, d, J 8.5Hz), 7.41(2H, s), 6.88-6.86(1H, m), 6.85-6.81(2H, m) and 5.72(2H, s); Anal. Calcd for C15H11N7O4.1.0 H2O: C, 48.52; H, 3.53, N, 26.24. Found: C, 48.68; H, 3.20; N, 26.24. 177 AL 65 mp 245.9-247.0° C.; IR &ngr;max(DR)/cm−1 3284, 3194, 1654, 1609, 1523; NMR &dgr;H (400MHz, DMSO) 8.41(1H, t, J 6.0Hz), 8.14-8.13(1H, m), 7.92(1H, dd, J 1.0, 3.5Hz), 7.73(1H, t, J 7.5Hz), 7.37(2H, br s), 7.21(1H, d, J 7.5Hz), 6.93 (1H, d, J 7.5Hz), 6.88-6.86(1H, m), 5.74(2H, s), 4.28(2H, d, J 6.0Hz), 1.88 (3H, s); Anal. Calcd for C17H16N8O2.0.5 H2O.0.1 C3H7NO: C, 54.58; H, 4.69, N, 29.80. Found: C, 54.90; H, 4.43; N, 29.46. 178 R 20 mp 216.7-218.4° C.; IR &ngr;max(DR)/cm−1 3854, 3143, 2569, 2004, 1654, 1518, 1437, 1279, 1207, 1037 and 868; NMR &dgr;H(400MHz, DMSO) 1.90(3H, s), 4.48 (2H, d, J 6.0Hz), 5.73(2H, s), 6.82-6.89(2H, m), 7.15-7.23(1H, m), 7.25-7.46 (4H, m), 7.91(1H, d, J 3.5Hz), 8.12-8.15(1H, m), 8.39(1H, t, J 5.5Hz). 179 B 11 Mp 215.8-216.9° C.; IR &ngr;max(Nujol)/cm−1 3482 and 3305; NMR &dgr;H(400MHz, DMSO) 8.13-8.11(1H, m), 7.91-7.89(1H, d, J 3.5Hz), 7.55-7.52(1H, dd, J 3.0, 5.0Hz), 7.42-7.40(1H, m), 7.39-7.34(2H, s), 7.11-7.08(1H, dd, J 1.5, 5.0Hz), 6.87-6.85(1H, dd J 1.5, 3.5Hz) and 5.66-5.64(2H, s); Anal. Calcd for C13H10N6OS: C, 52.34; H, 3.38, N, 28.16. Found: C, 52.53; H, 3.57; N, 28.22. 180 C 25 mp 278.4-279.9° C.; IR &ngr;max(DR)/cm−1 3468, 3184, 2967, 1735, 1604, 1436, 1322, 1234 and 1204; NMR &dgr;H(400MHz, DMSO) 7.87(1H, d, J 3.0Hz), 7.30 (2H, br s), 6.80(1H, t, J 8.0Hz), 6.58(1H, dd, J 1.0, 8.0Hz), 6.51(1H, dd, J 3.0, 1.0Hz), 6.11(1H, d, J 7.0Hz), 5.54(2H, s), 4.93(2H, br s), 2.45(3H, s) and 2.1 (3H, s). 181 B 12 IR &ngr;max(Nujol)/cm−1 3501 and 3316; NMR &dgr;H(400MHz, DMSO) 8.13-8.11 (1H, m), 7.90-7.87(1H, dd, J 1.0, 3.5Hz), 7.43-7.32(2H, s), 7.40-7.37(1H, d, J 5.0Hz), 6.90-6.87(1H, d, J 5.0Hz), 6.86-6.84(1H, dd, J 2.0, 3.5Hz), 5.73-5.72(2H, s), and 2.37-2.35(3H, s). 182 AM 30 mp 92.3-92.7° C.; IR &ngr;max(DR)/cm−1 3124, 3073, 2926, 1609, 1520, 1411; NMR &dgr;H(400MHz, DMSO) 8.18-8.17(1H, m), 7.93(1H, d, J 3.0Hz), 7.80(1H, t, J 7.5Hz), 7.37(1H, d, J 7.5Hz), 7.19(1H, d, J 7.5Hz), 6.87(1H, dd, J 1.5, 3.5Hz), 5.94-5.75(3H, m), 5.78(2H, s), 5.28-5.07(6H, m), 4.48(2H, s), 4.43-4.12 (4H, m), 4.02-3.99(2H, m); Anal. Calcd for C24H25N7O2: C, 65.00; H, 5.68, N, 22.10. Found: C, 65.23; H, 5.80; N, 21.60. 183 B 27 mp 152.0-153.5° C.; IR &ngr;max(DR)/cm−1 3515, 3300, 3183, 2934, 2822, 1631, 1450, 1434; NMR &dgr;H(400MHz, DMSO) 7.89(1H, d, J 3.0Hz), 7.79(1H, t, J 7.5Hz), 7.33(2H, br s), 7.34(1H, d, J 7.5Hz), 7.02(1H, d, J 7.5Hz), 6.53-6.51 (1H, m), 5.74(2H, s), 4.43(2H, s), 2.46(3H, s), 3.33(3H, s); Anal. Calcd for C17H17N7O2: C, 58.11; H, 4.88, N, 27.89. Found: C, 57.75; H, 4.85; N, 27.59. 184 C 76 mp 219.7-220.4° C.; IR &ngr;max(DR)/cm−1 3450, 3312, 2920, 2728, 1737, 1638, 1438, 1354, 1326, 1291 and 1234; NMR &dgr;H(400MHz, DMSO) 7.85(1H, d, J 3.0Hz), 7.30(2H, br s), 7.01(2H, d, J 8.5Hz), 6.52-6.47(3H, m), 5.41(2H, s), 5.12(2H, s) and 2.44(3H, s). 185 B 15 mp 155.6-157.1° C.; IR &ngr;max(DR)/cm−1 3332, 3197, 2857, 1655, 1605, 1525, 1420; NMR &dgr;H(400MHz, DMSO) 8.14-8.13(1H, m), 7.92(1H, d, J 3.5Hz), 7.79(1H, t, J 7.5Hz), 7.37(1H, d, J 7.5Hz), 7.36(2H, br s), 7.05(1H, d, J 7.5Hz), 6.88-6.86(1H, m), 5.98-5.86(1H, m), 5.76(2H, s), 5.29-5.24(1H, m), 5.17-5.13(1H, m), 4.48(2H, s), 4.06-4.00(2H, m); Anal. Calcd for C18H17N7O2: C, 59.50; H, 4.72, N, 26.97. Found: C, 59.39; H, 4.70; N, 26.99. 186 B 23 mp 149.0-149.3° C.; IR &ngr;max(DR)/cm−1 3514, 3295, 3168, 2861, 1634, 1502, 1435; NMR &dgr;H(400MHz, DMSO) 7.88(1H, d, J 3.5Hz), 7.79(1H, t, J 7.5Hz), 7.37(1H, d, J 7.5Hz), 7.33(2H, br s), 7.04(1H, d, J 7.5Hz), 6.52-6.51(1H, m), 5.96-5.86(1H, m), 5.74(2H, s), 5.30-5.24(1H, m), 5.17-5.13(1H, m), 4.49(2H, s), 4.06-4.00(2H, m), 2.46(3H, s); Anal. Calcd for C19H19N7O2.0.2 H2O: C, 59.90; H, 5.13, N, 25.73. Found: C, 59.71; H, 5.02; N, 25.64. 187 B 20 mp 191.7-191.9° C.; IR &ngr;max(Nujol)/cm−1 3501, 3307, 3189, 2974, 1611, 1527 and 1338; NMR &dgr;H(400MHz, DMSO) 8.12-8.15(1H, m), 7.91(1H, d, J 3.5Hz), 7.76(1H, d, J 8.5Hz), 7.67(1H, d, J 2.0Hz), 7.44-7.36(2H, s), 7.16(1H, dd, J 8.5, 2.0Hz), 6.87-6.85(1H, m), 5.78(2H, s), 3.22(1H, quin, J 6.5Hz) and 1.22(6H, d J 6.5Hz). 188 B 32 mp 228.9-229.9° C.; IR &ngr;max(DR)/cm−1 3461, 3317, 3195, 1606, 1504, 1320, 1026 and 818; NMR &dgr;H(400MHz, DMSO) 8.16-8.14(1H, m), 7.98(1H, d, J 8.0Hz), 7.94(1H, d, J 3.5, 1.0Hz), 7.91(1H, d, J 8.0Hz), 7.78-7.73(1H, m), 7.64-7.58 (1H, m), 7.36(1H, d, J 8.5Hz), 7.36(2H, br s), 6.88(1H, dd, J 3.5, 1.5Hz) and 5.98(2H, s). 189 K 23 NMR &dgr;H(400MHz, DMSO) 8.14-8.12(1H, m), 7.92-7.89(1H, dd, J 1.0, 3.5Hz), 7.35-7.31(2H, d, J 8.5Hz), 7.28-7.16(2H, s), 6.88-6.85(1H, dd, J 1.5, 3.5Hz), 5.66-5.64(2H, s), and 2.82-2.80(3H, s); M/Z 322(M+H)+. 190 B 37 mp 290.2-290.3° C.; IR &ngr;max(DR)/cm−1 3491, 3338, 3205, 3128, 2936, 1710, 1616, 1490, 1458; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.93(1H, t, J 7.5Hz), 7.90(1H, dd, J 1.0, 3.5Hz), 7.84(1H, d, J 7.5Hz), 7.56(1H, d, J 7.5Hz), 7.34(2H, br s), 6.86(1H, dd, J 2.0, 3.5Hz), 6.69(1H, q, J 7.5Hz), 2.48 (3H, s), 1.98(3H, d, J 7.5Hz); Anal. Calcd for C17H15N7O2: C, 58.45; H, 4.33, N, 28.05. Found: C, 58.26; H, 4.42; N, 27.67. 191 C 16 mp 186.1-189.1° C.; IR &ngr;max(DR)/cm−1 3458, 1598, 1509, 1460, 1329, 1267 and 1220; NMR &dgr;H(400MHz, DMSO) 11.73(1H, s), 7.59(1H, s), 7.17(1H, s), 6.97 (1H, t, J 7.8Hz), 6.95-6.83(2H, br s), 6.45(1H, dd, J 1.5, J 8.0Hz), 6.40(1H, d, J 8.0Hz), 6.38-6.31(1H, m), 5.47(2H, s) and 5.13(2H, s). 192 Q 2 NMR &dgr;H(400MHz, CD3OD) 8.84(1H, d, J 4.5Hz), 8.77(1H, d, J 8.0Hz), 8.33 (1H, t, J 1.7Hz), 8.2(1H, dd, J 2.0, 8.0Hz), 8.06(1H, td, J 7.8, 2.0Hz), 7.81 (1H, d, J 7.5Hz), 7.65-7.58(2H, m) and 5.88(2H, s); M/Z 349(M+H)+; Retention time 1.77 min. 193 B 6 mp 253.6-254.0° C.; IR &ngr;max(DR)/cm−1 3320, 1611, 1414, 1315, 1255, 1026 and 767; NMR &dgr;H(400MHz, DMSO) 2.01(3H, s), 5.59(2H, s), 6.84-6.88(1H, m), 7.22(2H, d, J 8.5Hz), 7.36(2H, s), 7.54(2H, d, J 8.5Hz) 7.90(1H, d, J 3.5Hz), 8.11-8.14(1H, m), 9.97(1H, s). 194 B 36 mp 136.5-137.6° C.; IR &ngr;max(Nujol)/cm−1 3489, 3311, 3195, 2954, 1774 and 1613; NMR &dgr;H(400MHz, DMSO) 8.24(1H, s), 8.04(1H, d, J 2.0Hz), 8.00 (1H, d, J 3.5Hz), 7.96(1H, dd, J 8.5, 2.0Hz), 7.52-7.44(2H, s), 7.40(1H, d, J 8.5Hz), 6.99-6.95(1H, m), 5.83(2H, s), 5.54(2H, s), 3.66(2H, t, J 8.0Hz), 0.93(2H, t, J 8.0Hz) and 0.00(9H, s); Anal. Calcd for C21H25N7O5Si.0.1 H2O: C, 51.97; H, 5.23, N, 20.20. Found: C, 51.97; H, 5.19; N, 19.86. 195 B 12 IR &ngr;max(Nujol)/cm−1 3652, 3506, 3307, 3196, 2990, 2878, 1633, 1521 and 1344; NMR &dgr;H(400MHz, DMSO) 8.14(1H, s), 7.94-7.88(2H, m), 7.46(1H, s), 7.40 (2H, s), 7.23(1H, dd, J 8.5, 2.0Hz), 6.88-6.85(1H, m), 5.78(2H, s), 2.80(2H, q, 7.5Hz) and 1.17(3H, t, J 7.5Hz); Anal. Calcd for C17H15N7O3.0.25 H2O: C, 55.21; H, 4.22, N, 26.51. Found: C, 55.47; H, 4.12; N, 26.25. 196 B 23 mp 178.4-179.0° C.; IR &ngr;max(Nujol)/cm−1 3469 and 3311; NMR &dgr;H(400MHz, DMSO) 8.13-8.11(1H, m), 7.90-7.88(1H, dd, J 1.0, 3.5Hz), 7.37-7.32(2H, s), 7.32-7.29(1H, dd, J 1.5, 5.5Hz), 6.92-6.89(1H, dd, J 3.5, 5.5Hz), 6.87-6.84 (2H, m), 4.70-4.64(2H, t, J 7.0Hz), and 3.53-3.48(2H, t, J 7.0Hz); Anal. Calcd for C14H12N6OS: C, 53.84; H, 3.87; N, 26.89. Found: C, 53.98; H, 3.87; N, 26.50. 197 B 22 mp 188.3-188.5° C.; IR &ngr;max(DR)/cm−1 3324, 3189, 2964, 1649, 1513; NMR &dgr;H (400MHz, DMSO) 8.14-8.13(1H, m), 7.93(1H, d, J 3.5Hz), 7.67(1H, t, J 7.5Hz), 7.34(2H, br s), 7.20(1H, d, J 7.5Hz), 6.89(1H, d, J 7.5Hz), 6.87-6.86 (1H, m), 5.75(2H, s), 2.93(1H, sept, J 7.0Hz), 1.12(6H, d, J 7.0Hz); Anal. Calcd for C17H17N7O: C, 60.88; H, 5.11, N, 29.22. Found: C, 61.03; H, 5.13; N, 28.95. 198 B 27 IR &ngr;max(DR)/cm−1 3466, 3312, 3187, 2958, 2850, 1639, 1511, 1221, 1047, 756 and 599; NMR &dgr;H(400MHz, DMSO) 8.13(1H, s), 8.09(1H, s), 7.91(1H, d, J 3.0Hz), 7.72(1H, d, J 8.5Hz), 7.68(1H, s), 7.42(1H, d, J 8.5Hz), 7.37(2H, br s), 6.88-6.83(1H, m), 5.82(1H, d, J 9.5Hz), 5.77(2H, s), 3.90-3.80(1H, m), 3.77-3.64(1H, m), 2.45-2.30(1H, m), 2.10-1.88(2H, m), 1.80-1.63(1H, m), 1.62-1.49(2H, m). 199 B 7 mp 226.5-227.9° C.; IR &ngr;max(DR)/cm−1 3466, 3316, 3182, 2962, 1645, 1606, 1546, 1514, 1473; NMR &dgr;H(400MHz, DMSO) 8.14-8.13(1H, m), 7.92(1H, d, J 3.0Hz), 7.33(2H, br s), 7.07-7.06(1H, m), 6.88-6.86(2H, m), 5.71(2H, s), 2.88(1H, sept, J 7.0Hz), 2.82(1H, sept, J 7.0Hz), 1.14(6H, d, J 7.0Hz), 1.09 (6H, d, J 7.0Hz). 200 K 99 mp > 300° C. dec; IR &ngr;max(DR)/cm−1 3100, 1662, 1465, 1281, 1032, 782 and 592; NMR &dgr;H(400MHz, DMSO) 8.16-8.13(1H, m), 8.07(1H, s), 7.92(1H, d, J 3.5Hz), 7.68(1H, s), 7.54(1H, d, J 8.5Hz), 7.35(1H, dd, 8.5, 1.5Hz), 6.87(1H, dd, J 3.5, 2.0Hz) and 5.76(1H, s) 201 K 99 IR &ngr;max(Nujol)/cm−1 2999, 1656, 1530 and 1461; NMR &dgr;H(400MHz, DMSO) 11.10(1H, s), 8.14(1H, d, J 1.0Hz), 7.92(1H, d, J 3.5Hz), 7.72(1H, d, J 2.5Hz), 7.61(1H, dd, J 8.5, 2.5Hz), 7.0(1H, d, J 8.5Hz), 6.86-6.88(1H, m), 5.67 (2H, s) and 5.11-5.16(3H, s). 202 B 32 mp 210.5-211.6° C.; IR &ngr;max(FILM)/cm−1 3352, 3204, 3001, 1659, 1569, 1510, 1440; NMR &dgr;H(400MHz, DMSO) 8.14(1H, m), 7.93(1H, d, J 3.5Hz), 7.76 (1H, t, J 7.5Hz), 7.43(1H, d, J 7.5Hz), 7.36(2H, br s), 7.03(1H, d, J 7.5Hz), 6.87(1H, dd, J 2.0, 3.5Hz), 6.75(1H, dd, J 10.5, 17.5Hz), 6.09(1H, dd, J 2.0, 17.5Hz), 5.78(2H, s), 5.43(1H, dd, J 1.5, 10.5Hz); Anal. Calcd for C16H13N7O: C, 60.18; H, 4.10, N, 30.69. Found: C, 60.14; H, 4.20; N, 30.39. 203 AS 12 IR &ngr;max(Nujol)/cm−1 3514, 3298 and 1761; NMR &dgr;H(400MHz, DMSO) 8.16-8.15 (1H, m), 7.89-7.86(1H, dd, J 1.0, 3.5Hz), 7.80-7.40(2H, s), 6.89-6.86 (1H, dd, J 1.5, 3.5Hz), and 1.66-1.64(9H, s). 204 B 16 mp 143.6-144.5° C.; IR &ngr;max(DR)/cm−1 3644, 3315, 3195, 2978, 1743, 1608, 1163, 1086 and 746; NMR &dgr;H(400MHz, DMSO) 8.14-8.10(1H, m), 8.05(1H, d, J 8.0Hz), 7.88(1H, d, J 3.5Hz), 7.81(1H, s), 7.66(1H, d, J 7.5Hz), 7.42 (2H, br s), 7.34(1H, t, J 8.0Hz), 7.23(1H, t, J 8.0Hz), 6.85(1H, dd, J 3.5, 2.0Hz), 5.78(2H, s) and 1.63(9H, s) 205 B 19 IR &ngr;max(DR)/cm−1 3431, 3325, 3217, 1646, 1504, 1431; NMR &dgr;H(400MHz, DMSO) 9.87-9.86(1H, m), 8.14(1H, m), 8.05(1H, t, J 8.0Hz), 7.94-7.92 (1H, m), 7.88(1H, d, J 8.0Hz), 7.52(1H, d, J 8.0Hz), 7.38(2H, br s), 6.88-6.87 (1H, m), 5.91(2H, s); Anal. Calcd for C15H11N7O2.0.3 H2O: C, 55.15; H, 3.58, N, 30.01. Found: C, 55.33; H, 3.35; N, 29.64. 206 B 30 IR &ngr;max(film)/cm−1 3327, 3209, 2987, 1730, 1664, 1390, 1168, 959, 745 and 664; NMR &dgr;H(400MHz, DMSO) 8.16(1H, s), 8.09(1H, d, J 8.0Hz), 7.97-7.92 (2H, m), 7.47(1H, d, J 7.5Hz), 7.44-7.35(2H, br s), 7.31(1H, t, J 7.5Hz), 7.20 (1H, t, J 7.0Hz), 6.89(1H, dd, J 3.5, 1.5Hz), 6.03-5.96(3H, m) and 1.64(9H, s) 207 AF 71 mp 289.1-289.3° C.; IR &ngr;max(DR)/cm−1 3442, 3317, 3189, 1649, 1607, 1519, 1332, 1118, 1023 and 763; NMR &dgr;H(400MHz, DMSO) 11.21(1H, br s), 8.13 (1H, s), 7.91(1H, d, J 3.5Hz), 7.46(1H, d, 8.0Hz), 7.38(2H, br s), 7.33(1H, d, J 8.0Hz), 7.06(1H, t, J 8.0Hz), 6.96(1H, t, J 7.0Hz), 6.86(1H, dd, J 3.5, 1.5Hz), 6.31(1H, s) and 5.79(2H, s) 208 B 4 NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.91-7.88(1H, dd, J 1.5, 3.5Hz), 7.46-7.36(2H, s), 6.98-6.96(1H, d, J 3.5Hz), 6.87-6.84(1H, dd, J 1.5, 3.5Hz), 6.72-6.69(1H, d, J 3.5Hz), 5.76-5.74(2H, s), 2.52-2.48(2H, h, J 2.0, 3.5Hz) and 1.20-1.14(3H, t, J 7.5Hz); M/Z 327(M+H)+. 209 B 17 mp > 250° C.; dec; IR &ngr;max(DR)/cm−1 3489, 3316, 2919, 1610, 1326, 1037, 862, 760 and 593; NMR &dgr;H(400MHz, DMSO) 8.13-8.11(1H, m), 7.90(1H, d, J 2.5Hz), 7.38(2H, br s), 6.92(1H, d, J 2.0Hz), 6.88(1H, d, J 8.0Hz), 6.86(1H, dd, J 3.5, 2.0Hz), 6.79(1H, dd, J 8.0, 1.5Hz), 6.00(2H, s) and 5.56(2H, s). 210 C 36 IR &ngr;max(DR)/cm−1 3427, 3318, 3201, 2966, 1605, 1503, 1415, 1281, 1027 and 762; NMR &dgr;H(400MHz, DMSO) 1.08(3H, t, J 7.0Hz), 2.39(2H, q, J 7.0Hz), 4.91(2H, s), 5.44(2H, s), 6.54(1H, d, J 8.0Hz), 6.80-9.62(2H, m), 6.97(1H, s), 7.34(2H, s), 7.89(1H, s), 8.12(1H, s). Anal. Calcd for C17H17N7O.0.6 H2O: C, 58.98; H, 5.30; N, 28.32. Found: C, 59.37; H, 5.02; N, 28.05. 211 AT 13 mp 257.1-257.3° C.; IR &ngr;max(DR)/cm−1 3491, 3343, 3205, 3131, 2971, 1973, 1691, 1626, 1499, 1437, 1239, 1030 and 764; NMR &dgr;H(400MHz, DMSO) 6.26 (2H, s), 6.86-6.91(1H, m), 7.33(2H, s), 7.63(2H, t, J 7.5Hz), 7.77(1H, t, J 7.5Hz), 7.94(1H, d, J 3.0Hz), 8.11-8.16(3H, m). 212 R 58 IR &ngr;max(DR)/cm−1 3321, 1608, 1438, 1304, 1025 and 757; NMR &dgr;H(400MHz, DMSO) 5.67(2H, s), 6.86-6.88(1H, m), 7.05(1H, d, J 7.5Hz), 7.20(1H, dd, J 5.0, 3.5Hz), 7.35(1H, t, J 8.0Hz), 7.39(2H, s), 7.55-7.58(1H, m), 7.72(1H, d, J 7.5Hz), 7.85(1H, dd, J 5.0, 1.0Hz), 7.92(1H, d, J 3.5Hz), 7.98(1H, dd, J 3.5, 1.0Hz), 8.12-8.15(1H, m), 10.24(1H, s). 213 AU 29 IR &ngr;max(DR)/cm−1 3285, 1975, 1625, 1461; NMR &dgr;H(400MHz, DMSO) 8.14 (1H, m), 7.92(1H, d, J 3.0Hz), 7.80(1H, t, J 7.5Hz), 7.44(1H, d, J 7.5Hz), 6.98(1H, d, J 7.5Hz), 6.87(1H, dd, J 1.5, 3.5Hz), 5.75(2H, s), 4.52(2H, s). 214 R 43 IR &ngr;max(DR)/cm−1 3321, 2956, 1610, 1234, 1027 and 757; NMR &dgr;H(400MHz, DMSO) 0.99(9H, s), 2.14(2H, s), 5.63(2H, s), 6.85-6.89(1H, m), 6.94(1H, d, J 8.0Hz), 7.27(1H, t, J 7.5Hz), 7.33-7.45(3H, m), 7.59(1H, d, J 9.0Hz), 7.92 (1H, d, J 3.5Hz), 8.12-8.15(1H, m). 215 R 52 IR &ngr;max(DR)/cm−1 3510, 3278, 1631, 1425, 1293, 1217, 1024 and 757; NMR &dgr;H (400MHz, DMSO) 0.71-0.79(4H, m), 1.72(1H, tt, J 5.5, 7.0Hz), 5.63(2H, s), 6.85-6.89(1H, m), 6.96(1H, d, J 8.0Hz), 7.27(1H, t, J 7.5Hz), 7.32-7.45 (3H, m), 7.55(1H, d, J 8.0Hz), 7.92(1H, dd, J 3.5, 1.0Hz), 8.12-8.15(1H, m), 10.19(1H, s). Anal. Calcd for C19H17N7O2.0.15 H2O: C, 60.36; H, 4.61; N, 25.93. Found: C, 60.89; H, 4.62; N, 25.54. 216 B 15 mp 178.3-178.5° C.; IR &ngr;max(DR)/cm−1 3472, 3324, 3194, 2964, 1641, 1598, 1510; NMR &dgr;H(400MHz, DMSO) 8.14(1H, m), 7.92(1H, dd, J 1.0, 3.5Hz), 7.66(1H, t, J 8.0Hz), 7.35(2H, br s), 7.17(1H, d, J 8.0Hz), 6.90(1H, d, J 8.0Hz), 6.87(1H, dd, J 2.0, 3.5Hz), 5.73(2H, s), 2.63(2H, t, J 7.5Hz), 1.59(2H, sext, J 7.5Hz), 0.83(3H, t, J 7.5Hz); Anal. Calcd for C17H17N7O.0.1 C4H8O2: C, 60.72; H, 5.21, N, 28.49. Found: C, 60.85; H, 5.22; N, 28.29. 217 B 16 mp 146.7-149.3° C.; IR &ngr;max(DR)/cm−1 3518, 3323, 2955, 1605, 1511; NMR &dgr;H (400MHz, DMSO) 8.14-8.13(1H, m), 7.92(1H, d, J 3.5Hz), 7.79(1H, t, J 7.5Hz), 7.35(2H, br s), 7.35(1H, d, J 7.5Hz), 7.05(1H, d, J 7.5Hz), 6.87(1H, dd, J 1.5, 3.5Hz), 5.75(2H, s), 4.46(2H, s), 3.22(2H, d, J 6.5Hz), 1.77-1.87(1H, m), 0.85(6H, d, J 6.5Hz); Anal. Calcd for C19H21N7O2.0.5 H2O: C, 58.75; H, 5.71, N, 25.24. Found: C, 58.87; H, 5.49; N, 24.92. 218 B 14 mp 196.0-196.1° C.; IR &ngr;max(DR)/cm−1 3481, 3325, 3203, 1646, 1607, 1518, 1488; NMR &dgr;H(400MHz, DMSO) 8.14(1H, m), 7.92(1H, d, J 3.5Hz), 7.80 (1H, t, J 7.5Hz), 7.50(1H, d, J 7.5Hz), 7.38(2H, br s), 7.04(1H, d, J 7.5Hz), 6.87(1H, dd, J 1.5, 3.5Hz), 5.77(2H, s), 4.64(2H, s). 219 C 37 IR &ngr;max(DR)/cm−1 3480, 3379, 3199, 2958, 2761, 2104, 1879, 1776, 1659, 1516, 1439, 1334, 1024, 762 and 575; NMR &dgr;H(400MHz, DMSO) 1.10(6H, d, J 7.0Hz), 2.92(1H, sept, J 6.5Hz), 4.93(2H, s), 5.44(2H, s), 6.54(1H, d, J 8.0Hz), 6.80-6.88(2H, m), 7.09(1H, d, J 2.0Hz), 7.34(2H, s), 7.88(1H, d, J 3.5Hz), 8.10-8.13(1H, m). Anal. Calcd for C18H19N7O.0.3 H2O: C, 60.93; H, 5.57; N, 27.63. Found: C, 60.77; H, 5.50; N, 27.42. 220 AV 26 mp 223.3-223.4° C.; NMR &dgr;H(400MHz, DMSO) 8.14(1H, m), 7.92(1H, dd, J 1.0, 3.5Hz), 7.82(1H, t, J 7.5Hz), 7.37(1H, d, J 7.5Hz), 7.36(2H, br s), 7.07 (1H, d, J 7.5Hz), 6.87(1H, dd, J 1.5, 3.5Hz), 5.78(2H, s), 4.18(2H, s). 221 AW 7 NMR &dgr;H(400MHz, DMSO) 9.48-9.45(1H, s), 8.12-8.10(1H, m), 7.90-7.88 (1H, dd, J 1.0, 3.5Hz), 7.36-7.30(2H, s), 7.17-7.12(2H, dd, J 2.0, 8.5Hz), 6.86-6.84(1H, dd, J 2.0, 3.5Hz), 6.74-6.70(2H, dd, J 2.0, 8.5Hz) and 5.53-5.51 (2H, s); M/Z 309(M+H)+. 222 B 18 IR &ngr;max(DR)/cm−1 3483, 3319, 3200, 2961, 1953, 1709, 1612, 1439, 1343, 1220, 995 and 761; NMR &dgr;H(400MHz, DMSO) 6.37(2H, s), 6.86-6.91(1H, m), 7.35(2H, s), 7.94(1H, d, J 3.0Hz), 8.15(1H, s), 8.37(2H, d, J 8.5Hz), 8.43 (2H, d, J 8.5Hz). Anal. Calcd for C16H11N7O4.0.2 H2O: C, 52.09; H, 3.11; N, 26.58. Found: C, 51.94; H, 3.05; N, 26.27. 223 B 41 IR &ngr;max(DR)/cm−1 4013, 3601, 3456, 3209, 2959, 2237, 1938, 1708, 1625, 1505, 1171, 1002, 827 and 733; NMR &dgr;H(400MHz, DMSO) 6.33(2H, s), 6.84-6.91 (1H, m), 7.34(2H, s), 7.94(1H, d, J 3.5Hz), 8.09-8.18(3H, m), 8.28(2H, d, J 8.0Hz). Anal. Calcd for C17H11N7O2.0.7 H2O: C, 57.05; H, 3.49; N, 27.39. Found: C, 56.97; H, 3.12; N, 27.37. 224 AX 54 IR &ngr;max(DR)/cm−1 3423, 3321, 3212, 1641, 1511, 1420, 1316, 1136 and 780; NMR &dgr;H(400MHz, DMSO) 0.87(3H, t, J 7.5Hz), 1.54-1.66(2H, m), 2.96-3.04 (2H, m), 5.65(2H, s), 6.85-6.88(1H, m), 7.00-7.03(2H, m), 7.10-7.16 (1H, m), 7.30(1H, t, J 7.5Hz), 7.36(2H, s), 7.91(1H, dd, J 3.5, 1.0Hz), 8.12-8.15 (1H, m), 9.79(1H, s). Anal. Calcd for C18H19N7O3S: C, 52.29; H, 4.63; N, 23.70. Found: C, 52.22; H, 4.70; N, 23.36. 225 AX 47 IR &ngr;max(DR)/cm−1 3477, 3319, 3114, 1609, 1479, 1414, 1349, 1162, 956 and 763; NMR &dgr;H(400MHz, DMSO) 5.63(2H, s), 5.85-6.89(1H, m), 6.92(1H, t, J 1.5Hz), 7.02-7.11(3H, m), 7.26-7.33(2H, m), 7.37(2H, s), 7.93(1H, dd, J 3.5, 1.0Hz), 8.12-8.15(1H, m), 10.62(1H, s). 226 AY 58 mp 221.4-221.5° C.; IR &ngr;max(DR)/cm−1 3569, 3134, 2701, 2421, 1656, 1460; NMR &dgr;H(400MHz, DMSO) 8.14(1H, m), 7.92(1H, dd, J 1.0, 3.5Hz), 7.88 (1H, t, J 7.5Hz), 7.48(1H, d, J 7.5Hz), 7.16(1H, d, J 7.5Hz), 6.88-6.87(1H, m), 5.80(2H, s), 4.27-4.24(2H, m), 2.60-2.56(3H, m). 227 B 24 IR &ngr;max(DR)/cm−1 4011, 3491, 3377, 3210, 3125, 2975, 2663, 2106, 1924, 1740, 1618, 1438, 1201, 1004, 796 and 752: NMR &dgr;H(400MHz, DMSO) 1.14(6H, t, J 6.5Hz), 3.46(4H, q, J 6.5Hz), 6.00(2H, s), 6.76(2H, d, J 9.0Hz), 6.87(1H, s), 7.26(2H, s), 7.85-7.97(3H, m), 8.13(1H, s), Anal. Calcd for C20H21N7O2.0.6 H2O: C, 59.72; H, 5.56; N, 24.38, Found: C, 60.00; H, 5.40; N, 24.03. 228 B 26 mp 164.3-169.3° C.; IR &ngr;max(DR)/cm−1 3376, 3199, 2964, 1659, 1613, 1516, 1441; NMR &dgr;H(400MHz, DMSO) 8.53(1H, d, J 2.0Hz), 8.12-8.11(1H, m), 7.89(1H, d, J 3.5Hz), 7.62(1H, dd, J 2.5, 8.0Hz), 7.35(2H, br s), 7.26(1H, d, J 7.5Hz), 6.85(1H, dd, J 1.5, 3.5Hz), 5.67(2H, s), 2.99(1H, sept, J 7.0Hz), 1.20 (6H, d, J 7.0Hz); Anal. Calcd for C17H17N7O.0.5 H2O: C, 59.29; H, 5.27, N, 28.47. Found: C, 59.28; H, 5.16; N, 28.23. 229 B 40 mp 258.2-258.4° C.; IR &ngr;max(DR)/cm−1 3367, 3200, 2932, 1671, 1243, 1178, 1033, 797 and 610; NMR &dgr;H(400MHz, DMSO) 8.12-8.07(3H, m), 7.91(1H, d, J 3.5Hz), 7.15-7.09(4H, m), 6.85(1H, dd, J 3.5, 1.5Hz), 6.10(2H, s) and 3.89(3H, s). 230 B 25 IR &ngr;max(DR)/cm−1 3436, 3320, 3208, 2977, 1609, 1370, 1323, 1155, 1025, 840 and 768; NMR &dgr;H(400MHz, DMSO) 8.12-8.10(1H, m), 7.89(1H, d, J 3.5Hz), 7.78(1H, d, J 4.0Hz), 7.73(1H, d, J 2.5Hz), 7.33(2H, br s), 6.88-6.84 (2H, m), 6.76(1H, d, J 4.0Hz), 6.07(2H, s) and 1.50(9H, s). 231 AF 76 mp 321.8-322.2° C.; IR &ngr;max(DR)/cm−1 3993, 3233, 1645, 1515, 1437, 1336, 1102, 854 and 759; NMR &dgr;H(400MHz, DMSO) 11.56(1H, br s), 8.13-8.11 (1H, m), 7.91(1H, d, J 3.5Hz), 7.58(1H, d, J 2.0Hz), 7.55(1H, t, J 3.5Hz), 7.42(2H, br s), 6.86(1H, dd, J 3.5, 2.0Hz), 6.73(1H, d, J 2.0Hz), 6.52(1H, dd, J 3.0, 2.0Hz) and 5.94(2H, s). 232 AX 20 IR &ngr;max(DR)/cm−1 3216, 1713, 1610, 1505, 1421, 1185, 1124, 1026, 886 and 763; NMR &dgr;H(400MHz, DMSO) 2.13(3H, s), 2.35(3H, s), 5.62(2H, s), 6.85-6.88 (1H, m), 6.90-6.94(1H, m), 6.98-7.03(1H, m), 7.11(1H, d, J 8.0Hz), 7.30 (1H, t, J 7.5Hz), 7.31(2H, s), 7.91(1H, d, J 3.5Hz), 8.11-8.14(1H, m), 10.46 (1H, s). 233 AV 40 mp 219.7-222.3° C.; IR &ngr;max(DR)/cm−1 3326, 3191, 2821, 2772, 1595, 1504, 1432; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.91(1H, dd, J 1.0, 3.5Hz), 7.74(1H, t, J 7.5Hz), 7.35(1H, d, J 7.5Hz), 7.31(2H, br s), 6.98(1H, d, J 7.5Hz), 6.86(1H, dd, J 2.0, 3.5Hz), 5.74(2H, s), 3.46(2H, s), 2.15(6H, s); Anal. Calcd for C17H18N8O: C, 58.28; H, 5.18, N, 31.97. Found: C, 57.94; H, 5.17; N, 31.70. 234 AV 55 mp 168.3-168.5° C.; IR &ngr;max(DR)/cm−1 3416, 3322, 3180, 2911, 1646, 1612, 1509, 1436; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.91(1H, dd, J 1.0, 3.5Hz), 7.74(1H, t, J 7.5Hz), 7.32(1H, d, J 7.5Hz), 7.31(2H, br s), 7.02(1H, d, J 7.5Hz), 6.87-6.86(1H, m), 5.75(2H, s), 3.69(2H, s), 1.92(3H, s); Anal. Calcd for C16H15N7OS.0.2 H2O: C, 53.83; H, 4.35, N, 27.46. Found: C, 53.74; H, 4.29; N, 27.13. 235 B 3 mp 231.6-231.7° C.; IR &ngr;max(DR)/cm−1 3642, 3320, 3198, 1727, 1533, 1437, 1223, 1029, 842 and 639; NMR &dgr;H(400MHz, DMSO) 8.18(1H, d, J 7.5Hz), 8.13(1H, s), 8.00-7.93(2H, m), 7.91(1H, d, J 3.5Hz), 7.89-7.82(1H, m), 7.34(2H, br s), 6.87(1H, dd, J 3.5, 1.5Hz) and 6.01(2H, s). 236 AX 32 NMR &dgr;H(400MHz, DMSO) 2.19(3H, s), 3.50(3H, s), 5.58(2H, s), 6.84-6.97 (3H, m), 7.08(1H, d, J 8.0Hz), 7.20(1H, t, J 7.5Hz), 7.35(2H, s), 7.58(1H, s), 7.91(1H, d, J 3.0Hz), 8.13(1H, s) and 10.14(1H, s); retention time 0.97 min. 237 AV 40 mp 259.3-259.4° C.; IR &ngr;max(DR)/cm−1 3323, 3202, 1607, 1511; NMR &dgr;H(400MHz, DMSO) 8.12-8.11(2H, m), 7.91(2H, dd, J 1.0, 3.5Hz), 7.70-7.66(2H, m), 7.30(4H, br s), 7.10(4H, d, J 8.0Hz), 6.85(2H, dd, J 1.5, 3.5Hz), 5.73(4H, s), 4.23(4H, s), 2.78(3H, s). 238 AV 17 mp 238.2-238.6° C.; IR &ngr;max(DR)/cm−1 3189, 2908, 1653, 1592, 1470; NMR &dgr;H (400MHz, DMSO) 8.13-8.12(1H, m), 7.91(1H, d, J 3.0Hz), 7.85(1H, t, J 7.5Hz), 7.43(1H, d, J 7.5Hz), 7.30(2H, br s), 7.23(1H, d, J 7.5Hz), 6.87-6.85 (1H, m), 5.81(2H, s), 4.56(2H, s), 2.87(3H, s). 239 AV 71 mp 205.8-206.0° C.; IR &ngr;max(Nujol)/cm−1 3502, 3304, 3185, 2923, 1628, 1510; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.92(1H, d, J 3.0Hz), 7.83 (1H, t, J 8.0Hz), 7.33(1H, d, J 8.0Hz), 7.30(2H, br s), 7.17(1H, d, J 8.0Hz), 6.87-6.86(1H, m), 5.79(2H, s), 4.31(2H, s), 2.84(3H, s), 2.67(3H, s); Anal. Calcd for C17H18N8O3S: C, 49.27; H, 4.38, N, 27.02. Found: C, 49.14; H, 4.49; N, 26.74. 240 C 24 mp 254.3-254.5.° C.; IR &ngr;max(DR)/cm−1 3443, 3342, 3187, 1647, 1593, 1513, 1414, 1300, 1268 and 1225; NMR &dgr;H(400MHz, DMSO) 7.37(2H, s), 6.96(1H, t, J 7.8Hz), 6.46(1H, dd, J 1.0, J 8.0Hz), 6.40(2H, d, J 7.5Hz), 6.33(1H, s), 5.56(2H, s), 5.2(2H, s), 2.5(3H, s) and 2.44(3H, s). 241 C 17 NMR &dgr;H(400MHz, DMSO) 8.11-8.09(1H, m), 7.89-7.86(1H, dd, J 1.0, 3.5Hz), 7.32-7.27(2H, s), 7.22-6.95(1H, t, J 9.0Hz), 6.85-6.83(1H, dd, J 2.0, 3.5Hz), 6.35-6.29(2H, m), 5.48-5.46(2H, s) and 5.46-5.44(2H, s); Retention time 1.18 min. 242 B 15 IR &ngr;max(DR)/cm−1 3850, 3667, 2923, 1730, 1601, 1464, 1023, 751 and 593; NMR &dgr;H(400MHz, DMSO) 3.68(1H, dd, J 16.0, 5.5Hz), 3.88(1H, dd, J 16.0, 9.0Hz), 6.05(1H, dd, J 8.5, 5.5Hz), 6.84-6.89(1H, m), 7.29(2H, s), 7.57(1H, t, J 7.0Hz), 7.72(1H, d, J 7.5Hz), 7.78-7.87(2H, m), 7.91(1H, d, J 3.5Hz), 8.13 (1H, s). Anal. Calcd for C17H12N6O2.0.2 H2O: C, 60.87; H, 3.72; N, 25.02. Found: C, 60.89; H, 3.68; N, 24.85. 243 AF 53 mp > 300° C. dec; IR &ngr;max(DR)/cm−1 3212, 2923, 1642, 1605, 1510, 1461, 1377, 1023 and 757; NMR &dgr;H(400MHz, DMSO) 11.16(1H, br s), 8.12(1H, s), 7.91 (1H, d, J 3.5Hz), 7.44-7.36(3H, m), 7.29(1H, s), 6.86(1H, dd, J 3.5, 1.5Hz), 6.58(1H, s), 6.42-6.38(1H, m), 5.87(2H, s) and 2.27(3H, s). 244 BB 7 IR &ngr;max(Nujol)/cm−1 3319, 2924, 1646, 1606, 1462; NMR &dgr;H(400MHz, DMSO) 9.54(1H, s), 8.27-8.26(1H, m), 8.12-8.11(1H, m), 7.90(1H, d, J 3.5Hz), 7.71(1H, d, J 8.0Hz), 7.32(2H, br s), 7.17-7.15(1H, m), 7.11-7.09(1H, m), 6.86-6.85(1H, m), 5.59(2H, s), 2.18(3H, s). 245 B 22 IR &ngr;max(Nujol)/cm−1 3849, 3500, 3298, 3174, 2924, 1698, 1631, 1604, 1456, 1379, 1226, 1027, 953 and 753; NMR &dgr;H(400MHz, DMSO) 1.91(3H, d, J 7.0Hz), 6.63(1H, q, J 7.0Hz), 6.84-6.87(1H, m), 7.32(2H, s), 7.54(2H, t, J 8.0Hz), 7.66(1H, tt, J 7.5, 2.0Hz), 7.88(1H, d, J 3.5Hz), 7.98-8.03(2H, m), 8.11-8.12 (1H, m). Anal. Calcd for C17H14N6O2: C, 61.07; H, 4.22; N, 25.12. Found: C, 60.72; H, 4.27; N, 24.75. 246 BE 81 IR &ngr;max(Nujol;)/cm−1 3313, 3189, 2924, 1605, 1461, 1377, 1236, 1026 and 762; NMR &dgr;H(400MHz, DMSO) 11.62(1H, br s), 8.11(1H, dd, J 2.0, 1.0Hz), 7.90 (1H, d, J 3.5Hz), 7.41(1H, t, J 2.5Hz), 7.37-7.29(3H, m), 6.94(1H, d, J 11.0Hz), 6.85(1H, dd, J 3.5, 2.0Hz) 6.52-6.47(1H, m) and 5.71(2H, s). 247 B 28 mp 134.5-134.6° C.; IR &ngr;max(Nujol)/cm−1 3306, 3189, 2924, 1635, 1610, 1580; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.92-7.91(1H, m), 7.79-7.75 (1H, m), 7.35(1H, d, J 8.0Hz), 7.31(2H, br s), 7.03(1H, d, J 7.5Hz), 6.86(1H, dd, J 3.5, 1.5Hz), 5.74(2H, s), 4.46(2H, s), 3.65(1H, sept, J 6.0Hz), 1.12(6H, d, J 6.0Hz); Anal. Calcd for C18H19N7O2.1.2 H2O: C, 55.86; H, 5.57, N, 25.33. Found: C, 55.80; H, 5.41; N, 25.05. 248 B 11 mp 158.9.-161.3° C.; IR &ngr;max(Nujol)/cm−1 3301, 3185, 2923, 1636, 1611, 1570, 1536, 1501, 1324 and 1210; NMR &dgr;H(400MHz, DMSO) 7.88(1H, d, J 3.0Hz), 7.66(1H, t, J 7.5Hz), 7.27(2H, br s) 7.18(1H, d, J 7.5Hz), 6.89(1H, d, J 7.5Hz), 6.51(1H, dd, J 1.0, J 3.5Hz), 5.71(2H, s), 2.69(2H, q, J 7.5Hz), 2.46 (3H, s) and 1.15(3H, J 7.5Hz). 249 BE 76 IR &ngr;max(DR;)/cm−1 3319, 2928, 1605, 1334, 1226, 1027, 737 and 528; NMR &dgr;H (400MHz, DMSO) 11.47(1H, s), 8.14-8.09(1H, m) 7.89(1H, d, J 3.5Hz), 7.48(1H, d, J 3.0Hz), 7.38-7.27(3H, m), 6.94(1H, d, J 13.0Hz), 6.85(1H, dd, J 3.5, 2.0Hz), 6.52-6.47(1H, m) and 5.81(2H, s). 250 BE 68 IR &ngr;max(DR)/cm−1 3318, 2923, 1640, 1579, 1455, 1377, 1079, 1022, 750 and 588; NMR &dgr;H(400MHz, DMSO) 11.13(1H, br s), 8.23(1H, s), 8.05-8.04(1H, m), 7.43(1H, d, J 3.5Hz), 7.30(2H, s), 7.00(1H, t, J 7.0Hz), 6.90(2H, s), 6.80-6.77 (1H, m), 6.73(1H, d, J 6.5Hz), 6.51(1H, s) and 5.63(2H, s). 251 BE 42 mp 294.0-294.2° C.; IR &ngr;max(DR)/cm−1 3498, 3414, 1612, 1318, 1235, 102, 765 and 589; NMR &dgr;H(400MHz, DMSO) 11.24(1H, br s), 8.12(1H, s), 7.91(1H, d, J 3.5Hz), 7.53(1H, s), 7.39(1H, t, J 2.5Hz) 7.36-7.26(3H, m), 6.88-6.82 (1H, m), 6.43-6.38(1H, m) and 5.76(2H, s) 252 BF 44 mp 200.2-201.2° C. IR &ngr;max(DR)/cm−1 3390, 3205, 2924, 1725, 1648, 1603, 1508, 1423, 1332, 1277 and 1158; NMR &dgr;H(400MHz, DMSO) 8.12(1H, s), 7.90(1H, d, J 3.5Hz), 7.35-7.25(4H, m), 7.07-6.97(3H, m), 6.86(1H, dd, J 1.5, J 3.5Hz), 6.45(2H, t, J 7.5Hz), 6.37(1H, s), 6.32(1H, t, J 6.0Hz), 5.49(2H, s) and 4.16(2H, s, J 6.0Hz). 253 B 18 mp 181.8-182.1° C.; IR &ngr;max(DR)/cm−1 3362, 3208, 2988, 1654, 1601, 1513; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.91(1H, d, J 3.5Hz), 7.68 (1H, m), 7.29(2H, br s), 6.87-6.85(1H, m), 6.74(1H, d, J 7.5Hz), 6.68(1H, d, J 8.0Hz), 5.69(2H, s), 4.07(2H, q, J 7.0Hz), 1.12(3H, t, J 7.0Hz). 254 B 14 mp 190.8-190.9° C.; IR &ngr;max(DR)/cm−1 3514, 3292, 3158, 2984, 1615, 1500; NMR &dgr;H(400MHz, DMSO) 7.88(1H, d, J 3.5Hz), 7.65(1H, dd, J 7.0, 8.0Hz), 7.25(2H, br s), 6.72(1H, d, J 7.0Hz), 6.68(1H, d, J 8.0Hz), 6.52-6.50(1H, m), 5.67(2H, s), 4.08(2H, q, J 7.0Hz), 2.46(3H, s), 1.12(3H, t, J 7.0Hz). 255 BF 20 mp 184.5-184.6° C.; IR &ngr;max(DR)/cm−1 3202, 1649, 1601, 1509, 1436, 1331, 1277 and 1221; NMR &dgr;H(400MHz, DMSO) 8.43(1H, d, J 4.89Hz), 8.12(1H, dd, J 0.8, 3.5Hz), 7.91(1H, dd, J 0.9, 3.5Hz), 7.65(1H, td, J 1.7, 7.7Hz), 7.30 (2H, br s), 7.25(1H, d, J 7.9Hz), 7.15(1H, dd, J 4.9, 7.5Hz), 7.0(1H, t, J 7.8Hz), 6.86(1H, dd, J 1.7, 3.5Hz), 6.48-6.36(4H, m), 5.49(2H, s), 4.27(2H, s); Anal. Calcd for C21H18N8O.0.3 H2O: C, 62.46; H, 4.64, N, 27.75. Found: C, 62.66; H, 4.57; N, 27.36. 256 B 6 Mp 167.6-168.1° C. IR &ngr;max(DR)/cm−1 3509, 3304, 3178, 1609, 1494, 1421, 1325, 1127, 839 and 752. NMR &dgr;H(400MHz, DMSO) 2.05(3H, d, J 7.0Hz), 6.14(1H, q, J 7.0Hz), 6.84-6.88(1H, m), 7.30(2H, s), 7.52(2H, d, J 8.5Hz), 7.73(2H, d, J 8.0Hz), 7.91(1H, dd, J 3.5, 1.0Hz), 8.11-8.13(1H, m). Anal. Calcd for C17H13N6F3O: C, 54.55; H, 3.50; N, 22.44. Found: C, 54.52; H, 3.65; N, 22.06. 257 BE 75 IR &ngr;max(DR)/cm−1 3459, 3348, 3187, 2960, 1648, 1513, 1351, 1244, 1011, 837 and 759; NMR &dgr;H(400MHz, DMSO) 11.18(1H, br s), 8.11(1H, s), 7.89(1H, d, J 3.0Hz), 7.42(1H, d, J 7.5Hz), 7.37-7.26(3H, m), 7.21(1H, d, J 11.0Hz), 6.89-6.81(1H, m), 6.43-6.37(1H, s) and 5.72(2H, s). 258 BE 94 mp > 300° C.; dec; IR &ngr;max(DR)/cm−1 3441, 3318, 2990, 1612, 1285, 1083, 839 and 593; NMR &dgr;H(400MHz, DMSO) 11.29(1H, br s), 8.12(1H, s), 7.91(1H, d, J 3.5Hz), 7.41-7.29(3H, m), 7.22(1H, dd, J 10.0, 2.5Hz), 6.90(1H, dd, J 9.5, 2.5Hz), 6.86(1H, dd, J 3.5, 1.5Hz), 6.30(1H, s) and 5.79(2H, s). 259 B 50 mp 228.4-228.5° C.; NMR &dgr;H(400MHz, DMSO) 8.13-8.12(1H, m), 7.91 (1H, d, J 3.5Hz), 7.34(2H, br s), 7.18(2H, s), 6.87-6.85(1H, m), 5.67(2H, s), 2.22(6H, s). 260 B 8 mp 150.3-151.0° C. IR &ngr;max(DR)/cm−1 3510, 3306, 3183, 1633, 1495, 1423, 1240, 1029 and 753; NMR &dgr;H(400MHz, DMSO) 2.02(3H, d, J 7.0Hz), 6.05 (1H, q, J 7.0Hz), 6.83-6.88(1H, m), 7.10-7.22(3H, m), 7.30(2H, s), 7.40 (1H, dt, J 8.0, 6.5Hz), 7.91(1H, dd, J 3.5, 1.0Hz), 8.10-8.13(1H, m). Anal. Calcd for C16H13N6OF.0.25 H2O: C, 58.44; H, 4.14; N, 25.56. Found: C, 58.48; H, 3.98; N, 25.40. 261 BE 91 IR &ngr;max(DR)/cm−1 3472, 3318, 3184, 2922, 1651, 1595, 1478, 1417, 1329, 1218, 1097, 1015, 870, 767 and 545; NMR &dgr;H(400MHz, DMSO) 11.50(1H, s), 8.11 (1H, s), 7.90(1H, d, J 3.5Hz), 7.47(1H, s), 7.42(1H, t, J 3.0Hz), 7.33(2H, s), 7.19(1H, s), 6.86-6.84(1H, m), 6.53-6.51(1H, m), 5.71(2H, s). 262 C 34 mp 250.1-261.3° C.; IR &ngr;max(DR)/cm−1 3325, 3205, 2968, 1603, 1488; NMR &dgr;H (400MHz, DMSO) 8.11-8.10(1H, m), 7.89-7.87(1H, m), 7.28(2H, br s), 6.85-6.83 (1H, m), 6.81(2H, s), 5.40(2H, s), 4.56(2H, br s), 2.03(6H, s). 263 K 72 IR &ngr;max(DR)/cm−1 2825, 2021, 1645, 1453, 1394, 1286, 1171, 1030, 779 and 619; NMR &dgr;H(400MHz, DMSO) 2.02(3H, d, J 7.0Hz), 6.07(1H, q, J 7.0Hz), 6.85-6.88(1H, m), 7.13-7.18(1H, m), 7.25(1H, d, J 8.5Hz), 7.36(1H, d, J 8.0Hz), 7.47(1H, t, J 7.5Hz), 7.92(1H, d, J 3.5Hz), 8.12-8.14(1H, m). Anal. Calcd for C16H15N7O.2HCl.0.8 H2O: C, 47.02; H, 4.59; N, 23.99. Found: C, 46.87; H, 4.43; N, 23.71. 264 B 26 mp 162.0-162.6° C.; IR &ngr;max(DR)/cm−1 3319, 3206, 2932, 1644, 1505; NMR &dgr;H (400MHz, DMSO) 8.13-8.12(1H, m), 7.92-7.91(1H, m), 7.68-7.64(1H, m), 7.31(2H, br s), 7.21(1H, d, J 7.5Hz), 6.92(1H, d, J 8.0Hz), 6.86(1H, dd, J 3.5, 1.5Hz), 5.74(2H, s), 3.58(2H, t, J 6.5Hz), 3.16(3H, s), 2.84(2H, t, J 6.5Hz); M/Z 352(M+H)+. 265 B 15 NMR &dgr;H(400MHz, DMSO) 8.12-8.11(1H, m), 7.92-7.90(1H, m), 7.47(1H, d, J 8.0Hz), 7.28(2H, br s), 6.91(1H, d, J 8.0Hz), 6.86(1H, dd, J 2.0, 3.5Hz), 5.73-5.69(1H, m), 2.60-2.46(2H, m), 2.39(3H, s), 2.20(3H, s), 0.87(3H, t, J 7.0Hz); M/Z 350(M+H)+. 266 AK 99 NMR &dgr;H(400MHz, DMSO) 8.22-8.17(2H, m), 7.94(1H, d, J 2.01Hz), 7.73-7.63 (2H, m), 7.37(1H, d, J 2.5Hz) and 5.86(2H, s); M/Z 338(M+H)+; Retention time 1.74 min. 267 B 58 mp 255.6-255.7° C.; IR &ngr;max(DR)/cm−1 3512, 3294, 3179, 2960, 2692, 1745, 1638, 1432 and 1371; NMR &dgr;H(400MHz, DMSO) 7.88(1H, d, J 3.51Hz), 7.81 (1H, dd, J 1.0, J 8.0Hz), 7.46-7.29(2H, br s), 7.40(1H, t, J 7.8Hz), 7.23(1H, d, J 8.0Hz), 6.51(1H, dd, J 1.0, 3.5Hz), 5.78(2H, s) and 2.46(6H, s). 268 B 40 mp 248.1-249.0° C. IR &ngr;max(DR)/cm−1 3507, 3308, 3190, 2952, 1626, 1571, 1519, 1434, 1348 and 1291; NMR &dgr;H(400MHz, DMSO) 8.22(2H, d, J 8.5Hz), 7.89(1H, d, J 3.5Hz), 7.49(2H, d, J 9.0Hz), 7.36(2H, br s), 6.52(1H, dd, J 1.0, 3.5Hz), 5.83(2H, s) and 2.46(3H, s). 269 B 18 NMR &dgr;H(400MHz, DMSO) 8.14-8.12(1H, m), 7.92-7.90(1H, dd, J 1.0, 3.5Hz), 7.42-7.34(2H, s), 7.26-7.25(4H, s), 6.87-6.85(1H, dd, J 1.5, 3.5Hz), 5.66-5.64(2H, s), 3.15-3.13(3H, s) and 1.38-1.36(9H, s). 270 H 46 NMR &dgr;H(400MHz, DMSO) 8.22-8.13(2H, m), 7.75-7.65(3H, m), 7.59(1H, dd, J 1.5, J 3.0Hz), 7.34(2H, br s), 6.96(1H, dd, J 1.5, J 3.5Hz), 6.45(1H, t, J 3.2Hz), 5.85(2H, s) and 1.22(9H, s); M/Z 437(M+H)+; Retention time 4.36 min. 271 Q 40 NMR &dgr;H(400MHz, DMSO) 8.21-8.17(2H, m), 7.71-7.63(2H, m), 7.48(2H, br s), 5.87(2H, s), 2.50(3H, s) and 2.44(3H, s); M/Z 383(M+H)+; Retention time 3.69 min. 272 B NMR &dgr;H(400MHz, DMSO) 8.18(1H, dd, J 9.6, 2.0Hz), 8.13(1H, d, J 1.6Hz), 8.05(1H, dd, J 8.4, 2.4Hz), 7.90(1H, d, J 3.2Hz), 7.45(1H, t, J 8.0Hz), 7.38 (2H, br s), 6.86(1H, dd, J 3.6, 2.0Hz) and 5.84(2H, s). 273 B NMR &dgr;H(400MHz, DMSO) 8.13-8.09(1H, m), 7.89(1H, d, J 3.5Hz), 7.66 (1H, d, J 3.5Hz), 7.39(1H, s), 7.29(2H, br s), 6.85(1H, dd, J 3.5, 2.0Hz), 6.68 (1H, d, J 3.5Hz), 6.65(1H, s), 2.27(3H, s) and 1.52(9H, s). 274 BA 99 IR &ngr;max(Nujol)/cm−1 3313, 2923, 1693, 1603; NMR &dgr;H(400MHz, DMSO) 8.78 (1H, br s), 8.12-8.11(1H, m), 7.90(1H, d, J 3.5Hz), 7.34-7.31(3H, m), 7.13-7.12 (1H, m), 7.08-7.05(1H, m), 6.86-6.85(1H, m), 5.58(2H, s), 4.08(2H, q, J 7.0Hz), 2.16(3H, s), 1.21(3H, t, J 7.0Hz).

[0445] Adenosine Receptor Binding

[0446] Binding Affinities at hA2A Receptors

[0447] The compounds were examined in an assay measuring in vitro binding to human adenosine A2A receptors by determining the displacement of the adenosine A2A receptor selective radioligand [3H]-CGS 21680 using standard techniques. The results are summarised in Table 3. 3 TABLE 3 Example Ki (nM) Example 3 3 Example 4 4 Example 5 3 Example 8 3 Example 11 2 Example 12 7 Example 13 2 Example 15 4 Example 41 2 Example 57 2 Example 78 3 Example 92 2 Example 107 2 Example 120 1 Example 149 1 Example 156 2 Example 169 2 Example 188 1 Example 202 1 Example 209 1 Example 221 2 Example 233 4 Example 255 4

[0448] Evaluation of Potential Anti-Parkinsonian Activity In Vivo

[0449] Haloperidol-Induced Hypolocomotion Model

[0450] It has previously been demonstrated that adenosine antagonists, such as theophylline, can reverse the behavioural depressant effects of dopamine antagonists, such as haloperidol, in rodents (Mandhane S. N. et al., Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 1997, 328, 135-141). This approach is also considered a valid method for screening drugs with potential antiparkinsonian effects. Thus, the ability of novel adenosine antagonists to block haloperidol-induced deficits in locomotor activity in mice can be used to assess both in vivo and potential antiparkinsonian efficacy.

[0451] Method

[0452] Female TO mice (25-30 g) obtained from TUCK, UK, are used for all experiments. Animals are housed in groups of 8 [cage size−40 (width)×40 (length)×20 ( height)cm] under 12 hr light/dark cycle (lights on 08:00 hr), in a temperature (20≅2° C.) and humidity (55±15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.

[0453] Drugs

[0454] Liquid injectable haloperidol (1 ml Serenance ampoules from Baker Norton, Harlow, Essex, each containing haloperidol BP 5 mg, batch # P424) are diluted to a final concentration of 0.02 mg/ml using saline. Test compounds are typically prepared as aqueous suspensions in 8% Tween. All compounds are administered intraperitoneally in a volume of 10 ml/kg.

[0455] Procedure

[0456] 1.5 hours before testing, mice are administered 0.2 mg/kg haloperidol, a dose that reduces baseline locomotor activity by at least 50%. Test substances are typically administered 5-60 minutes prior to testing. The animals are then placed individually into clean, clear polycarbonate cages [20 (width)×40 (length)×20 (height) cm, with a flat perforated, Perspex lid]. Horizontal locomotor activity is determined by placing the cages within a frame containing a 3×6 array of photocells linked to a computer, which tabulates beam breaks. Mice are left undisturbed to explore for 1 hour, and the number of beams breaks made during this period serves as a record of locomotor activity which is compared with data for control animals for statistically significant differences.

[0457] 6-OHDA Model

[0458] Parkinson's disease is a progressive neurodegenerative disorder characterised by symptoms of muscle rigidity, tremor, paucity of movement (hypokinesia), and postural instability. It has been established for some time that the primary deficit in PD is a loss of dopaminergic neurones in the substantia nigra which project to the striatum, and indeed a substantial proportion of striatal dopamine is lost (ca 80-85%) before symptoms are observed. The loss of striatal dopamine results in abnormal activity of the basal ganglia, a series of nuclei which regulate smooth and well co-ordinated movement (Blandini F. et al., Glutamate and Parkinson's Disease. Mol. Neurobiol. 1996, 12, 73-94). The neurochemical deficits seen in Parkinson's disease can be reproduced by local injection of the dopaminergic neurotoxin 6-hydroxydopamine into brain regions containing either the cell bodies or axonal fibres of the nigrostriatal neurones.

[0459] By unilaterally lesioning the nigrostriatal pathway on only one-side of the brain, a behavioural asymmetry in movement inhibition is observed. Although unilaterally-lesioned animals are still mobile and capable of self maintenance, the remaining dopamine-sensitive neurones on the lesioned side become supersenstive to stimulation. This is demonstrated by the observation that following systemic administration of dopamine agonists, such as apomorphine, animals show apronounced rotation in a direction contralateral to the side of lesioning. The ability of compounds to induce contralateral rotations in 6-OHDA lesioned rats has proven to be a sensitive model to predict drug efficacy in the treatment of Parkinson's Disease.

[0460] Animals

[0461] Male Sprague-Dawley rats, obtained from Charles River, are used for all experiments. Animals are housed in groups of 5 under 12 hr light/dark cycle (lights on 08:00 hr), in a temperature (20±2° C.) and humidity (55±15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.

[0462] Drugs

[0463] Ascorbic acid, desipramine, 6-OHDA and apomorphine (Sigma-Aldrich, Poole, UK). 6-OHDA is freshly prepared as a solution in 0.2% ascorbate at a concentration of 4 mg/mL prior to surgery. Desipramine is dissolved in warm saline, and administered in a volume of 1 ml/kg. Apomorphine is dissolved in 0.02% ascorbate and administered in a volume of 2 ml/kg. Test compounds are suspended in 8% Tween and injected in a volume of 2 ml/kg.

[0464] Surgery

[0465] 15 minutes prior to surgery, animals are given an intraperitoneal injection of the noradrenergic uptake inhibitor desipramine (25 mg/kg) to prevent damage to nondopamine neurones. Animals are then placed in an anaesthetic chamber. and anaesthetised using a mixture of oxygen and isoflurane. Once unconscious, the animals are transferred to a stereotaxic frame, where anaesthesia is maintained through a mask. The top of the animal's head is shaved and sterilised using an iodine solution. Once dry, a 2 cm long incision is made along the midline of the scalp and the skin retracted and clipped back to expose the skull. A small hole is then drilled through the skill above the injection site. In order to lesion the nigrostriatal pathway, the injection cannula is slowly lowered to position above the right medial forebrain bundle at −3.2 mm anterior posterior, −1.5 mm medial lateral from bregma, and to a depth of 7.2 mm below the duramater. 2 minutes after lowing the cannula, 2 VAL of 6-OHDA is infused at a rate of 0.5 &mgr;l/min over 4 minutes, yeilding a final dose of 8 &mgr;g. The cannula is then left in place for a further 5 minutes to facilitate diffusion before being slowly withdrawn. The skin is then sutured shut using Ethicon W501 Mersilk, and the animal removed from the strereotaxic frame and returned to its homecage. The rats are allowed 2 weeks to recover from surgery before behavioural testing.

[0466] Apparatus

[0467] Rotational behaviour is measured using an eight station rotameter system provided by Med Associates, San Diego, USA. Each station is comprised of a stainless steel bowl (45 cm diameter×15 cm high) enclosed in a transparent Plexiglas cover running around the edge of the bowl, and extending to a height of 29 cm. To assess rotation, rats are placed in cloth jacket attached to a spring tether connected to optical rotameter positioned above the bowl, which assesses movement to the left or right either as partial (45°) or full (360°) rotations. All eight stations are interfaced to a computer that tabulated data.

[0468] Procedure

[0469] To reduce stress during drug testing, rats are initially habituated to the apparatus for 15 minutes on four consecutive days. On the test day, rats are given an intraperitoneal injection of test compound 30 minutes prior to testing. Immediately prior to testing, animals are given a subcutaneous injection of a subthreshold dose of apomorphine, then placed in the harness and the number of rotations recorded for one hour. The total number of full contralatral rotations during the hour test period serves as an index of antiparkinsonian drug efficacy.

Claims

1. The use of a compound of formula (I):

281

wherein

R1 is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7;

R2 is selected from aryl attached via an unsaturated carbon;

R3 is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6 and SO2R7;

R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an NR5R6 group, R5 and R6 may be linked to form a heterocyclic group, or where R4, R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic group; and

R7 is selected from alkyl and aryl,

or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors may be beneficial.

2. Use according to claim 1 wherein R1 is selected from alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7.

3. Use according to claim 1 wherein R1 is selected from alkyl, alkoxy, alkylthio, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7.

4. Use according to claim 1 wherein R1 is selected from NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7.

5. Use according to claim 1 wherein R1 is selected from NR5R6.

6. Use according to claim 1 wherein R1 is NH2.

7. Use according to claim 1 wherein R1 is selected from haloalkyl and arylalkyl.

8. Use according to any preceding claim wherein R2 is not ortho,ortho-disubstituted.

9. Use according to any preceding claim wherein R2 is not substituted at either ortho position.

10. Use according to any preceding claim wherein R2 is a heteroaryl group.

11. Use according to claim 10 wherein R2 is a heteroaryl group which is attached to the pyrimidine ring of formula (I) such that a heteroatom is adjacent to the unsaturated carbon atom attached to said pyrimidine ring.

12. Use according to claim 10 or 11 wherein R2 is an N, O or S-containing heteroaryl group.

13. Use according to any of claims 10 to 12 wherein R2 is selected from furyl, thienyl, pyridyl, thiazolyl, pyrazolyl, triazolyl, pyrrolyl and oxazolyl.

14. Use according to any of claims 10 to 12 wherein R2 is selected from 2-furyl, 2-thienyl, 2-thiazolyl, 2-pyridyl, 3-pyrazolyl, 2-pyrrolyl, 4-triazolyl and 5-oxazolyl.

15. Use according to any of claims 10 to 12 wherein R2 is selected from furyl, thienyl, pyridyl, thiazolyl and pyrazolyl.

16. Use according to any of claims 10 to 12 wherein R2 is selected from 2-furyl, 2-thienyl, 2-thiazolyl, 2-pyridyl and 3-pyrazolyl.

17. Use according to any of claims 10 to 12 wherein R2 is 2-furyl.

18. Use according to any of claims 1 to 9 wherein R2 is phenyl.

19. Use according to any preceding claim wherein R3 is selected from H and substituted alkyl.

20. Use according to claim 19 wherein R3 is selected from alkyl substituted by aryl, cycloalkyl, non-aromatic heterocyclyl, CN, CO2R5, CONR5R6,CONR4NR5R6 or C(═NR4)NR5R6.

21. Use according to claim 19 wherein R3 is selected from alkyl substituted by aryl.

22. Use according to claim 21 wherein R3 is selected from (CR9R10)nR11 wherein n is 1 to 6, R9 and R10 are independently selected from H, alkyl and aryl, and R11 is selected from the group consisting of substituted aryl (including heteroaryl) groups.

23. Use according to claim 22 wherein R11 is selected from mono-, di- or tri-substituted aryl groups represented by the formula Ar(R12)a(R13)b(R14)c wherein Ar is an aryl group; wherein R12, R13 and R14 are substituent group(s), the same or different; and wherein a, b and c are 0 or 1 such that a+b+c≧1.

24. A use according to claim 22 or 23 wherein n is 1 to 3.

25. A use according to claim 22 or 23 wherein n is 1.

26. A use according to any of claims 22 to 25 wherein the or each R9 and R10 are selected from H and alkyl.

27. A use according to any of claims 22 to 25 wherein at least one of the or each R9 and R10 is H.

28. A use according to any of claims 22 to 25 wherein both the or each R9 and R10 are H.

29. Use according to any of claims 23 to 28 wherein R12, R13 and R14 are independently selected from NR5R6, alkyl, alkoxy, halogen, NO2, CN, hydroxy, NHOH, CHO, CONR5R6, CO2R5, NR4COR5, NR4CO2R7, NR4SO2R7, OCO2R7 and aryl.

30. Use according to any of claims 23 to 28 wherein R12, R13 and R14 are independently selected from NR5R6, alkyl and halogen.

31. Use according to claim 29 or 30 wherein R12, R13 and R14 are independently selected from alkyl, and said alkyl is substituted alkyl and is selected from alkoxyalkyl, hydroxyalkyl, aminoalkyl and haloalkyl.

32. Use according to claim 29 or 30 wherein R12, R13 and R14 are independently selected from unsubstituted alkyl, NH2 and fluoro.

33. A use according to any of claims 22 to 32 wherein said substituted aryl group R11 or Ar is selected from phenyl, pyridyl, indolyl, furyl, thienyl, isoindolyl, indolinyl, isoxazolyl, oxazolyl, thiazolyl, pyrazinyl, pyrimidinyl, quinolinyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, indazolyl, benzodioxolyl and dihydrobenzofurayl.

34. Use according to any of claims 22 to 32 wherein said substituted aryl group R11 or Ar is selected from phenyl, pyridyl, indolyl, furyl and thienyl.

35. Use according to claim 34 wherein said substituted aryl group R11 or Ar is selected from phenyl, thienyl, furyl and pyridyl.

36. Use according to claim 34 wherein said substituted aryl group R11 or Ar is selected from phenyl, 2-thienyl, 2-furyl and 2-pyridyl.

37. Use according to any of claims 1 to 18 wherein R3 is selected from (CR9R10)nR8 wherein n is 1 to 6, R9 and R10 are independently selected from H alkyl and aryl, and R8 is selected from cycloalkyl, non-aromatic heterocyclic, CN, CO2R5, CONR5R6, CONR4NR5R6 and C(═NR4)NR5R6.

38. Use according to claim 37 wherein n, R9 and R10 are as set out in any claims 24 to 28

39. Use according to claim 37 wherein R is selected from CONR5R6, R5 is hydrogen and R6 is selected from unsubstituted alkyl and arylalkyl.

40. Use according to any of claims 1 to 18 wherein R3 is selected from CONR5R6, R5 is H and R6 is selected from arylalkyl, preferably arylmethyl.

41. Use according to claim 1 wherein the compound is selected from:

7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N,N-bis(2-fluorobenzyl)-3-(2-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

7-(2-furyl)-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

methyl 3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)methylbenzoate

3-(3,5-dimethoxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-chloro-2-thienyl)methyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)phenyl-(1-methyl-1H-imidazol-4-yl)sulphonamide

5-amino-N-benzyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinmidin-3-ylcarboxamide

7-(2-furyl)-3-(3-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-aminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

ethyl 5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylacetate

3-(3yanobenzyl)7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-5-amine

7-(2-furyl)-3-(3-(3-pyridyl)propyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-trifluoromethylbenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-hydroxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(5-methyl-2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(1H-pyrazol-3-yl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(5-thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-methylbenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetic acid

3-(3-chlorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(1H-pyrazol-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

7-(2-furyl)-3-methyl-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetamide

(5-amino-7-(2-firyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-(3-chlorophenyl)acetamide

7-(2-furyl)-3-(6-methoxy-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

7-(2-furyl)-3-(2-thienylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(2-thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(2-thienyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(6-methyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

3-(2-fluorobenzyl)-7-(5-methyl-2-thiazolyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

tert-butyl N-(3-(5-amino7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-3-ylmethyl)benzyl)carbamate

3-(2,5-dimethoxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

3-(2,6-difluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(4-methyl-2-thiazolyl)-3H-[1,2,3]triazolo[4,5]pyrimidine-5-amine

7-(2-thienyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

6-chloro-N-(7-(2-firyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridine-3-carboxamide

3-(3-nitrobenzyl)-7-(5-thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminomethylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrmidine-5-amine

3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidin3-ylmethyl)-N,N-dimethylbenzamide

3-(3-aminobenzyl)-7-(2-thienyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N-methylbenzamide

3-(3-aminobenzyl)-7-(5-thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluoro-5-methoxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-(2-pyridyl)acetamide

(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-(2-pyridylmethyl)acetamide

(5-amino-7-(2-furyl)-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-N-phenylacetamide

3-(3,5-dinitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(5-methyl-2-furyl)-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2,3-difluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2,4-difluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

7-(5-methyl-2-furyl)-3-(6-methyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2,6-difluorobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-5-amine

7-(5-methyl-2-furyl)-3-(2-thienylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-chlorobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-methoxy-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-methylbenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2,5-difluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-methoxy-5-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine

3-(5-amino-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-3-ylmethyl)-N-methylbenzamide

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)benzyl)acetamide

3-(2-fluorobenzyl)-7-(5-oxazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-chloro-2-pyridylmethyl)-7-(2-furyl)-3H-[ 1,2,3]triazolo[4,5-d]pyrmidine-5-amine

3-(6-fluoro-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-methoxybenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl N-(3-(5-amino-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)benzyl)carbamate

3-(2-aminobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride

3-(3,5-diaminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

3-(3-aminomethylbenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride

7-(2-furyl)-3-(2-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluoro-5-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-amino-2-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluorobenzyl)-7-(1H-triazolo4yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-chloro-2-pyridylmethyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(5-methyl-2-furyl)-3-(6-phenyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminobenzyl)-7-(2-thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-amino-2-fluorobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)benzyl)-3-methylbenzamide

7-(5-methyl-2-furyl)-3-(4-nitro-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-hydroxylamino-2-pyridylmethyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-methyl-3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-amino-2-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-amino-4methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3,5-dimethylisoxazol4-ylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

7-(2-furyl)-3-(3-methyl-2-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-cyclohexylmethyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-methylnitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-methyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(5-methyl-2-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4amino-3-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)benzoic acid

3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)benzamide

7-(2-furyl)-3-(2-methylthiazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-5-amine

3-(3-aminomethylbenzyl)-7-(1H-pyrazol-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N-isopropyl-N-methylbenzamide

3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-N-isopropylbenzamide

3-(2-amino-5-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-cyano-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(5-methyl-2-pyrazinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(8-quinolinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-phenylthiazol4-ylmethyl)3H-[I,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(4-methyl-2-thiazolyl)-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-chloro-3-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(1,2,5-benzoxadiazol-5-yl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(6-methoxymethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

3-benzyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-amino4chlorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-nitro-2-pyridyhnethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-hydroxylamino-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

7-(2-furyl)-3-(6methyl-4-nitro-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-hydroxylamino-6-methyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4chloro-2-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-amino-4-chlorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-cyanobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3,4-dimethoxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine trifluoroacetate salt

7-(5-methyl-2-furyl)-3-(3-methyl-4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-amino-3-methylbenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(5-methyl-3-oxazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

7-(2-furyl)-3-(3-methyl4pyridylmethyl)-3H-[1,2,3]triazolo[4,5)pyrimidine-5-amine

3-(1,2,5-benzothiadiazol4-ylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-pyrazinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

3-(4-fluoro-3-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

3-(3-nitrobenzyl)-7-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-methyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

tert-butyl N-(2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)-4-pyridylmethyl)carbamate

7-(2-furyl)-3-(3-methoxy-4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-ethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-ethylpyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

tert-butyl 7-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)indole-1-carboxylate

tert-butyl 4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)indole-1-carboxylate

7-(2-furyl)-3-(4-indolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

tert-butyl N-(4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)benzyl)carbamate

3-(4aminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo4,5-d]pyrimidine-5-amine

tert-butyl 5-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)indole-1-carboxylate

tert-butyl N-(4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-3-ylmethyl)-2-fluorophenyl)carbamate

3-(4-aminomethylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(5-ethyl-2-furyl)-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl 6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-3-ylmethyl)indole-1-carboxylate

3-(4-amino-3-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl (4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)-3,5-difluorophenyl)carbonate

3-(2,6-difluoro-4-hydroxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminobenzyl)7-(5-ethyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminobenzyl)-7-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(6-indolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(5-indolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyriridine-5-amine

7-(2-furyl)-3-(7-indolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-fluoro-2-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2,6-difluoro4-methoxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl N-(2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)benzyl)carbamate

3-(1H-benzotriazol-5-ylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-dpyrimidine-5-amine

7-(2-furyl)-3-(2-methylnitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)phenylacetamide

3-(2-amninomethylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-(N,N-dimethylamine)benzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

3-(4-difluoromethoxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

7-(2-furyl)-3-(6-phthalimidomethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine5-amine

3-(3-aminofluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2,3dihydrobenzofuran-5-ylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-bromo-2-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine

7-(2-furyl)-3-(2,3,5-trifluorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluoro-5-iodobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-furylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-amino-5-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl (5-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)-2-nitrophenyl)carbonate

3-(4-amino-3-hydroxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-amino-3-fluorobenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-aminobenzyl)-7-(1H-pyrazol-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-hydroxy-4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N-(6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2-pyridylmethyl)acetamide

N-(2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)benzyl)acetamide

7-(2-furyl)-3-(3-thienylmethyl)-3H-[1,2,3]triazolo(4,5-d]pyrimidine-5-amine

3-(3-amino-2-methylbenzyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-methyl-2-thienyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-allyloxymethyl-2-pyridylmethyl)-N,N-diallyl-7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

3-(6-methoxymethyl-2-pyridylmethyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

3-(4-aminobenzyl)-7-(5-methyl-2-furyl)3H-[I,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-allyloxymethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

3-(6-allyloxymethyl-2-pyridylmethyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3-isopropyl4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(quinolin-2-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(4-(N-methylamino)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(6-methyl-2-pyridyl)propanone

3-(3-aminobenzyl)-7-(1H-pyrrole-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-nitrobenzyl)-7-(2-pyridyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine

N-(4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)phenyl)acetamide

7-(2-furyl)-3-(4-nitro-2-(2-trimethylsilylethoxy)methoxybenzyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

3-(3-ethyl-4-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-(2-thienylmethyl))-3H-[1,2,3]triazolo[4,5-d]pyrmidine-5-amine

7-(2-furyl)-3-(6-isopropyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(1-(2H-tetrahyropyran-2-yl)indazol-5-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4,6-diisopropyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(5-indazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(2-hydroxy4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine

7-(2-furyl)-3-(6-vinyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl 5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-carboxylate

tert-butyl 3-(5-amino-7-(2-firyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)indole-1-carboxylate

6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)pyridine-2-carboxaldehyde

tert-butyl 2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-3-ylmethyl)indole-1-caboxylate

3-(2-indolylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-5-amine

3-(5-ethyl-2-thienybnethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(3,4-methylenedioxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-amino-3-ethylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-phenylethanone

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-methyl)phenyl)thiophene-2-carboxamide

7-(2-furyl)-3-(6-hydroxymethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride

N-(3-(5-amino-7-(2-firyl)-3H-[1,2,3]triazolo[4,5-d]pyrmidine-3-methyl)phenyl)-3,3-dimethylbutanamide

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-methyl)phenyl)cyclopropanecarboxamide

7-(2-furyl)-3-(6-n-propyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(6-isobutyloxymethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-bromomethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

3-(4-amino-3-isopropylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-aminomethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-hydroxybenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(4-nitrophenyl)ethanone

4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylacetyl)-benzonitrile

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)phenyl)propanesulphonamide

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5]pyrimidin-3-ylmethyl)phenyl)-5-amine

7-(2-furyl)-3-(6-(N-methylamino)methyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5d]pyrimidine-5-amine hydrochloride

2-(5-amino-7-(2-furyl)-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(4-(N,N-diethylamino)phenyl)ethanone

7-(2-furyl)-3-(6-isopropyl-3-pyridylmethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine-5-amine

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(4-methoxyphenyl)ethanone

tert-butyl 7-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)-5-chloroindole-1-carboxylate

3-(5-chloro-7-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)phenyl)-3,5-dimethylisoxazol-4-ylsulphonamide

3-(6-(N,N-dimethylamine)methyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(6-methylthiomethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine5-amine

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-(2-nitrophenyl)ethanone

N-(3-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)phenyl)-1,2-dimethyl-1H-imidazol-4-ylsulphonamide

N,N-bis(6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2-pyridylmethyl)methanesulphonamide

7-(2-furyl)-3-(6-methylsulphonylmethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N-(6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2-pyridylmethyl)-N-methyl methanesulphonamide

3-(3-aminobenzyl)-7-(4,5-dimethyl-2-thiazolyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

3-(4-amino-2-fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-indanone

7-(2-furyl)-3-(5-methyl-7-indolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

N-(4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)-2-methylphenyl)formamide

2-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-1-phenylpropanone

3-(7-fluoro-5-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrinidine-5-amine

7-(2-furyl)-3-(6-isopropoxymethyl-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine5-amine

3-(6-ethyl-2-pyridyhmethyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-chloro-5-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(7-bromo-5-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-chloro-5-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-(4-fluorobenzylamino)benzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-ethoxy-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(6-ethoxy-2-pyridylmethyl)-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-(2-pyridylmethylamino)benzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(1-(4-trifluoromethylphenyl)ethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

3-(6-fluoro-5-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(5-fluoro-2-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3,5-dimethyl4-nitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(1-(3-fluorophenyl)ethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(7-chloro-5-indolyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(4-amino-3,5-dimethylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(1-(3-aminophenyl)ethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

7-(2-furyl)-3-(6-(2-methoxyethyl)-2-pyridylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine5-amine

7-(2-furyl)-3-(l-(5,6methyl-2-pyridyl)propyl)-3H-[I,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(3-nitrobenzyl)-7-(1H-pyrazol-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine hydrochloride

7-(5-methyl-2-furyl)-3-(2-methyl-3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5amine

7-(5-methyl-2-furyl)-3-(nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl N-(4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)phenyl)-N-methylcarbamate

tert-butyl 2-(5-amino-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyimidin-7-yl)pyrrole-1-carboxylate

7-(4,5-dimethylthiazol-2-yl)-3-(3-nitrobenzyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine-5-amine

3-(2-fluoronitrobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine

tert-butyl 7-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-ylmethyl)-5-methylindole-1-carboxylate, and

ethyl N-(4-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)-2-methylphenyl)carbamate.

42. Use according to claim 1 wherein the compound is selected from:

3-(2fluorobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine;

7-(2-furyl)-3-(3-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine;

3-(3-aminobenzyl)-7-(2-furyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine-5-amine;

3-(3-aminobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine;

7-(2-furyl)-3-(3-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine;

7-(2-furyl)-3-(2-nitrobenzyl)-3H-[2,3]triazolo[4,5-d]pyrimidine-5-amine;

3-(2-aminobenzyl)-7-(2-furyl)3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine; and

3-(3-cyanobenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine.

43. A method of treating or preventing a disorder in which the blocking of purine receptors may be beneficial comprising administration to a subject in need of such treatment an effective dose of a compound as set out in any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof.

44. A use or method according to any preceding claim wherein the disorder is caused by the hyper functioning of purine receptors.

45. A use or method according to any preceding claim wherein the purine receptors are adenosine receptors.

46. A use or method according to claim 45 wherein the adenosine receptors are A2A receptors.

47. A use or method according to any preceding claim wherein the disorder is a movement disorder.

48. A use or method according to claim 47 wherein the movement disorder is Parkinson's disease.

49. A use or method according to claim 48 for treatment of drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning or post-traumatic Parkinson's disease.

50. A use or method according to claim 47 wherein the movement disorder is progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity or other disorders of the basal ganglia which result in dyskinesias.

51. A use or method according to any one of claims 47 to 50 wherein the compound of formula (I) is in combination with one or more additional drugs useful in the treatment of movement disorders, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.

52. A use or method according to claim 51 wherein said additional drug(s) useful in the treatment of movement disorders is/are a drug useful in the treatment of Parkinson's disease.

53. A use or method according to claim 51 or 52 wherein the or one of the additional drugs is L-DOPA or a dopamine agonist.

54. A use or method according to any one of claims 1 to 46 wherein said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy.

55. A use or method according to claim 54 wherein said cognitive or memory impairment disorder is Alzheimer's disease.

56. Use of a compound as set out in any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for neuroprotection in a subject.

57. A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound as set out in any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof.

58. A use or method according to claim 56 or 57 wherein said medicament or said method is for neuroprotection in a subject suffering from or at risk from a neurodegenerative disorder.

59. A use or method according to claim 58 wherein said neurodegenerative disorder is a movement disorder.

60. A use or method according to claim 59 wherein said movement disorder is a disorder as set out in claim 48, 49 or 50.

61. A use or method according to any one of claims 1 to 60 wherein the subject is human.

62. A compound as set out in any one of claims 1 to 42, or a pharmaceutically acceptable salt or prodrug thereof, for use in therapy.

63. A compound as set out in any one of claims 1 to 42, per se, other than compounds wherein R1 is H and R3 is methyl.

64. A compound according to claim 63 other than compounds wherein R3 is methyl.